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Abstract  
Drug hypersensitivity reactions are a significant cause of patient morbidity 
and mortality. They are difficult to predict in the clinic and during the drug 
development process. This is because mechanisms have not been fully elucidated. In 
fact, recent data using T-cells cloned from hypersensitive human patients have 
questioned the long-standing hapten concept, which states that a drug must bind 
irreversibly to protein to initiate a T-cell response. The work described herein was 
performed  to  investigate  the  chemical  and  cellular  mechanisms  of  β-lactam-induced 
skin and liver injury and in particular to understand the relationship between drug-
protein adduct formation and the activation of antigen-specific T-cells.  
 Β-lactam antibiotics, such as piperacillin, provide the cornerstone of 
treatment and reduce the rate of decline in lung function in patients with cystic 
fibrosis, but use is limited by a high frequency of hypersensitivity reactions. Using 
the lymphocyte transformation test, drug-responsive lymphocytes were found in 
approximately 70% of clinically diagnosed piperacillin hypersensitive patients. By 
cloning over 400 antigen-specific CD4+, CD8+ and CD4+CD8+ T-cells, the T-cell 
proliferative response and cytokine secretion to piperacillin was shown to be 
concentration-dependent and highly drug-specific. Mass spectrometry revealed 
irreversible binding of piperacillin to selective lysine residues on albumin and a 
synthetic albumin conjugate stimulated piperacilin-specific clones via a processing-
dependent pathway. These results describe the cellular processes that underlie 
piperacillin hypersensitivity. 
 Approximately 20% of hypersensitive patients with cystic fibrosis develop 
multiple reactions that restrict therapeutic options. To explore the mechanistic basis 
of  multiple  β-lactam hypersensitivity, albumin binding profiles and T-cell responses 
against three commonly prescribed drugs; piperacillin, meropenem and aztreonam, 
were studied. PBMC responses were characterized using the lymphocyte 
transformation test and IFN-γ   ELIspot.   Clones   were   generated   and   found   to  
proliferate and release cytokines following stimulation with all three drugs. 
However, crossreactivity with the different drugs was not observed. Each compound 
formed distinct haptens with lysine residues on albumin, which may explain the 
highly drug-specific T-cell   response.   These   data   indicate   that   multiple   β-lactam 
reactions are instigated through priming naïve T-cells against the different drugs.   
 The role of the adaptive immune system in reactions that target liver has not 
been defined. For flucloxacillin, a delay in the reaction onset and identification of 
HLA-B*57:01 as a susceptibility factor are indicative of an immune pathogenesis. 
Thus, flucloxacillin-responsive CD4+ and CD8+ T-cells were characterized from 
patients with liver injury. Clones expressed the gut-homing chemokine receptors 
CCR4 and CCR9 and secreted IFN-γ,   Th2   cytokines   and   cytolytic   molecules  
following drug stimulation. In contrast to the piperacillin clones, flucloxacillin 
clones were activated with several structurally-related   β-lactam antibiotics. 
Furthermore, naïve CD8+ T-cells from volunteers expressing B*57:01 were 
activated with flucloxacillin when dendritic cells presented the drug antigen. 
Activation of CD8+ cells from patients and volunteers was processing-dependent 
and restricted by HLA-B*57:01, which effectively links the genetic association to 
the iatrogenic disease. 
In conclusion, the studies described herein provide novel insight into the way in 
which  β-lactam antibiotics interact with protein and activate T-cells that are thought 
to be the ultimate mediators of drug hypersensitivity reactions in skin and liver.   
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1.1 Introduction 
Immune-mediated reactions to drugs are difficult to predict. They can be exceedingly 
severe in nature which means they are a major problem for clinicians and researchers 
in the pharmaceutical industry. It has been reported recently that susceptibility to 
adverse drug reactions is increased with the possession of particular human 
leukocyte antigen (HLA) alleles. However were this relates to a highly HLA-
restricted drug-specific T-cell response is not yet known.    
 
1.2 Adverse drug reactions  
1.2.1 Definitions of adverse drug reactions  
The World Health Organisation (WHO) in 1972 defined adverse drug reactions as 
follows: “A  response   to  a  drug   that   is   anxious  and  unintended  and  occurs  at  doses  
normally used in man for the prophylaxis, diagnosis or therapy of disease, or for 
modification  of  physiological  function”  (WHO, 1972).  
 
However a more comprehensive and relevant definition has been suggested by 
(Edwards and Aronson, 2000):   “An   appreciably harmful or unpleasant reaction, 
resulting from an intervention related to the use of a medicinal product, which 
predicts hazards from future administration and warrants prevention or specific 
treatment,  or  alteration  of  the  dosage  regimen”.   
 
The second definition is more useable as suggested by the authors for the reason that 
it refers to severe reactions, involves reactions caused by prescription error and 
involves reactions caused by excipients or contaminants.  
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1.2.2 Impact of adverse drug reactions  
Nearly 3% (Zhang et al., 2012) of new therapeutic compounds will eventually be 
withdrawn from the market because of safety concerns, mostly in the first two years 
after approval, in spite of rigorous strategies including pre-clinical and clinical 
testing.   
 
Adverse drug reactions (ADRs) have been identified as a significant health problem 
that requires a thorough investigation because of their high incidence and related 
severity. A prospective study in 2004 found that approximately 6.5% of 
hospitalizations, more than eighteen thousand patients in the North-West of England  
, were related to an adverse drug reaction (Pirmohamed et al., 2004). The most 
prevalent age group were the elderly (median age in non-ADR group = 66; median 
age in ADR group = 76) and among women (52% in non-ADR group; 59% in ADR 
group) (Pirmohamed et al., 2004). This is compatible with other data collected from 
different centres around the UK (incidence of ADRs 20.6/10,000 female patients vs. 
12.9/10,000 male patients) (Martin et al., 1998). Lack of reporting in males might be 
the cause of higher prevalence of ADRs in females. Patients recovered from their 
ADRs in the majority of cases, but still 2.3% of ADRs were categorised as being the 
main causality for patient mortality (Pirmohamed et al., 2004). In total, 0.2% of 
mortalities in hospitalised patients were related to ADRs (Lazarou et al., 1998; 
Pirmohamed et al., 2004). Based on this analysis, Lazarou et al. proposed that ADRs 
represent between the sixth and fourth most important reason for death in the USA 
(Lazarou et al., 1998).   
 
ADRs also have serious economic consequences besides their direct threat to patient 
health safety. Pirmohamed et al. proposed that ADRs represent a major financial 
burden as it cost the NHS over four hundred million pounds sterling per annum 
(Pirmohamed et al., 2004). Moreover, a substantial investment is being lost by 
pharmaceutical companies following compound withdrawal in the late stage of 
development. Several estimates suggest that the financial cost of getting a new drug 
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compound to market can reach up to eight hundred million dollars (DiMasi et al., 
2003).   
 
1.2.3 Classification of adverse drug reactions  
An array of drugs with different indications has been reported to cause serious 
adverse drug reactions [Table 1.1]. The prevalence of ADRs varies greatly for 
different drugs. Reactions can generally be categorised in to two main groups; type 
A and type B (Park et al., 1998).   
 
Drug Medical indication Adverse reaction 
Frequency 
of ADR in 
study 
population 
Date 
withdrawn 
Reference 
Abacavir HIV Hypersensitivity 5-8% Still in use 
(Mallal et al., 
2002) 
Carbamazepine Epilepsy SJS/TEN 0.1-0.01% Still in use 
 (Vittorio and 
Muglia, 1995) 
Flucloxacillin 
Staphylococcal 
infection 
Cholestatic/mixed 
liver injury 
0.0085% Still in use 
(Russmann et 
al., 2005) 
Isoniazid Tuberculosis Hepatotoxicity 10-20% Still in use 
 (Mitchell et al., 
1976) 
Rifampicin Tuberculosis Hepatotoxicity <5% Still in use 
 (Grosset and 
Leventis, 1983) 
Troglitazone Diabetes Hepatotoxicity 1.9% 2000 
 (Watkins and 
Whitcomb, 
1998) 
Warfarin Anti-coagulant Bleeding 10-16% Still in use 
 (Wysowski et 
al., 2007) 
Ximelagatran Thromboembolism hepatotoxicity 7.9% 2006 
 (Lee et al., 
2005) 
 
Table 1.1- Examples of various adverse drug reactions  
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Type A (on-target) reactions are in general a dose function, resulting in overstated 
pharmacological outcome. They can be affected by enzyme inhibition and or 
induction by concomitant therapies, or by metabolism or drug transporters. In the 
majority of cases reactions can be controlled through adjustment of the dose, or by 
careful monitoring of medications. The majority of ADRs fall under the category of 
type A reactions. Type B (off-target) reactions are less frequent, when compared to 
type A reactions, however they are a common cause of drug mortality/morbidity as a 
result of their unpredictable and severe nature. Effects are not related to 
pharmacological actions, reactions are only observed in a minority of exposed 
individuals. It is extremely difficult to determine the underlying mechanisms behind 
off-target reactions.  
 
A minority of ADRs cannot be categorised under the umbrella of the above 
classification therefore the following definitions may also be relevant (Edwards and 
Aronson, 2000):  
 Type C (Chronic): These reactions are accompanied with using a 
particular drug for a long duration e.g. prednisolone treatment causes 
iatrogenic   Cushing’s   syndrome   as   a   result   of   elevated   glucocorticoid  
levels.   
 Type D (Delayed): These types of reactions can be observed years after 
the end of treatment. Secondary tumours resulting from alkylating agents 
is an example of a delayed reaction. This definition is also applicable to 
teratogenic compounds resulting in adverse effects to the embryo of 
mothers who are being treated while pregnant e.g. birth defects can be 
seen with valproate and thalidomide treatment.        
 Type E (End of use): Take place upon drug withdrawal. They can be 
avoided in some instances by a gradual dose reduction. For example, 
sudden anticonvulsant withdrawal may cause seizures whereas β-
adrenoreceptor antagonists’ withdrawal is accompanied with unstable 
angina.   
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Unsafe drugs are still going on to the market despite rigorous in vitro and in vivo 
strategies of testing. A better understanding of underlying mechanisms is thus 
needed to develop strategies for better-quality screening of new chemical 
compounds.  
 
1.3 Immunological reactions 
The immune system is involved in type B (off-target) reactions. Adverse drug 
reactions caused by an immune response have a tendency to be severe in nature and 
are very difficult to predict as there are limited preclinical screens able to 
recapitulate the immune system complexity either in vitro or in vivo. These types of 
reactions will be the main focus of this thesis.             
   
1.3.1 Classification of immunological reactions 
Drug hypersensitivity reactions can be defined as a severe adverse drug reaction 
which is caused by an immune response despite of therapeutic agent effectiveness 
and safety. In 1963, Gell and Coombs were the first to group immunological 
reactions in to four categories based on the type and main clinical characteristics of 
the immune response. Antibody mediated reactions are represented as type I-III 
reactions, while reactions caused by T-cells are represented as type IV reactions. 
Gell and Coombs classification is still commonly in use today, with the additional 
subdivision of type IV reactions presented lately (Pichler, 2003). Table 1.2 
summarised the main characteristics of each reaction type. However, it must be 
noticed that overlap between reaction features is an often seen in clinical practice, 
especially with regard to the release of specific mediators. Type IV (delayed type T-
cell mediated) reactions will be discussed in more detail later.        
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Extended 
Coombs and Gell 
classification 
Type of 
immune 
response 
Pathologic 
characteristics 
 
Clinical 
symptoms 
 
Drug binding 
Cell 
type 
Type I IgE 
Mast cell 
degranulation 
Urticaria and 
anaphylaxis 
Covalent 
B-
cell 
Type II IgG and FcR 
FcR dependant cell 
destruction 
Blood cell 
dyscrasia 
Covalent 
B-
cell 
Type III 
IgG and 
complement or 
FcR 
Immunocomplex 
deposition 
Vasculitis  Covalent 
B-
cell 
Type IVa Th1 (IFN-у) 
Monocyte 
activiation 
Eczema 
Covalent/non-
covalent 
T-
cells 
Type IVb 
Th2 (IL-5 and 
IL-4) 
Eosinophilic 
inflamation 
MPE, BE 
Covalent/non-
covalent 
T-
cells 
Type IVc 
CTL (perforin 
and granzyme 
B) 
CD4+ or CD8+ 
cytotoxicity 
MPE, 
eczema, BE 
and PE 
Covalent/non-
covalent 
T-
cells 
Type IVd T-cells (IL-8) 
Neutrophil 
recruitment and 
activation 
PE 
Covalent/non-
covalent 
T-
cells 
 
Table 1.2- Extended Coombs and Gell classification of immune-mediated adverse drug 
reactions. MPE (Maculopapular exanthema), BE (Bullous exanthema), PE (Pustular 
exanthema). Adapted from (Pichler, 2003). 
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1.4 Immune activation  
1.4.1 Components of the immune system  
The immune response includes both innate and adaptive immunity. Innate immunity 
is a generalised, non-specific reaction usually resulting from infection or tissue 
trauma/damage. Adaptive immunity is an acquired reaction, which in particular 
recognises antigens. An enormous range of cell types are included in both innate and 
adaptive immune responses. Most but not all of the immune cells are continuously 
replaced as they have short life span. Pluripotent stem cells located in the bone 
marrow are the main origin of all cell types, which depend on different stimuli, 
involving hormones and cytokines for differentiation. Immune cells are grouped into 
categories, each with a particular task.  
 
Lymphocytes 
Leukocytes or white blood cells are immune cells involved in defending the body 
against foreign materials and infectious disease. Approximately 20% of the 
leukocytes found in blood are lymphocytes. Lymphoid progenitor cells produce 
natural killer (NK), B and T cell subsets and each one of them have their unique 
developmental pathways and functions. Initially B-cells develop in the foetal liver 
then they migrate to the bone marrow for further maturation. Production and 
secretion of antibodies is the main function of B-cells. Immunoglobulins are 
expressed by B-cells and they serve as antigen receptors. B-cells proliferate and 
differentiate in to either memory or plasma cells following antigen exposure. The 
antibodies secreted by plasma cells exhibit the same antigenic specificity as the 
immunoglobulins expressed on the cell surface. These antibodies have a number of 
functions including complement fixation, the shielding or neutralisation of viral 
components and coating or opsonisation of antigen to enhance phagocytosis. Long-
lasting memory cells are also produced but in a small number. They circulate in an 
inactive state but promptly respond when exposed to the antigen again. This can be 
related to the high affinity IgA or IgG molecules expressed on memory cells, where 
as naïve cells express lower affinity IgD and IgM molecules. B-cells can be 
recognised experimentally by the expression of cell surface markers (e.g. CD19). 
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Immediate hypersensitivity reactions to   drugs   such   as   the   β-lactam antibiotics are 
associated by the release of specific IgE antibodies (Torres et al., 2003).   
 
T-cells originate from the thymus. Antigenic specificity of T-cell is determined by T-
cell receptors and each T-cell will express only one TCR since they recognise only a 
small number of antigens. The TCR, in comparison to B-cells, recognises only a 
small part of the antigen with just a limited number of amino acids. When exposed to 
an antigen, antigen-specific T-cells bearing the corresponding TCR will divide and 
differentiate to produce an abundant population of effector T-cells. A great number 
(>95%) of newly developed thymocytes will be removed by positive selection 
(Romagnani, 2006). Some T-cells will die as a result of negligence as their expressed 
TCRs have no affinity for MHC-peptide complexes. After that surviving cells go 
through negative selection which stimulates apoptosis only in T-lymphocytes 
expressing TCRs with high affinity for self-peptides that exist on the medullary 
epithelial cell surface (Romagnani, 2006). T-cells subsets express either CD8 or CD4 
molecules. Initially this was thought to relate to the function of effector T-cells; 
CD8+ T-cells were denoted as cytotoxic cells while CD4+ T-cells were helper cells. 
However, this peculiarity is no longer 100% applicable as some CD4+ T-cells can 
also exhibit cytotoxic activity (Marshall and Swain, 2011).  
 
Effector cytotoxic CD8 T cells (CTLs) provide important protection against a range 
of intracellular viral and bacterial infections and are in charge for anti-tumour 
responses (Barber et al., 2006; Bos et al., 2012; Condotta et al., 2012). Infected cells 
exhibit pathogenic peptides derived from cytosolic proteins which can be recognised 
by CD8 T cells, as MHC class I proteins present on the surface of almost each 
nucleated cell of the body. The significance of CTL function is highlighted in 
different settings of diseases such as chronic viral infections involving human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus (HCV) 
and tumours involving melanoma, prostate, lung and ovarian malignancies which are 
an outcome of CTL dysfunction (Shin and Wherry, 2007; Matsuzaki et al., 2010; 
Chou et al., 2012; Fourcade et al., 2012; Prado-Garcia et al., 2012). Activated 
antigen-specific CD8 T cells start to secrete IL-2 upon dendritic cell mediated 
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competent co-stimulation and antigen stimulation in the lymph node. This functions 
in an autocrine mode by binding to its high affinity IL-2R on the surface of T cell, 
therefore driving its functional differentiation and exponential clonal expansion into 
effector CTLs (Boyman and Sprent, 2012). CD8 T cell differentiation is mainly 
dependent on the transcriptional activity of T-box transcription factors, T box 
expressed in eomesodermin (EOMES) and T cells (T-bet) (Kaech and Cui, 2012). 
Then the resultant CTLs enter into the blood stream and migrate to infection sites 
where their effector activity generally uttermost at day seven post-infection (Obar et 
al., 2008). Cytotoxic T lymphocytes attack infected cells via various mechanisms 
including cytokine secretion and cellular-mediated cytotoxicity (Topham et al., 
1997; La Gruta et al., 2004). CTLs secrete cytolytic effector molecules including the 
pore-forming perforin and proteases granzyme A and B upon antigen recognition in 
combination with MHC I on the target cell. Perturbation of the target cell membrane 
by perforin enhances the entry of granzyme A and B which starts a caspase apoptotic 
dependent pathway, eventually leading to cell death (Lieberman, 2003). In addition, 
CTLs secrete proinflammatory cytokines such as TNF-α  and  INF-γ  (La Gruta et al., 
2004). Inhibition of viral replication and promotion of MHC I expression on infected 
cells are enhanced by INF-γ.  This result in increasing infected cells probability of 
being targeted by activated CTLs. Secretion of TNF-α   stimulates   innate   immune  
cells and activates caspase-dependent cellular apoptosis through ligation with its 
TNFR-1 cognate receptor on the target cell. Co-stimulation is vital for CTL effector 
role. Obviously, CD28 signalling is accompanied with stimulation of IL-2 secretion. 
Subsequently, this initiates functional differentiation of CTLs via increasing perforin 
and granzyme expression (Janas et al., 2005; Williams et al., 2006).  
 
One of the important factors that affect the CTL effector response is the CD8 TCR 
antigen affinity. In general, cross-presented tumour or self-antigens with low avidity 
will be disregarded by CD8 T cells, leading to absence in effector response even in 
the existence of a viral infection (Bos and Sherman, 2010). CD8 T cells with a 
higher affinity for the tumour antigens, leads to enhanced granzyme B and perforin 
expression, induction of tumour irradiation and decline in co-inhibitory receptor 
expression (Bos et al., 2012). In these situations the requirement for greater CTL 
effector function is enabled by the provision of CD4 T cell help (Bos and Sherman, 
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2010). CD8 T cell stimulation and differentiation is enhanced by CD4 T cells 
through different mechanisms including secretion of IL-2 and IFN-γ   and   activated  
CD4 T cell (Bos and Sherman, 2010). CD4 T cells can also directly interact with 
dendritic cells through ligation of CD40:CD40L. This allows upregulation of 
dendritic cell CD80/86 co-stimulatory receptor expression, leading to more 
proficient priming of CTL immune response (Bos and Sherman, 2010).  
 
CD4+ T-cells can be divided based on the cytokines they secrete. Naïve cells are 
named as type 0 (Th0) cells, prior to antigenic exposure. When IL-2 is present, Th0 
cells are activated and convert into Th1 cells. In contrast, in the presence of IL-4, 
Th2 cells will be produced. Subsequently Th1 cells secrete IL-2 and IFN-γ, while 
Th2 cells secrete IL-13, IL-4, IL-5 and IL-9 when activated (Mosmann and Coffman, 
1989). These various cytokine profiles then affect the immune response that takes 
place; Th1 cytokines induce cell-mediated immunity while a humoral (B-cell) 
response will be induced in the presence of Th2 cytokines. One of the relatively 
newly discovered T-cell subset is the Th17 secreting cells (Harrington et al., 
2005).These cells are believed to play a role in some diseases such as multiple 
sclerosis and rheumatoid arthritis (Tesmer et al., 2008). It is believed that IL-17 
secreting T-cells can develop along this lineage following a signal from IL-1β  
(Acosta-Rodriguez et al., 2007). Drug-specific T-cells with differing cytokine 
profiles have been isolated from the peripheral blood of patients with different forms 
of drug-induced skin reaction. In contrast, the role of T-cells in drug-induced liver 
injury is less well-defined.     
 
A small number of lymphocytes are classified as natural killer (NK) cells based on 
expression of the cell surface marker CD56. They respond promptly to viral 
infection as they do not express antigen receptors. NK killing activity is mediated by 
granzyme and perforin molecules which are released either directly or in vesicles. It 
was thought previously that NK cell activation is non-specific; however recent 
studies show activation is dependent upon the expression of a number of activating 
and inhibitory receptors. Killer-cell immunoglobulin-like receptors (KIRs) are an 
example of one of the inhibitory receptors and they are specific for a variety of 
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ligands including MHCclass I molecules. CD244, DAP-12 and NKG2D are all 
considered as activating receptors (Lanier, 2008).  The balance between the activities 
of these receptors is the main determinant of the activation state of the NK cell.  
 
Phagocytes  
The main role of the phagocyte is to engulf and digest pathogens such as bacteria. 
This can be attained in different ways and the various phagocyte subsets are 
discussed below.   
 
The myeloid progenitor cell is the origin of monocytes. Monocytes migrate into 
tissues after circulating in blood. They then differentiate into macrophages. 
Macrophages have the ability to break down pathogens as they have numerous 
lysosomes containing digestive enzymes. Cell surface expression of CD14 is used as 
a marker to identify these cells in vitro. Generally, macrophages remain in tissues 
when matured and only a small number will return to the circulation. Highly-
specialised macrophages that reside in liver are known as kupffer cells. 
  
Approximately 70% of the leukocytes found in the blood are neutrophils. 
Chemoattractants such as IL-8 influence the migration of neutrophils into the tissue 
as they are somewhat short lived in the circulation. Neutrophils contain several 
different granule types hence they are often referred to as granulocytes. These 
include acidic lysosomes and tertiary, secondary and primary granules. They contain 
digestive molecules such as myeloperoxidase and lactoferrin. Neutrophils are 
recruited to sites of local tissue damage and activation results in degranulation and 
consequently recruitment of other cell types.  
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Accessory cells  
Accessory cells work along with lymphocytes to induce an immunological response. 
Mast cells, basophils and eosinophils cells all have a granular morphology and 
secrete different mediators when stimulated. Major basic protein is the main 
constituent of eosinophil granules and it is a cationic molecule able to directly 
destroy pathogens. Eotaxin and IL-5 secretion results in eosinophil recruitment to an 
inflammation site. The main mediators of the inflammatory response i.e. 
prostaglandins, cytokines, leukotrienes are synthesised by eosinophil. Basophil 
granules comprise inflammatory mediators such as leukotrienes, IL-4 and histamine. 
The main constituent of mast cell granules is also histamine. 
 
 Dendritic cells (DCs) are often referred to as professional antigen presenting cells. 
Circulating DCs that have low levels of costimulatory molecule and MHC class II 
expression and low T-cell activation potential, but high endocytic activity are 
referred to as immature cells and they develop into mature DCs upon antigenic 
exposure. Maturation leads to an increase in costimulatory molecule expression 
(Sallusto et al., 1998), decreased endocytic capability (Cella et al., 1996), but 
increased levels of MHC class II expression (Sallusto et al., 1995). Other signals that 
enhance maturation of dendritic cells include toll-like receptor signalling by 
components of bacteria and secretion of damage-associated molecular patterns 
(DAMPs) such as heat shock proteins, HMGB1 and uric acid, and release of 
pathogen associated molecular patterns (PAMPs) such as lipopolysaccharide (LPS) 
(Shi et al., 2003). 
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1.4.2 Antigen processing, presentation and cross presentation                                                                                     
The key element of adaptive immunity is specific-antigen recognition by T-cells. As 
mentioned previously, the TCRs expressed by T-cells are specific for MHC-peptide 
complexes. Appropriately, most antigens must be presented in the context of an 
MHC molecule to be recognised.  
 
Antigen-presenting cells follow two distinct pathways for antigen processing [Figure 
1.1]. The first pathway involves intracellular antigens bound to MHC class I 
molecules. Viral infection is one of the usual forms of intracellular antigen.Viral 
proteins are secreted into the cell cytosol of the host following virus entrance and 
replication. Proteosomes degrade the proteins either in the nucleus or cytosol. 
Subsequently, peptides are translocated to the endoplasmic reticulum (ER) through a 
transporter accompanied by antigen processing (TAP)-dependent pathway. The 
MHC class I heterodimer is then formed in the ER with the peptide fragment needed 
for stability (Neefjes et al., 2011). For antigen presentation, the complex is released 
and travels to the surface of the cell. MHC molecules not associated with peptides 
are returned to the cytosol to be degraded (Hughes et al., 1997). Intracellular derived 
peptides are presented to CD8+ T-cells by MHC class I molecules.  
 
The second pathway involves extracellular antigens. Highly specialised antigen-
presenting cells such as macrophages and dendritic cells are the only cells which can 
process antigens in this particular way. Pathogens enter the cell by phagocytosis and 
enclosed into an endosomal vesicle where they are digested by enzymes into peptide 
fragments. MHC class II molecules are transported in membrane-enclosed vesicles 
from the endoplasmic reticulum. These vesicles then fuse with the endosome 
permitting peptide loading to occur. MHC class II molecules are then transported to 
the plasma membrane in order to present their loaded peptide fragments to CD4+ T-
cells (Neefjes et al., 2011).   
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Figure 1.1- Antigen processing and presentation. Extra and intra-cellular pathways of 
processing.  Extracellular antigens engulf by phagocytosis and degraded by endosomal 
enzymes. MHC class II molecules are transported in vesicles coming from the endoplasmic 
reticulum (ER) and golgi apparatus. These vesicles fuse together with the phagolysosome 
and this is where loading of peptide occurs. The peptide bound MHC is then transported to 
the surface of the cell where the antigen is displayed. Intracellular antigens are broken 
down in the proteasome. Peptides are transported to the ER through TAP and attach to 
MHC class I molecules. The peptide bound MHC is then transported again to the golgi 
where it is loaded into a vesicle and trafficked to the surface of the cell. Adapted from 
(Neefjes et al., 2011).    
 
Some dendritic cell subsets particularly the CD8+ lymphoid dendritic cells can 
uniquely present exogenous cell associated antigens from infected or dying cells in 
the  context  of  MHC  I  molecules  to  naïve  CD8  T  cells,  a  phenomenon  called  “cross-
presentation” (den Haan et al., 2000; Belz et al., 2005). In the case of intracellular 
viral infection, presentation of MHC I peptide complex to CD8 T cells depends on 
the dendritic cell to be infected itself as shown with the classical endogenous MHC I 
pathway. However, viruses can make use of certain mechanisms to severely 
encumber MHC I presentation in infected dendritic cells therefore avoiding cytotoxic 
CD8 T cell immunity (Nopora et al., 2012). Mechanisms of cross priming provides a 
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way by which uninfected dendritic cells can stimulate CD8 T cell immune responses 
via the processing of cell-associated antigens derived from endogenous viral infected 
cells (Nopora et al., 2012). Moreover, it is important for priming CD8 T cell anti-
tumour reactions in response to exogenous tumour self-antigens expressed by 
unhealthy or dying cells (Hoffmann et al., 2000). Not like, the exogenous MHC II 
pathway, cross-presentation takes place in early endosomes or nascent phagosomes 
(Houde et al., 2003) typified by their neutral pH and mostly depends on their 
exogenous material transport into the cytosol for proteasomal degradation (Blum et 
al., 2013). Thus, maturation of phagosomes into advanced proteolytic active 
endosome compartments is not essential. Similar to MHC I presentation, cross-
presentation is a constitutive process in immature dendritic cells and has a significant 
role in maintaining CD8 T cell tolerance (Kurts et al., 1998). This proceeds via 
immature dendritic cell presentation of extracellular self-antigens in the context of 
MHC I to autoreactive CD8 T cells, which leads to their deletion from the T cell 
repertoire and eventually prevents the beginning of autoimmune responses (Kurts et 
al., 1997; Kurts et al., 1998; Heath and Carbone, 2001). For instance the cross-
presentation of cell-associated antigens derived from necrotic or apoptotic cells. 
These cells are internalised via phagocytic mechanisms into phagosomes and are 
incompletely degraded, after that they are expulsed to the cytosol and headed for 
proteasomal degradation (Blum et al., 2013). The consequential antigenic peptides 
are then transported to the endoplasmic reticulum through TAP where they are 
loaded onto MHC I molecules and transported to the cell surface (Kovacsovics-
Bankowski and Rock, 1995). The phagosome itself is also able to obtain the 
optimum components for efficient exogenous MHC I peptide loading through fusion 
with endoplasmic reticulum derived vesicles. In this respect, the acquired dying cell 
is to some extent degraded in the endoplasmic reticulum fused phagosome and the 
yielded proteins are transported from the fused phagosome to the cytosol through the 
transporter Sec61, where they are directed to the proteasome for more degradation. 
The yielded peptides are then returned back into the phagosome through TAP where 
the peptide is loaded onto the MHC I and transported to the dendritic cell surface 
(Houde et al., 2003). Cross-presentation can also carry on through proteasome 
independent mechanism and TAP (Bachmann et al., 1995). In this mechanism, 
acquired dying cells are transported through the phagosome to vacuolar post-golgi 
compartments where they are degraded into smaller peptide fragments through 
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proteases. Recycled MHC I from the dendritic cell surface is attained within these 
phagocytic vesicles. The peptide is then loaded onto the MHC I and the MHC I 
peptide complex is transported afterword to the dendritic cell surface (Trombetta and 
Mellman, 2005).                           
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1.4.3 Intracellular signalling following activation of TCR 
A signalling cascade is triggered when the MHC-peptide is engages with the TCR. 
This cause cellular differentiation, proliferation and/ or growth factor/cytokine 
release. The process of the signal transfer across the cell membrane (TCR-triggering) 
is complex, and not fully understood. Currently suggested models propose either 
conformational segregation, aggregation or change of the TCR-CD3 complex 
(Choudhuri et al., 2005). Much more is understood about the signalling cascades 
after TCR triggering. An early event in T-cell signalling is stimulation of tyrosine 
protein phosphorylation by the Src kinases Fyn and Lck (Nel, 2002). 
Immunoreceptor tyrosine phosphorylation based activation motifs (ITAMs) within 
CD3 by itself functions as a docking site for other proteins particularly ZAP-70 
(Smith-Garvin et al., 2009). In this manner the TCR comes to be a phosphorylation 
site for an enormous range of substrates commencing multiple signalling pathways 
that eventually result in T-cell activation. ZAP-70 targets are the SH2 domain-
containing leukocyte phospho-protein of 76kDa (SLP-76) and a transmembrane 
adapter protein linker for T-cells (LAT). The eventual consequences of TCR 
activation involve activation of enzymes (e.g. PKC, ERK, JNK), release of 
transcription factors (e.g. STAT3, NFAT) and the production of signalling molecules 
such as DAG and Ca2+.   
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1.5 Drug-induced skin injury (DISI)  
In T-cell mediated hypersensitivity reactions, the skin is the organ most frequently 
involved; either in isolation or as a component of a generalised hypersensitivity 
reaction. The reason why skin is affected much more commonly than other organs 
may be due to the rich vascularisation, large surface area, dense network of T-cells 
and APCs ready to stimulate an immunological response (Keller et al., 2005; Clark 
et al., 2006). The severity of skin injury symptoms depend on both the individual and 
the chemical/drug administered. Reaction severity ranges from mild inflammation to 
life-threatening reactions such as Stevens-Johnson syndrome.   
 
The   term   “drug   induced   skin   injury”   was   proposed   by   Pirmohamed   and   his  
colleagues in the Phenotype Standardisation Project (PSP). The main objective of 
this consortium was to improve the phenotyping of various types of severe adverse 
drug reaction (Pirmohamed et al., 2011b). Mainly three types of adverse drug 
reactions were included under the umbrella of this project: drug induced skin injury 
(DISI), drug induced liver injury (DILI) and drug induced torsade de pointes 
(DITdP). The main goal for the PSP was to address the necessity for sufficient 
cohorts of patients to study the genomic basis of certain adverse drug reactions to 
determine individuals at risk. The project also aimed to ensure correct 
epidemiological patient classification to enable regulators, industry researchers and 
clinicians to correctly identify various types of adverse drug reactions (Pirmohamed 
et al., 2011a). The focus in the following discussion will be mainly on the serious 
types of adverse drug reactions involved in both DISI and DILI.     
 
Drugs can stimulate various forms of DISI including maculopapular exanthema 
(MPE), acute generalised exanthematous pustulosis (AGEP), Steven-Johnson 
Syndrome (SJS), toxic epidermal necrolysis (TEN) and drug reaction/rash with 
eosinophilia and systemic symptoms (DRESS). The immune pathophysiology and 
clinical features of these serious reactions is discussed below.    
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1.5.1 Immune cells in the skin  
Traditionally, it was thought that the skin is no more than a biochemical and physical 
barrier defending organisms from external agents. However, in recent years it has 
been revealed to have an important role in the immunological response, as its cellular 
components includes macrophages, mast cells, keratinocytes, dermal dendritic cells 
and epidermal Langerhans cells, which function as static skin constituents to release 
proinflamatory cytokines and enhance the recruitment of other cells that are part of 
the dynamic immune response. These cells include antigen-presenting cells (APCs) 
such as macrophages, monocytes, dendritic cells and T lymphocytes expressing skin-
homing receptors such as the cutaneous lymphocyte antigen (CLA) and chemokine 
receptors (e.g. CCR6, CCR4, CCR10), which represent the cellular baseline of the 
immune memory within the skin (Bos and Kapsenberg, 1993; Blanca et al., 2000; 
Fernandez et al., 2009).  
 
Keratinocytes are located in the epidermis and plays a key role in DISI. 
Keratinocytes detect pathogens by expressing several pattern recognition receptors, 
including Toll-like receptors (TLRs) that identify a wide range of pathogen 
components, Nod-like receptors (NLRs) Nod1 and Nod2, which react to bacterial 
peptidoglycan and NLR pyrin domain-comprising proteins that interact with fungal 
and viral pathogens. C-type lectins such as dectin-1 respond to fungal infections, 
whereas expression of RIG-I-like receptors (RLRs) supports detection of viral RNA 
(Heath and Carbone, 2013).  
 
Keratinocytes can release immense range of microbiocides including antimicrobial 
peptides   such   as   β-defensins and LL-37, as well as S100 and RNases family 
members. Chemokines and cytokines can also be produced by keratinocytes in 
response to pathogen invasion, including CCL20, CXCL11, CXCL10, CXCL9, IL-
33, IL-18, IL-10, IL-6, IL-1α,  IL-1β  and  TNF-α  (Nestle et al., 2009; Meephansan et 
al., 2012). Cytokines support effectors and direct the immune response to guarantee 
effective elimination of pathogens, whereas chemokines are crucial regulators of 
effector cell migration in the skin (Zhu et al., 2010; Nagao et al., 2012).  
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Dendritic cell (DC) subsets existed in the human skin have been studied extensively. 
There are four different subsets of DCs in the human skin including Langerhans 
cells, CD14+ DCs, CD1c+ DCs and a recently identified CD141+ DC subset 
(Haniffa et al., 2012). The CD141+ DC subset is important for viral immunity and 
CD8+ T-cell responses. The other important DC subset is the Langerhans cells, 
which are located in the epidermis above the keratinocytes. Traditionally, 
Langerhans cells were thought to be responsible for priming skin immunity. 
Furthermore, researchers have shown they have an important role in the initiation of 
immune responses against contact allergens (Allan et al., 2003; Kaplan et al., 2005). 
It has also been shown that Langerhans cells play a role to priming skin immunity 
against pathogens such as bacteria (e.g. Staphylococcus aureaus) and yeast (e.g. 
Candida albicans) through differential stimulation of Th17, Treg and effector T-cell 
(Heath and Carbone, 2013). 
 
A  number   of   αβ  T-cells reside in the skin may have a memory phenotype. These 
memory T-cells are CD4+ and CD8+ positive, with approximately 10% of the CD4+ 
T-cells expressing Foxp3 representing a Treg phenotype (Heath and Carbone, 2013). 
A subset of cells is called tissue-resident memory cells (TRM); these cells are 
disconnected from the blood circulation and remain permanently in the skin. These 
cells are thought to provide protection against a range of pathogens (Gebhardt et al., 
2009).                                             
 
1.5.2 Clinical presentation and mechanisms of DISI  
The reasons why a drug administered parentally or orally commonly targets the skin 
have not be fully defined. Most of DISI (>90%) is benign MPE (Hunziker et al., 
1997). Reactions initially appear on the upper extremities and trunk then spread 
more widely (Roujeau, 2005). Usually reactions are detected in the first two weeks 
after drug treatment; however, reactions with a later onset have been reported.  
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All types of DISI differ in the effector cell phenotype and cytokine secretion profile 
of activated T-cells. CD8+ T-cells are thought are thought to be dominant in TEN, 
whereas CD4+ T-cells dominate in MPE and AGEP. Research studies on skin have 
revealed that IL-5 is the main cytokine in MPE. IL-5 is important as it is involved in 
the recruitment of eosinophils to the site of inflammation (Pichler et al., 1997). IFN-γ  
and IL-8 are released by drug-specific T-cell in pateints with AGEP (Britschgi et al., 
2001; Roujeau, 2006). IFN-γ   upregulates   MHC   class   II   on   keratinocytes   surface  
making them more prone to T-cell mediated killing, while IL-8 is involved in the 
recruitment of neutrophils to the site of inflammation (Friedmann et al., 1994; 
Roujeau, 2006). Patients with SJS/TEN have high levels of granulysin in their blister 
fluids (Nassif et al., 2004b; Chung et al., 2008), together IFN-γ  and  TNF-α,  which 
collectively induce keratinocyte cytotoxicity(Friedmann et al., 1994).  
 
DRESS is also known as hypersensitivity syndrome (HSS). DRESS begins later than 
other types of DISI and can be seen even after 2-6 weeks after treatment initiation. 
Liver involvement can increase the mortality rate of DRESS up to 10% (Roujeau, 
2005). Drug-specific T-cells that release high levels of IFN-γ  and  IL-5 are detected 
in the blood of patients with DRESS (Naisbitt et al., 2003b). Viral reactivation is 
frequently observed in the course of DRESS; thus, it can be utilised as a diagnostic 
criterion (Suzuki et al., 1998; Tohyama et al., 1998). Still, it is not fully understood 
what role this reactivation has in the pathophysiology of the disease and whether it is 
a consequence or cause of the clinical manifestations. Reactivation of human herpes 
virus 6 (HHV-6) is detected by increasing levels of particular viral DNA and IgG. 
However, this usually is not measurable until many weeks after symptoms appear 
(Shiohara et al., 2006). Thus, it is likely that viral reactivation is caused by T-cell 
activation. Transient increases in virus-specific immunoglobulins against HHV-7, 
Epstein-Barr virus (EBV) and cytomegalovirus (CMV) have also been detected in 
patients with DRESS (Aihara et al., 2001; Descamps et al., 2003; Picard et al., 
2010). Cells from skin lesions have been analysed and found to contain high levels 
of HHV-6 DNA and express viral antigen at an early stage (Suzuki et al., 1998). 
Therefore it is still theoretically possible that certain clinical manifestations result 
from virus-specific T-cells expansion (Shiohara et al., 2006).  
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SJS/TEN is the most serious form of DISI. The main characteristic is blistering skin 
lesions. Nowadays, it is believed that both SJS and TEN are involved within the 
same disease spectrum with different degree of skin detachment and this difference 
is being used to delineate each type (Bastuji-Garin et al., 1993; Mockenhaupt, 2011). 
SJS and TEN have a high mortality rate with approximately 10% and >30%, deaths 
reported respectively. Death usually happens as a consequence of pulmonary 
symptoms or sepsis. Treatment often requires a specialist from burns unit with 
expertise in dealing with extensive skin loss. Table 1.3 illustrates the common 
characteristics of SJS/TEN and DRESS.  
 
TEN is a CD8+ T-cell mediated reaction (Schwartz et al., 2013). Histopathology 
shows that keratinocyte death in the epidermis initially results from apoptosis, which 
subsequently leads to necrosis and skin detachment (Paul et al., 1996). NK T-cells 
are also involved in the pathogenesis as the skin lesions contain high numbers of 
these cells (Chung et al., 2008). Blister fluid contains high levels of the soluble 
mediator granulysin and granulysin levels have been shown to correlate with clinical 
severity (Chung et al., 2008). Therefore, measurement of granulysin levels in the 
serum of patients with TEN can be used as an early diagnostic marker (Abe et al., 
2009).             
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Symptom 
Drug-induced skin injuries 
SJS TEN DRESS 
Mucous membrane >90% >90% <30% 
Erosions Several sites Several sites Mouth and lips 
Detachment of epidermis 
Yes <10% of 
BSA 
Yes >30% of 
BSA 
No 
Hyperkeratosis/desquamation No No Usual 
Neutropenia NO 30% No 
Eosinophilia No No 90% 
Atypical lymphocytes No No 30-40% 
Respiratory tract 
Bronchial 
Erosions/ARDS 
Bronchial 
Erosions/ARDS 
Interstitial 
pneumonitis 
Liver Hepatitis 10% Hepatitis 10% Hepatitis 60% 
Heart No No Myocarditis 
Lymph node enlarged No No Usual 
Viral reactivation Occasional Occasional Frequent 
 
Table 1.3- Features of the most serious DISI. (BSA) body surface area, (ARDS) acute 
respiratory distress syndrome. Adapted from (Bachot and Roujeau, 2001).   
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1.6 Drug-induced liver injury (DILI)  
Drug-induced liver injury is a rare but serious health problem with an incidence rate 
of 1 in 10,000 and 1 in 100,000 (Holt and Ju, 2006). DILI is one of the main causes 
for the withdrawal of newly marketed drugs. Identifying hepatotoxic drugs during 
the development process is not easy, because reactions are not predictable in pre-
clinical animal models or in in vitro humanised experimental systems (Kaplowitz, 
2005). This is particularly applicable with the idiosyncratic reactions that are thought 
to involve the immune system (Holt and Ju, 2010). DILI is usually seen when the 
drug is marketed and exposed to several thousand patients (Watkins, 2005). Cautious 
monitoring is needed, because liver injury is often not seen until weeks or even 
months after the initiation of drug treatment (Wilke et al., 2007).  
 
1.6.1 Immune cells in the liver 
The liver is an organ that is rich in haematologic and lymphoid cells. A vast array of 
immune cells which participate in both innate and adaptive immunological responses 
are present. The innate cells in the liver include kupffer cells (liver resident 
macrophages), NK cells, NK T-cells and liver sinusoidal endothelial cells. They 
come in to contact with the antigens circulating in the blood passing via the liver 
sinusoids and act as a first line protection. For the liver, it is vital to maintain a 
tolerance state to a wide range of antigens, as it is constantly exposed to antigens 
from the gastro-intestinal tract. This is accomplished by the host genetics and by 
maintaining high stimulus threshold before activation (Knolle and Gerken, 2000).  
Kupffer cells and sinusoidal endothelial cells are able to present antigens to T-cells, 
which may activate their effector function. The subsequent response is primarily 
based on the local production of chemokine and cytokine, since they control the 
recruitment of immune cells to the site of inflammation and/ or infection (Knolle and 
Gerken, 2000).        
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1.6.2 Mechanisms of DILI 
Liver cell injury occurs in different patterns based on the affected organelles. Cell 
membrane injury can lead to disturbance of calcium homeostasis: Mg+2 and Ca2+ 
ATPases are essential molecules that sustain the intracellular balance. Reactive drug 
metabolites can attach to important proteins resulting in loss of cellular integrity 
disturbance. Disturbed level of intracellular calcium leads to actin filament 
disassembly, cytoskeleton dispersal, bleeding of the cell membrane, and 
subsequently rupture and lysis of the cell (Watanabe and Phillips, 1986; Cullen, 
2005).  
 
Cholestatic and canalicular injury: to enable bile salt secretion a series of ATP-
dependent transporters are required. These transporters enhance bile movement from 
hepatocytes to the canalicular lumen. Chemicals that attach to canalicular transporter 
molecules can induce cholestasis leading to the prevention of bile formation or 
circulation within the lumen (Lee, 2003; Cullen, 2005).  
 
Metabolic bioactivation: Cytochrome P450 is a group of oxidising enzymes found in 
hepatocytes, within the smooth endoplasmic reticulum. They are responsible for 
phase-I drug oxidation, converting the parent compound into more hydrophilic 
intermediates that undergo phase-II conjugation. The most common mechanism of 
hepatocellular injury includes secretion of harmful reactive metabolites by the 
cytochrome P450 system. Conjugation by phase-II enzymes generally controls 
exposure to reactive intermediates and prevents toxicity. However, reactive 
metabolites with high energy may exceed the detoxification pathway and produce an 
adduct with cellular proteins. Adduct formation can inhibit essential cellular 
processes, resulting in stress and cellular injury through apoptotic or necrotic 
mechanisms (Baron and Merk, 2001; Oesch et al., 2007).  
 
Drugs can theoretically stimulate the hepatic adaptive immune system via either a 
prohapten/hapten mechanism or pharmacological interaction (p-i) pathway. To date, 
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there is only one study characterising drug-specific T-cell responses in patients with 
DILI. Maria and Victorino detected drug-specific proliferative responses in 
approximately 50% of patients with DILI using the lymphocyte transformation test 
(Maria and Victorino, 1997). However, these lymphocytes were not characterised in 
terms of phenotype and function and additional studies have not been forthcoming.             
 
1.6.3 Clinical presentation of DILI 
Clinical presentation of DILI can take the form of any of the following:  
 Acute hepatitis which presents as nausea, fever, malaise, jaundice (in certain 
pateints) and a raise in serum transaminases. Pathohistological examination 
reveals necrosis of liver parenchyma and infiltration of the portal tract with 
immune cells particularly eosinophils, plasma cells and lymphocytes. Viral 
hepatitis shows a similar pathohistological picture. Drugs such as 
carbamazepine, rifampicin and isoniazid are associated with this particular 
type of liver injury (Talbot, 1975).  
 Cholestatic hepatitis presents commonly with jaundice, high levels of 
conjugated bilirubin and serum transaminases. Pathohistological examination 
reveals retention of bile in bile canaliculi and hepatocytes. Other features of 
this type of DILI include infiltration of lymphocytes in the portal tract and 
minimal hepatocyte necrosis. The most common causative therapeutic drugs 
include methyldopa, chlorpromazine, dapsone, cotrimoxazole (Talbot, 1975) 
and flucloxacillin (Russmann et al., 2005).    
 One of the most severe forms of DILI is hepatic necrosis with confluent 
necrotic patches in liver parenchyma; hepatocytes are usually surrounded by 
fat infiltration. Patients pass in to coma following a period of restlessness. 
Eventually coagulopathy of blood and jaundice are apparent. Drugs 
associated with this fulminant type of liver injury e.g. monoamine oxidase 
inhibitors, halothane and imipramine (Talbot, 1975).     
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1.7 The major histocompatibility complex  
The key aspect of drug hypersensitivity research is individual variation. 
Susceptibility of certain individuals to a reaction is influenced by polymorphisms in 
drug metabolising enzymes. Recent genome-wide association studies however 
propose a much more important role for genes within the region of MHC. 
 
1.7.1 Location and variation  
 The MHC region consists of a cluster of genes around 3.4Mb on the short arm of 
chromosome 6. Genes in this particular region play an important role in both innate 
and adaptive immunity (Daly et al., 2001).  Within the human genome, the MHC 
region is the most polymorphic region. The MHC class I and II genes in humans are 
specifically termed as human leukocyte antigen (HLA) class I and II genes.  
 
1.7.2 MHC class I 
Almost all nucleated cells express MHC class I molecules. They include the HLA-A, 
HLA-B and HLA-C loci. Class I molecules involve one gene encoding a 
polymorphic  light  chain  (α)  and  share  a  common  β-chain  (β2m). The latter gene is not 
situated in the MHC region. β2m plays an important role in transporting newly 
synthesised MHC molecules to the cell surface. The peptide-binding groove can 
accommodate peptide of between lengths 9 and 11 amino acids and is constrained at 
both ends. Van der Waals forces and hydrogen bonds both help secure the peptide in 
place.  
 
1.7.3 MHC class II  
In comparison to the MHC class I molecules, class II molecules are only expressed 
by highly specialised antigen-presenting cells like B-cells, macrophages and 
dendritic cells. They include the HLA-DR, HLA-DQ and HLA-DP loci. Both genes 
for   the   α   and   β   chains   are   situated   in   the   MHC   region.   Unlike MHC class I 
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molecules, MHC class II molecules can accommodate longer peptides in their 
peptide-binding groove since they are open at both ends.  
 
1.7.4 MHC class III 
The MHC region is the site of many other genes besides the genes encoding antigen-
presenting MHC class I and II molecules. These genes play a key role in the 
immunological response. They involve loci encoding genes linking to the 
complement cascade, inflammatory mediators such as leukotrienes, heat shock 
proteins such as Hsp70 and cytokines such as TNF-α.   
 
1.7.5 HLA nomenclature  
 The array of HLA alleles that are now known were not anticipated when first 
discovered. Therefore several changes have been made to the way in which they are 
identified. HLA-A and HLA-B antigens were initially described by Dausset in 1958 
(Dausset, 1958). The HLA-C locus was not identified until the year 1970 (Thorsby et 
al., 1970). And eight years later, the first class II alleles were discovered (Albert et 
al., 1978). Original classification relied on serological typing using the 
microlymphocytotoxicity assay of (Terasaki and McClelland, 1964). T and B-
lymphocytes were collected from the patients and exposed to an array of antisera 
containing antibodies to each HLA molecule. Reactivity of the antibody was used to 
identify the antigens expressed at the cell surface. However, sequencing of the gene 
now means that individual amino acids variations that could not be identified using 
serologic techniques are now detectable. This required a new technique for naming 
alleles and it is this system that is still used today. The locus is identified by the letter 
immediately following HLA (e.g. A, B, C). The star immediately succeeding 
indicates that the allele has been allocated depending on molecular typing methods. 
Then a series of numbers follow this. The first two digit numbers indicate the type. 
In most cases this corresponds to the type that would be given by serology. The sub-
type is identified by the next two numbers. These numbers are assigned sequentially 
when new alleles are identified and highlight variations in the sequence of the amino 
acid. Both the fifth and sixth digits are used to signify polymorphisms that do not 
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influence the peptide sequence. Also digits number seven and eight can acknowledge 
polymorphisms in the non-coding region [Figure 1.2]. Nowadays, colons are utilised 
to separate each of these numbers. This classification allows 99 variations in each 
sub-type (i.e. variations are not any more constricted to two digits (Tait, 2011)). In 
order to provide information regarding allele expression, letters are included at the 
end of the numbered sequence, they include:  
 
 N - null allele i.e. not expressed at the surface of the cell   
 L -  low expression at the membrane of the cell 
 S - expressed in a form of soluble product  
 C - expressed in the cytosol and not in the cell membrane  
 A - aberrant expression  
 Q - questionable expression, mutation can affect expression 
 
To be able to discuss how to deal with the growing variety of HLA alleles, meetings 
are arranged on a regular basis. Next generation sequencing (NGS) signifies novel 
sequencing technologies that allow the generation of a high value of clonal 
sequences in a single sequencing run (Gabriel et al., 2014). Initially, next generation 
sequencing was introduced for quantitation of viral variants or genetic mutations in 
tumour tissues and for whole genome sequencing; more recently, the potential for 
HLA typing in a high resolution and high throughput analysis has been explored. It 
became very clear that the HLA system complexity allude to new challenges, 
particularly for bioinformatics. Realising the full potential of next generation 
sequencing will necessitate the development of particularly adapted software 
algorithms and typing strategies (Gabriel et al., 2014).           
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Figure 1.2 – Nomenclature of HLA allele.    
 
1.7.6 Mechanisms of T-cell activation by drugs 
The activation or stimulation of the immune system by small molecules such as 
drugs reveals an interesting dilemma knowing that the traditional target of the 
immune system is proteins or peptides. Different elements can determine drug 
antigenicity including: the environment i.e., viral or bacterial infection, drug i.e., 
drug chemistry and host i.e., metabolic system, disease and genetics. A number of 
various mechanisms by which a small molecule such as drug can interact with 
immune receptors have been postulated and are delineated below. These different 
mechanisms are not mutually exclusive.  
 
1.7.6.1 Hapten hypothesis  
Researchers in the 1930s were the first to provide an insight into the underlying 
mechanisms responsible for T-cell activation by small chemical allergens. Guinea 
pigs were sensitised by Landsteiner and Jacobs to chemically reactive low molecular 
weight compounds such as dinitrochlorobenzene (DNCB). The authors postulated 
that protein conjugation (adduct formation) may play an essential role in initiation of 
the observed immune response (Landsteiner and Jacobs, 1935). Low molecular 
weight chemicals   are not likely to act as a traditional antigens because of their small 
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size i.e., <1000 Da. Hence, the proposal that immune recognition only happens after 
a drug binds irreversibly to host proteins seemed logical. Landsteiner and Jacobs 
found a direct correlation between protein reactivity and immune sensitisation. This 
original observation resulted in the development of the hapten hypothesis. It is 
applicable to drugs such as the β-lactams antibiotics and to directly reactive protein 
chemicals. However, it should be noted that the origin of relevant protein 
modifications and the nature of antigenic peptide conjugates are yet to be defined. 
Furthermore, the majority of drugs are not directly protein reactive and need 
bioactivation through drug metabolism to be able to produce reactive intermediates 
capable of binding to protein covalently (Callan et al., 2009a; Castrejon et al., 2010a; 
Elsheikh et al., 2011). This is named the prohapten hypothesis. Chemical/drug 
modified proteins are then processed inside the cell where they are cleaved and 
linked with major histocompatibility (MHC) molecules, before being presented and 
recognised via specific T-cell receptors (TCRs) [Figure 1.3]. Also direct linkage to 
MHC molecules can occur, or to peptides which are attached already to an MHC 
molecule. The location of protein modifications (i.e. extracellular or intracellular) 
and antigen source is supposed to determine the processing form of protein; however 
this still requires experimental endorsement. Whether a CD4+ or CD8+ response 
occurs, is ultimately determined by the MHC molecule class that presents the drug-
derived antigen. Advanced mass spectrometry technical methods have been 
developed and used to precisely locate the residues of amino acid that are modified 
by drugs such as flucloxacillin (Jenkins et al., 2009a), sulfamethoxazole (Callan et 
al., 2009a)and piperacillin (Whitaker et al., 2011a) demonstrating that these may be 
highly specific.  
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Figure 1.3- Mechanisms of drug-specific T-cell activation (prohapten/hapten hypothesis). 
Antigenicity of drug occurs as a result of metabolism and consequent covalent proteins 
modification of host. Modified proteins of host are then processed inside the cell, cleaved 
into peptide fragments and linked with MHC molecules then translocated to the cell 
surface. T-cell receptor will then recognise the MHC/peptide complex. Antigens generated 
externally (outside of the cell) are processed through an endocytic pathway, attach to MHC 
class II molecules and stimulate a CD4+ T-cell response. Antigens generated inside the cell 
are processed through a proteasomal pathway, attach to MHC class I molecules, and 
stimulate a CD8+ T-cell response [see Figure 1.1].      
 
1.7.6.2 The pharmacological interaction (PI) concept  
 An alternative mechanism to the hapten hypothesis has been suggested. It has been 
named the PI concept (the pharmacological interaction of drugs with immune 
receptors) (Pichler, 2002a). The PI concept describes the capacity of inert drugs to 
stimulate an immunological response. It is based around results from in vitro assays 
with human cells from hypersensitive patients that are difficult to explain it with the 
hapten concept. Pichler and coworkers observed that drugs are presented in MHC 
molecules   expressed on glutaraldhyde fixed antigen presenting cells. These cells 
which do not process proteins can stimulate T-cell clones the same as non-fixed cells 
(Zanni et al., 1998). Glutaraldhyde prevents processing of an antigen but conserves 
their antigen presentation capability. Such findings have been observed by other 
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laboratories with sulfamethoxazole (Schnyder et al., 1997; Elsheikh et al., 2011), p-
phenylendiamine (Jenkinson et al., 2009), lamotrigine (Naisbitt et al., 2003b) and 
carbamazepine (Wu et al., 2006; Wu et al., 2007). Additionally, rapid Ca2+ release 
from T-cell clones and the internalisation of specific T-cell receptors following drug 
exposure were discordant with a hapten mechanism (Zanni et al., 1998; Wu et al., 
2006). A non-covalent direct association is believed to occur between the drug 
molecule, and either MHC molecule or TCR [Figure 1.4]. This interaction is readily 
reversible. Furthermore, as there is no de novo primary antigen formation it is 
suggested that activation through a PI mechanism indicates alloreactivity of the 
memory T-cell population (Adam et al., 2011).     
 
Figure 1.4- Mechanisms of drug-specific T-cell activation (p-i concept). A chemically inert 
drug can attach non-covalently and directly either to the T-cell receptor or to MHC 
molecule, stimulating an immune response. This may include hydrophobic interactions, 
hydrogen bonds or Van der Waals forces.     
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1.7.6.3 Danger/costimulation hypothesis  
Interactions between the innate and adaptive immune system helps to achieve the 
balance between immune stimulation and regulation. For the host, the first line of 
defence is the innate immune system where cells recognise non-self-antigens via 
pattern recognition receptors (PRR) and initiate a danger signal that directs the 
adaptive immune system through enhanced/altered co-stimulatory signalling. Co-
stimulatory signalling is an important element of dendritic cell maturation 
(Sanderson et al., 2007; Elsheikh et al., 2011). The danger model was described by 
Matzinger in 1994. It states that immunity is not a simple situation of non-self 
against self but it is determined by the milieu in which an antigen is presented to T-
cells (Matzinger, 1994). Matzinger states that at least two signals are required for 
immune activation. Signal one is represented by TCR engagement with an MHC-
peptide complex. However, alone this is not enough to stimulate an immunological 
response. The interaction of different co-stimulatory molecules expressed on the T-
cell and the antigen-presenting cell (APC) represents signal two. Immune tolerance 
will occur in the absence of signal two. Signal two can be modulated by several 
mechanisms. Both, endogenous damage associated molecular patterns (DAMPs) 
released from dead or damaged cells (e.g. HMGB1, heat shock proteins) and 
exogenous pathogen associated molecular patterns (PAMPs) (e.g. viral RNA, 
peptidoglycan, LPS) represent danger signals. Different drugs have been found to 
initiate danger signalling: (1) amoxicillin promotes a more mature phenotype for 
dendritic cells (Rodriguez-Pena et al., 2006), (2) abacavir promotes redistribution of 
heat shock protein in antigen-presenting cells (Martin et al., 2007), and (3) 
sulfamethoxazole metabolites increases CD40 expression in dendritic cells 
(Sanderson et al., 2007). However, it should be noted that these studies represent the 
“tip   of   the   iceberg”   in   our   understand   of   the   role   danger   signalling   play   in   the  
development of a hypersensitivity reaction in a susceptible patient. For example, it is 
not known whether danger signals are provided through infections; hence rendering 
an otherwise tolerant patient susceptible to a given reaction.  
 
36 
 
Furthermore, the PI concept states that danger signalling is not needed to promote 
hypersensitivity reactions. However, experimental evidence to support this is 
lacking.      
 
1.7.6.4 The terms used to describe small molecules  
The following defined terms will be used all through this thesis to illustrate the small 
molecules interactions with the immune system:  
 Immunogen: a molecule that can stimulate an immunological or a cellular 
response 
 Antigen: any molecule that can attach specifically to T-cell receptor or to 
an antibody 
 Prohapten: a small molecule, which undergo metabolism to able then to 
attach to larger macromolecules and stimulate an immune response. 
 Hapten: a small molecule that can stimulate an immune response only when 
attached to a larger macromolecule.  
 Co-stimulatory molecule: a molecule that can polarise or induce an 
immunological response to different antigens.  
 
Several of these characteristics can be exhibited by any drug. 
  
1.7.7 HLA associations and adverse drug reactions                 
Recent genome-wide association studies reveal that the genetic background of the 
patient is one of the main risk factors associated with drug hypersensitivity. In 2002, 
an association between abacavir hypersensitivity syndrome and HLA-B*57:01 was 
reported (Hetherington et al., 2002; Mallal et al., 2002) and from this time a variety 
of HLA markers have been identified for both liver (e.g. ximelagatran (Kindmark et 
al., 2008), flucloxacillin (Daly et al., 2009), lumiracoxib (Singer et al., 2010) and 
lapatinib (Spraggs et al., 2011)) and skin (e.g. carbamazepine (Chung et al., 2004; 
McCormack et al., 2011), nevirapine (Martin et al., 2005) and allopurinol (Hung et 
al., 2005)) reactions [Table 1.4]. Associations are not specifically associated with a 
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particular compound class or clinical manifestation. However, the associations 
observed for skin reactions have to date been stronger than those described for liver 
reactions. Moreover, some associations can be limited to certain ethnic group 
(Lonjou et al., 2008; McCormack et al., 2011) and this may relate to the various 
frequencies of risk alleles in various populations.  
 
Genetic association strength can be revealed by calculation of an odds ratio (OR). 
The value of this ratio compares the frequency of the risk allele in unaffected and 
affected groups (i.e. patients that have not experienced an adverse reaction and those 
that have) and can be directly calculated by producing a 2 x 2 table [Figure 1.5]. It 
provides an indication of effect size.       
 
 
Figure 1.5 – Calculation formula of odds ratios relating the association strength of specific 
HLA alleles with adverse drug reactions.    
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Drug HLA allele 
Reaction and 
ethnicity 
Odds ratio (95% 
CI) 
Reference 
Drug-induced skin injury (DISI) 
Abacavir B*57:01 HSS (Europeans) 1945 (110-34352) (Saag et al., 2008) 
Allopurinol B*58:01 
SJS 
(Han Chinese, 
Caucasian) 
580.3 (34.4-
9780.9) 
80 (34-187) 
(Hung et al., 2005; Lonjou et al., 
2008) 
Carbamazepine 
B*15:02 
 
A*31:01 
SJS/TEN (Han 
Chinese) 
All phenotypes 
(Europeans) 
1357 (193.4-
8838.3) 
25.93 (4.93-
116.18) 
(Chung et al., 2004; Hung et al., 
2006; McCormack et al., 2011) 
Lamotrigine B*38 
SJS/TEN 
(Caucasian) 
6.8 (2.6-18) (Lonjou et al., 2008) 
Nevirapine DRB1*01:01 
Hypersensitivity 
(Caucasian) 
4.8 (1.3-16.8) (Martin et al., 2005) 
Drug-induced liver injury (DILI) 
Flucloxacillin B*57:01 DILI (Caucasian) 80.6 (22.8-284.9) (Daly et al., 2009) 
Ximelagatran 
DRB1*07:01 
DQA1*02:01 
DILI (Caucasian) 
4.4 (2.2-8.9) 
4.4 (2.2-8.1) 
(Kindmark et al., 2007) 
Lumiracoxib DRB1*15:01 DILI (Caucasian) 5.3 (3.0-9.3) (Singer et al., 2010) 
Co-amoxiclav 
DRB1*15:01 
A*02:01 
DILI (Caucasian) 
2.3 (1.0-5.3) 
2.2 (1.6-3.2) 
(Hautekeete et al., 1999; O'Donohue 
et al., 2000; Donaldson et al., 2010; 
Lucena et al., 2011) 
Diclofenac DRB1*13 DILI (Caucasian) - (Daly and Day, 2009) 
Clometacin B*08 DILI - (Pariente et al., 1989) 
Ticlopidine A*33:03 DILI (Japanese) 13.0 (4.4-38.6) (Hirata et al., 2008) 
Lapatinib DQA1*02:01 DILI (Caucasian) 
2.2 (1.1-5.7) 
9.0 (3.2-27.4) 
(Spraggs et al., 2011) 
Antituberculosis 
(isoniazid, 
rifampicin, 
pyrazinamide) 
DQB1*02:01 DILI (Indian) 1.9 (1.0-3.9) (Sharma et al., 2002) 
 
Table 1.4- Summary of HLA-associated drug reactions. Adapted from (Yun et al., 2012; 
Kaniwa and Saito, 2013). 
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To use these alleles for screening prior to prescription a few considerations must be 
taken, involving prevalence of the allele, transferability across various populations, 
and the negative and positive predictive values (Phillips and Mallal, 2010). 
Nowadays genetic screening for both carbamazepine and abacavir (in Asian ancestry 
patients) is highly recommended prior to prescription and has been ultimately 
effective in reducing the incidence of hypersensitivity reactions toward these drugs 
(Rauch et al., 2006; Phillips and Mallal, 2009). As discussed earlier the 
physiological function of HLA molecules is to present pathogens-derived-peptides at 
the surface of the cell to T-cells. Therefore, the discovered genetic associations may 
indicate a functional consequence of polymorphism contained by the peptide-binding 
groove. Knowing this, in vitro assays using cells from patients with identified 
genetic background are needed and have been utilised in this thesis.  
  
In the latest study of induced liver injury by flucloxacillin, more than 80% of 
patients carried the HLA-B*57:01 allele in comparison to 6% of the control 
individuals (Daly et al., 2009). But, only 1 in 500 to 1 in 1000 individuals with the 
risk allele develops DILI when exposed to flucloxacillin despite of the strength of 
the association. This indicates that if prospective screening is introduced, many 
patients who may not develop a reaction will be refused treatment (Daly et al., 
2009). It has been estimated that more than 13000 patients will require testing to 
prevent only one case of flucloxacillin-induced liver injury, in comparison to only 13 
patients in abacavir hypersensitivity (Phillips and Mallal, 2010). Thus, it seems that 
the allele is important for the development of hypersensitivity but also other factors 
are required and yet to be described. This may involve history of concurrent 
medications or infection and the immune status of the individual. In this case 
scenario, HLA-typing may function as a diagnostic more than predictive marker test.  
 
Adverse drug reactions including a variety of prescribed drugs and influencing the 
skin, liver and other organs revealed strong associations with specific HLA alleles. 
For some reactions, HLA typing before prescription, so that those have the risk allele 
are not taken the drug associated with the reaction, displays high negative and 
positive predictive values. The best clinical application associate to the 
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hypersensitivity reaction is the one induced by abacavir. When this particular 
reaction is phenotyped in an accurate way, 100% of those who develop it are HLA-
B*57:01 positive. Presently, drug regulators worldwide recommend HLA-B*57:01 
genotyping prior to abacavir prescription. Severe skin rashes involving toxic 
epidermal necrosis and Stevens-Johnson syndrome can be induced by carbamazepine 
and some other anticonvulsant drugs. In particular East Asians, these reactions are 
highly associated with HLA-B*15:02 and this allele typing is now recommended 
before carbamazepine is prescribed in these populations. Other HLA allele 
associations have been defined for skin rash induced by nevirapine, carbamazepine 
and allopurinol and for liver injury induced by amoxicillin-clavulanate, 
flucloxacillin, ticlopidine, lapatanib and lumiracoxib. However, the suggestive 
values for typing HLA alleles linked with these adverse reactions are lesser. Clinical 
utility thus appears unlikely. Carrying out HLA typing is somewhat complex in 
comparison to genotyping tests for single nucleotide polymorphisms. With regard to 
HLA-B*57:01, the methods utilised commonly, involving use of DNA sequencing 
and sequence-specific oligonucleotide PCR primers are considered, alongside with 
their effective implementation. Genotyping single nucleotide polymorphisms tagging 
HLA alleles is an easier substitute to HLA typing but seems inefficiently accurate for 
clinical usage (Daly, 2014). The drugs flucloxacillin and abacavir will be discussed 
in greater detail as the identified HLA allele (B*57:01) is associated with both 
flucloxacillin and abacavir hypersensitivity.  
 
Flucloxacillin   is   a   β-lactam antibiotic used mainly for the treatment of 
staphylococcal infections. It acts by inhibiting the synthesis of peptidoglycan which 
is a vital constituent of bacterial cell walls. Even though well tolerated flucloxacillin 
use is accompanied by the appearance of cholestatic liver injury at an estimated rate 
of 8.5 in 100 000 new users. Reactions tend to develop in the initial 45 days of 
treatment (Russmann et al., 2005).  
 
Flucloxacillin metabolism is catalysed by CYP3A4. Flucloxacillin is transformed 
into a 5-hydroxymethyl metabolite, which has been shown in vitro to be toxic to 
human biliary cells (Lakehal et al., 2001). A substantial increase in lactate 
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dehydrogenase production was detected, when media from hepatocytes pre-treated 
with flucloxacillin was added to biliary epithelial cells cultures. 
 
Genome wide associations studies (GWAS) in 2009 found that 84% of patients 
(43/51) with flucloxacillin-induced liver injury expressed the HLA-B*57:01 allele, 
in comparison to only 5% of the control population (Daly et al., 2009). The 
identified HLA allele (B*57:01) is also associated with abacavir hypersensitivity. 
Therefore, this association may indicate the possibility of T-cells involvement in the 
reaction pathogenesis. Certainly flucloxacillin positive LTTs have been recorded 
previously (Maria and Victorino, 1997). However, the causes of liver injury are yet 
to be defined. It has been found that both flucloxacillin and the 5-hydroxymethyl 
metabolite bind covalently to albumin at very similar amino acid residues (Jenkins et 
al., 2009a). This has been illustrated both in vivo and also in vitro, where 
modification  could  be  observed  in  all  patients’  plasma.     
  
Abacavir is commonly used in a combination therapy for human immunodeficiency 
virus (HIV) treatment, as it is a nucleoside reverse transcriptase inhibitor (NRTI). 
Abacavir is an analogue of carbovir which was developed to decrease the poor 
solubility and toxicity accompanied by carbovir (Daluge et al., 1997).  
 
Abacavir is a guanine analogue and is able to reduce viral reverse transcriptase via 
chain termination of the developing viral RNA, and competition. Abacavir is a 
prodrug and needs intracellular phosphorylation, like other NRTIs, to form the active 
drug phosphorylation occurs in consecutive steps, where abacavir is firstly catalysed 
by adenosine phosphotransferase (Faletto et al., 1997).Viral reverse trancriptase is 
ultimately inhibited by carbovir triphosphate (Faletto et al., 1997).  
 
Abacavir hypersensitivity reactions were noticed early clinical developmental trials 
(Saag et al., 1998). Symptoms included skin rash, fever and nausea that were 
detectable 6 weeks after starting treatment (Hetherington et al., 2001). Two 
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independent groups in 2002 reported susceptibility to abacavir hypersensitivity 
resulted from an association with HLA-B*57:01 (Hetherington et al., 2002; Mallal et 
al., 2002). The benefit of screening for the risk allele prior to prescription was 
established by Mallal et al. in 2008. A double-blind long-scale randomised 
prospective study revealed that 100% of skin test diagnosed hypersensitive  patients’  
express B*57:01 (Mallal et al., 2008). Since these ground breaking studies,   
screening has been conducted globally leading to an ultimate reduction in the 
incidence of abacavir hypersensitivity (Phillips and Mallal, 2009).  
 
The immunological basis of abacavir hypersensitivity is well established. Abacavir 
induces the specific production of pro-inflammatory cytokines, including TNF-α  
(Martin et al., 2004)and IFN-γ  (Almeida et al., 2008) from  hypersensitive  patients’  
peripheral blood mononuclear cells, in vitro. Skin biopsies obtained from inflamed 
skin of hypersensitive patients reveal a significant infiltration of CD8+ T-cells, 
proposing that it is cytotoxic T-cell activity that causes tissue damage (Phillips et al., 
2002).  Following abacavir exposure, antigen-presenting cells are activated via 
Hsp70 redistribution; this resulted in the suggestion that the abacavir may stimulate 
signalling pathways resulting in efficient antigen presentation in individuals with the 
HLA-B*57:01 allele (Martin et al., 2007).   
 
Recently, innovative studies by Chessman et al. (2008) defined the role of HLA-
B*57:01 in the pathogenesis of the disease. Using lymphocytes from healthy 
volunteers expressing HLA-B*57:01 they described the highly selective binding of 
abacavir to amino acid residues located deep in the peptide binding cleft (Chessman 
et al., 2008). Illing et al. and others observation solved the crystal structure of the 
HLA-B*57:01 abacavir peptide binding interaction and proposed a completely novel 
mechanism of drug-specific T-cell activation (Illing et al., 2012). They were able to 
show by mass spectrometry that abacavir binding alters the confirmation of the 
peptide binding cleft and as such the repertoire of peptides that are ultimately 
displayed on the surface of antigen presenting cells. They propose that these so 
called  “altered-self”  peptides  and not abacavir provide signals to activate T-cells and 
ultimately abacavir hypersensitivity. However, it must be noted that the ability of 
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such peptides to stimulate T-cells in a B*57:01 restricted fashion has not been 
described.     
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1.8 Adverse drug reactions without HLA association 
1.8.1 Piperacillin  
Piperacillin is a piprazine ampicillin derivative (Oh et al., 2009). By the end of 
1970s, the drug was launched following thorough research on its antimicrobial 
efficacy compared with other available antibiotics. Piperacillin is effective against 
resistant microbes such as Pseudomonas aeruginosa and Klebsiella pneumonia 
(Jones et al., 1977; Ueo et al., 1977; Wise, 1977; Dickinson et al., 1978; Verbist, 
1978). In vitro experiments on bacterial cultures revealed a synergistic effect 
between aminoglycosides and piperacillin against Pseudomonas aeruginosa. 
Moreover,  piperacillin  activity  against  β-lactamase producing resistant bacteria (e.g. 
Escherichia coli, Haemophilus influenza, staphylococci) can be improved by 
combining piperacillin with tazobactam (Speich et al., 1998; Sweetman, 2009).  
 
Our investigation focussed on patients with a history of allergic reactions to 
piperacillin, aztreonam and meropenem. Piperacillin is a member of the pencillin 
class of antibiotics, which contains β-lactam and thiazolidine ring structures [Figure 
1.6]. Meropenem, a carbapenem, contains similar ring structures but the sulfur in the 
thiazolidine ring has been replaced with a carbon atom, and unsaturation has been 
introduced. Finally, aztreonam, a monobactam, contains an unfused β-lactam ring.   
 
 
Figure 1.6 - Chemical structures 
of piperacillin, meropenem, and 
aztreonam. 
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Piperacillin is administered as a sodium salt by intravenous or intramuscular 
injection as it is poorly absorbed from the intestine. The usual piperacillin dosage is 
3-4g every 4 or 6 hours, while the maximum daily dose for uncomplicated or mild 
infections is at 100 to 125 mg/kg. However, adults can be given piperacillin at 200 to 
300 mg/kg in divided doses daily intravenously if they are suffering from 
complicated or serious type of infections (Sweetman, 2009).  Approximately 20% of 
piperacillin in the blood circulation is attached to plasma proteins. Only 20% of 
piperacillin is excreted unchanged in bile, whereas 60% to 80% of a dose is excreted 
unchanged in the urine within 24 hours (Tjandramaga et al., 1978; Sweetman, 2009). 
In vivo duodenal samples and in vitro studies utilising microsomes of human liver 
revealed that a small piperacillin fraction is metabolised in the liver in to desethyl-
piperacillin and a glucuronide conjugate of the desethyl metabolite. Both desethyl-
piperacillin and desethyl-piperacillin glucuronide are detected in human bile and 
urine (Minami et al., 1991; Komuro et al., 1997; Ghibellini et al., 2006; Ghibellini et 
al., 2007). Moreover, piperacillin and desethyl-piperacillin are believed to form 
adducts with proteins, which may act as a functional antigens leading to piperacillin 
hypersensitivity reactions (Whitaker et al., 2011a).  
  
Multiple reports were published in the mid-1980s describing the high incidence of 
piperacillin reactions, particularly fever in patients with CF (Brock and Roach, 1984; 
Moss et al., 1984). However, the manufacturers’  suggested  that  mostly  patients  with  
CF are liable to hypersensitivity reactions and to support their view they cited 
reactions with other semisynthetic penicillins including carbenicillin (Sweetman, 
2009). Therefore, throughout this thesis piperacillin clones were tested against other 
structurally  related  β-lactams [Figure 1.7].  
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Figure 1.7 -Structurally related drugs to piperacillin.    
Piperacillin 
Penicillin G 
Ampicillin Amoxicillin 
Carbenicillin Cefoperazone 
Cefalexin 
7-Amino-desacetoxycephalosporanic acid 
D-penicillamine 
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To investigate drugs of our interest, cloning method was used throughout this thesis 
to generate enough numbers of T cell clones for further studies. T lymphocytes are a 
pool of cells with exceedingly different characteristics. Firstly, each cell that drives 
from a specific precursor has reordered its genes for the T cell receptor (TCR) in a 
different manner from other cells. Therefore, there is a great heterogeneity of T cells 
in peripheral blood resulted from different TCR expression by the cells that 
distinguish different epitopes. Additionally, T cells can be further divided in isolated 
subsets, which are differentiated by different molecules expression, such as CD8, 
CD4, CD45R and CD25. Such molecules are variably related to the function that a 
single T cell is intended to accomplish or to the differentiation stage in which at a 
certain time that cell belongs. Furthermore, the pool of peripheral cells also involves 
T lymphocytes with variable capacity to release function-associated cytokines. By 
analysing peripheral blood mononuclear cells (PBMC) many studies on T cell 
functions can be performed, however since PBMCs cells including a heterogenous 
population, in many experiments it might be difficult to attain a clear-cut data and to 
attribute a define function to a defined T cell population. The accessibility of T 
lymphocytes population that originate from the same progenitor (clone) with a 
distinctive function and phenotype may be of a great benefit. Oppositely, limitation 
on the results interpretation should be defined also when a clone is utilised. A clone 
will comprise cells that share similar phenotypic and functional characteristics, but 
they may not be demonstrative of the whole T lymphocytes population in in vivo 
settings (Mariotti and Nisini, 2009).      
 
One of the important sources for T cell clones is isolation of PBMC from patients 
with or shortly recovered from a specific disease, which is related to an antigen-
specific T cell expansion (Mariotti and Nisini, 2009). The next two figures illustrate 
the methods used throughout this thesis to study T-cell responses to antigen using 
both  volunteers  and  patients’  blood  samples [Figure 1.8; Figure 1.9].     
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 Figure 1.8- A schematic illustration to the methods used to study T-cell responses to 
antigen  using  patients’  blood  samples.      
 
Figure 1.9 - A schematic illustration to the methods used to study T-cell responses to 
antigen using volunteers’ blood samples.    
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1.9 Aims of the thesis  
β-lactam hypersensitivity remains one of the most common causes of immune-
mediated drug hypersensitivity.   Furthermore,   β-lactam antibiotics can induce both 
skin and liver injury. The incidence of hypersensitivity reactions to β-lactams is three 
times (28%) greater in CF patients in comparison to patients without CF (8%). The 
incidence of piperacillin reactions is the highest amongst all β-lactam antibiotics (30-
50%) (Parmar and Nasser, 2005; Burrows et al., 2007).  
 
Flucloxacillin   is   a   β-lactam antibiotic used mainly for the treatment of 
staphylococcal infections. Even though well tolerated flucloxacillin use is 
accompanied by the appearance of cholestatic liver injury at an estimated rate of 8.5 
in 100 000 new users. GWAS in 2009 found that 84% of patients with flucloxacillin-
induced liver injury expressed the HLA-B*57:01 allele. To date, there are no studies 
characterising the drug-specific immune response underlying both piperacillin and 
flucloxacillin hypersensitivity.   
 
The primary objective of this thesis was to study the role of T lymphocytes in 
patients  with  β-lactam mediated skin and liver injury. Secondary objectives were (1) 
to investigate the mechanisms of drug antigenicity and immunogenicity and (2) to 
determine whether the HLA associations linked to drug- induced liver injury relate to 
the HLA-restricted presentation of the drug-derived antigen.  
 
The two drugs piperacillin and flucloxacillin were selected as (1) their use in humans 
is associated with a high incidence of skin and liver injury, respectively and (2) large 
number of patients to promote the research.   
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2.1 Introduction  
Cystic fibrosis (CF) is a recessively inherited disease caused by mutations in the 
cystic fibrosis transmembrane conductance regulator (CFTR) gene. Caucasians have 
been reported to have the highest incidence of CF (1/2415 of live births in United 
Kingdom) (Dodge et al., 1997; Kirkby et al., 2009). In 1985 the disease was linked 
to the long arm of chromosome 7 (Tsui et al., 1985; Wainwright et al., 1985); 
subsequently the gene sequence which encoded a 1480 amino acid protein called the 
cystic fibrosis transmembrane conductor regulator (CFTR) was discovered (Kerem 
et al., 1989). To date over 1,900 mutations have been reported and the number 
continues to increase. CFTR functions as a cAMP-activated ATP-gated anion 
channel that transports chloride across epithelial cell membranes. Defective CFTR 
results in reduced chloride secretion across the apical airway epithelial membrane 
and increased sodium absorption basolateraly. This results in reduced airway surface 
liquid and defective ciliary function (Matsui et al., 1998). These thick viscid 
secretions provide a favourable environment for bacterial infection or colonisation. 
Ultimately this leads to frequent pulmonary exacerbations, airway destruction and 
bronchiectasis (Turcios, 2005). Respiratory failure and death is the outcome in 90% 
of CF patients (Dodge et al., 1997; Amos, 2007; Kirkby et al., 2009). Although it has 
been well recognised and established that impaired CFTR function influences 
adversely the secretory epithelium, the CFTR role in non-epithelial cells has received 
less consideration, or investigators faced difficulties investigating it (Mueller et al., 
2011). Surely, if the CFTR alters the immune cells function, it must be expected to 
lead to an abnormal immune response. Throughout the years the CFTR expression in 
lymphocytes has been well characterised, however the physiological significance of 
CFTR expression in lymphocytes is not clear. Some studies demonstrated its 
importance in volume regulation and cytolysis regulation of CD8 T cells. Other 
studies suggested that stimulation of Cl2 currents by CFTR in response to nitric 
oxide through a cyclic GMP-dependant mechanism is abnormal in T cells in patients 
with CF. A functional role for CFTR in lymphocytes has been documented by using 
electrophysiological studies, which recorded cyclic AMP-dependent Cl2 currents 
defect in lymphocytes from patients with CF. further studies of CFTR-deficient 
lymphocytes showed an activation of intracellular Ca2+ flux in response to TCR 
activation (Mueller et al., 2011). Thus the existence and function of CFTR within 
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lymphocytes has been demonstrated. To date, it has been hard to differentiate 
abnormal immune response observed in CF patients from the disease phenotype 
conveyed by epithelial cell dysfunction (Mueller et al., 2011).  
 
Presently, we are seeing a more wide range of clinical disease caused by CF since 
the advancement of genetic testing. The sweat test (pilocarpine iontophoresis) 
remains a significant diagnostic test of dysfunctional CFTR (O'Sullivan and 
Freedman, 2009; Hurt and Bilton, 2012). With regard to chloride concentration 
normal values are lower than 30mmol/litre. Patients with CF usually have readings 
more than 60mmol/litre. However, some patients have a borderline range of 30-
60mmol/litre. In such patients, nasal potential difference (NPD) testing is utilised to 
revealed CFTR dysfunction. NPD measures the transepithelial potential variance 
resulted from the transport of charged ions across nasal membranes (Hurt and Bilton, 
2012).    
 
The most resistible microbe colonising in the respiratory passages of patients with 
CF is Pseudomonas Aeruginosa (PA) (Stead et al., 1985; McKone and Aitken, 
2004). One of the antibiotics that is highly effective against PA is piperacillin, an 
antipseudomonal semisynthetic penicillin (Jones et al., 1977; Bodey and Le Blanc, 
1978).  A  β-lactamase inhibitor tazobactam is synergistically used with piperacillin to 
enhance its antimicrobial activity (Jones et al., 1979). However, due to the 
development of frequent hypersensitivity reactions, use of the drug combination is 
limited (Stead et al., 1985). The majority of reactions have a delayed onset of 1-2 
weeks (Pleasants et al., 1994). Usually, the reactions involve fever, arthritis and 
maculopapular or urticarial skin rashes (Pleasants et al., 1994; Wills et al., 1998). 
The incidence of hypersensitivity reactions to β-lactams is three times (28%) greater 
in CF patients in comparison to patients without CF (8%). The incidence of 
piperacillin reactions is the highest amongst all β-lactams (30-50%) (Parmar and 
Nasser, 2005; Burrows et al., 2007).  
 
The significant increase in survival rate in patients with CF over the past 70 years is 
mostly related to the better understanding of the role that chronic airway infection 
plays in the pulmonary disease pathogenesis. This has resulted into the development 
of new anti-infective treatment strategies to support the control of inflammation, 
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infection and progressive destruction of the airways (Kirkby et al., 2009). 
Advancement in genetic technology has many advantages such as assist in tailoring 
treatment regimens to patients with CF and makes current antibiotic therapies more 
effective, with less treatment burden and less potential for adverse effects. 
Furthermore, it is important to mention that recent advancement in pharmaceutical 
design and molecular genetics have led to the development of agents that can modify 
dysfunction and correct the underlying pathogenesis of pulmonary disease in patients 
with CF (Kirkby et al., 2009).  
 
T lymphocytes are believed to play a central role in the pathogenesis of drug-induced 
skin reactions in patients without CF. Traditionally, CD4+ T-cells support the 
humeral component of the immune response via the release of cytokines, whereas 
CD8+ T-cells mediate tissue injury directly through release of cytotoxic molecules 
(granzyme B, perforin, granulysin or FasL) (Schnyder et al., 1998; Yawalkar et al., 
2000; Pichler, 2002b; Naisbitt et al., 2007; Pichler, 2007; Martin et al., 2010). 
However recent studies challenge this classification. Drug-responsive CD4+ T-cells 
have been isolated from skin and blood of patients hypersensitive to drugs such as 
carbamazepine and sulfamethoxazole (Schnyder et al., 1997; Naisbitt et al., 2003a; 
Wu et al., 2007; Elsheikh et al., 2011) and shown to exert cytolytic activity. 
Furthermore, by characterising the phenotype and function of T-cells isolated from 
patients with different forms of cutaneous drug hypersensitivity reactions it has been 
possible to develop a classification system based on cellular pathophysiology.   
 
In patients with CF, drug hypersensitivity is considered as a major health problem.  
Hypersensitivity increases   patients’  morbidity   and   limits   the   choice   of   antibiotics,  
which  is  already  restricted  by  increasing  microbes’  resistance.  As  the  role  of  T-cells 
in hypersensitivity in patients with CF has not been defined, 28 patients with   
piperacillin hypersensitivity and 5 drug exposed tolerant controls were recruited, 
lymphocytes isolated and antigen-specific T-cell responses analysed. The double-
was found in 80% of the tolerant and hypersensitive patient groups (O'Sullivan and 
Freedman, 2009; Hurt and Bilton, 2012). Maculopapular exanthema (MPE) was the 
form of skin reaction in the hypersensitive patients. Flu-like symptoms, fever and 
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arthralgia were other clinical sings. The duration since the reaction first occurred 
ranged between 2-8 months, and the mean time to reaction onset was 6.3 days [Table 
2.1].    
  
2.2 Aims                                      
x Characterise the specificity and functionality of T cells by generating 
piperacillin-specific T cell clones from hypersensitive patients with CF.  
 
x Investigate T cells structural specificity by analysing additional β-lactam 
antibiotics and structurally related compounds.  
 
2.3 Patients and methods   
2.3.1  Patients’  demographics 
The medical records of around 375 cystic fibrosis patients who are receiving 
treatment in the Leeds Regional Adult Cystic Fibrosis Unit were included in the 
study and analysed. Approximately 25% of the patients had experienced a 
hypersensitivity reaction following exposure to piperacillin. Reactions occurred after 
intravenous drug administration for at least 48 hours. For this study, blood samples 
were collected from five piperacillin-tolerant patients who did not show any sign of 
an adverse reaction following treatment, and eight patients with a history of 
piperacillin hypersensitivity [Table 2.1]. At the time of the experimental work the 
mean age in the piperacillin-hypersensitive group was 23.7 years (20-30 years).  
 
2.3.2 Chemicals and reagents  
Foetal bovine serum (FBS) was obtained from Invitrogen, Paisley, UK. Human AB 
serum was obtained from Innovative Research (Michigan, USA). Lymphoprep was 
bought from Axis Shield (Nycomed, Dundee, UK). Tetanus toxoid (TT) was 
purchased from the Statens Serum Institute, Copenhagen, Denmark. 
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Interferon-γ   and   Interleukin-13 ELISpot kits including substrate and antibodies 
solution were bought from Mabtech, Stockholm, Sweden. The Fas ligand ELISpot 
kit was purchased from Abcam (Cambridge, UK). CD8-FITC and CD4-PE 
antibodies were obtained from BD Bioscience, Oxford, UK. Bio-Plex Pro Human 
Cytokine Th1/Th2 Panel was bought from Bio-Rad, Hertfordshire, UK. 
Recombinant human interleukin-2 (rhIL-2) was purchased from Peprotech, London, 
UK. [3H]-Thymidine and [51Cr]-Chromium were bought from Moravek (California, 
USA) and Perkin Elmer Life Sciences (Cambridge, UK), respectively.  
 
Cefalexin was obtained from Fluka Analyticals (Gillingham, Dorset, UK). All other 
reagents were purchased from Sigma-Aldrich, Gillingham, Dorset, UK.     
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Patient 
ID 
Age 
(y) 
Sex 
Details of the 
reaction 
Sputum 
classification 
Time to 
reaction 
Time since 
reaction 
Courses before 
reaction 
LTT 
Piperacillin-tolerant patients (days) (years)  - 
C1 25 M Tolerant Ch. PA    - 
C2 22 F Tolerant Ch. PA    - 
C3 18 F Tolerant Non PA    - 
C4 27 F Tolerant Ch. PA    - 
C5 26 F Tolerant Inter. PA    - 
Piperacillin-hypersensitive patients     
P1*§ 21 M MPE, fever Ch. PA 9 7 3 +++ 
P2* 24 M MPE Ch. PA 11 5 9 +++ 
P3* 30 F 
Fever, 
eosinophilia 
Inter. PA 7 2 14 ++ 
P4*§ 22 M MPE, fever BC 2 1 4 ++++ 
P5* 22 F Arthralgia Non PA 5 5 4 ++++ 
P6*§ 26 M MPE Ch. PA 5 2 3 ++++ 
P7* 18 M Flu-like illness Ch. PA 2 6 3 ++++ 
P8*§ 28 F 
Fever, 
arthralgia 
Ch. PA 9 6 7 +++ 
P9 29 F MPE Ch. PA 7 12 11 ++++ 
P10 29 M MPE  3 5 4 ++ 
P11 24 F 
 Delayed 
angioedema 
 6 3 4 - 
P12 24 M MPE  2 5 NA +++ 
P13 30 F Flu-like illness  3 1 9 ++ 
P14 45 F Fevers  11 5 14 - 
P15 22 F MPE  7 5 6 ++ 
P16 17 M MPE  4 6 11 - 
P17 24 F Arthralgia MPE  7 2 7 + 
P18 22 M Pruritis  5 4 11 + 
P19 31 F Flu-like illness  9 6 12 + 
P20 34 M MPE  2 10 11 - 
P21 32 M MPE  5 10 8 + 
P22 23 F Fevers unwell  5 3 12 + 
P23 29 M Tight chest  4 6 9 - 
P24 18 M Urticarial rash  2 5 NA - 
P25 40 M Fevers  10 12 11 - 
P26 29 F MPE  4 5 9 - 
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P27 34 F MPE  3 1 17 - 
P28 35 F MPE  7 10 17 - 
 
Table 2.1 – Clinical details of patients with cystic fibrosis. M: male, F: female, MPE: 
maculopapular exanthema, Ch. PA: chronic Pseudomonas Aeroginosa, Non PA: non- 
Pseudomonas Aeroginosa, Inter. PA: intermittent Pseudomonas Aeroginosa, BC: 
Burkholderia Cepacia, Stimulation index (SI) (+, SI 2-5; ++, SI 5-10; +++, SI 10-20; ++++, SI 
>20; -, no response), LTT, lymphocyte transformation test; NA, not available. (*)PBMCs of 
these patients were used in chapter 2, (§) PBMCs of these patients were used in chapter 3 
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2.3.3 Cell culture medium  
T-cell medium was consisted of RPMI 1640 supplemented with 10% human AB 
serum, 1000U/ml penicillin, 0.1mg/ml streptomycin, 2mM L-glutamine, 25mM 
HEPES  and  25μg/ml transferrin.  
 
Antigen-presenting cell medium was consisted of RPMI 1640 supplemented with 
10% foetal bovine serum, 1000U/ml penicillin, 0.1mg/ml streptomycin, 2mM L-
glutamine and 25mM HEPES. 
  
2.3.4 Isolation and storage of peripheral blood mononuclear cells from venous 
heparinised blood  
Peripheral blood mononuclear cells (PBMCs) were isolated from 70ml of blood, 
which was collected into heparinised vacutainer tubes. 15ml of blood was layered on 
top of 10ml of lymphoprep and the density gradient centrifugation (2000 rpm, 25 
min, 0 brake, at room temperature) was used for erythrocytes sedimentation. After 
that the PBMCs band was formed as a buffy coat layer between the lymphoprep 
layers and the plasma. The buffy coat layer containing the PBMCs was then gently 
aspirated from the interface with a sterile pasture pipette. PBMCs were washed twice 
in Hanks balanced salt solution (HBSS) to remove any residual lymphoprep using 
density centrifugation at 1800 rpm and 1500 rpm, respectively. Cell yield was then 
resuspended  in  10ml  HBSS.  An  aliquot  of  10μl  was  added  to  40μl  HBSS  and  then  
10μl  of  this  diluted  suspension  of  cell  was  added  to  trypan  blue  (10μl,  0.2%  w/v).  A  
10μl   aliquot   of   the   cell   suspension/   trypan blue mixture was then placed on a 
Neubauer haemacytometer (Sigma-Aldrich, Dorset, UK) and counted under a Leica 
DME microscope (Leica Microsystems, Milton Keynes). Cell viability was assessed 
by trypan blue [unstained (viable) and stained (non-viable)] and calculated by the 
following equation: percentage of viable cells = 100 x (number of viable cells/ total 
number of cells). Cell viability was typically more than 95%. Viable cells were 
resuspended in culture medium at the required concentration.  
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Freshly isolated PBMCs were resuspended in a freezing mixture of 90% foetal 
bovine serum (Invitrogen, Paisley, UK) containing 10% DMSO (sigma-Aldrich, 
Dorset, UK) at a concentration of 107 cells/ml. Cells were dispensed into cryovials 
(1ml/ vial) on ice. Cryovials were placed in a freezing container called Mr Frosty-
style which is filled with 70% isopropanol, and saved in -80°C freezer. After 24 
hours the cryovials were all transferred to liquid nitrogen. Cells should be thawed 
and processed quickly for better viability and recovery. To thaw the cells, warm 
RPMI was added into the cryovials containing cell suspension followed by 
transferring to a sterile 50ml tube containing warm RPMI. Cells were centrifuged 
using density gradient centrifugation for 5 minutes at 1500 rpm then resuspended in 
the required volume of warm culture medium. Cell viability and number were 
assessed as described above. 
  
2.3.5 In vitro enrichment of drug-specific T-cells  
2.3.5.1 Lymphocyte transformation test (LTT) 
The lymphocyte transformation test is particularly designed to detect the existence 
and proliferation of drug-specific memory T-cells   in   the   hypersensitive   patients’  
peripheral blood (Nyfeler and Pichler, 1997). Freshly isolated PBMCs (1.5 x 105, 
100μl)  were  cultured  with  piperacillin  (0.06-8mM),  or  tetanus  toxoid  (5μg/ml)  as  a  
positive control, in triplicate wells for six days, in 96-well U-bottomed tissue culture 
plates (37°C, 5% CO2). Cell cultures containing lymphocytes in the absence of 
piperacillin were considered as a negative control. [3H]-Thymidine   (0.5μCi/well)  
was added for the final 16 hours of incubation to measure proliferation. Plates were 
harvested and counted as count per minute (cpm) on a liquid scintillation counter 
(Wallac microbeta trilux, PerkinElmer, Cambridge, UK). Proliferative responses 
were calculated by comparing proliferation in drug treated cultures vs. control 
cultures. Stimulation index (SI = cpm in drug treated cultures/cpm in control 
cultures).  An  SI  ≥2  was  considered  as  a  positive  result  (Pichler and Tilch, 2004).  
 
 
60 
 
2.3.5.2 Enzyme-linked immunospot (ELISpot) assay 
Filter plates from MultiscreenHTS (Millipore, Watford, UK) were coated at 4°C 
overnight with interferon-γ  (IFN-γ)  and  interleukin-13 (IL-13) capture antibodies at 
(15µg/ml) and (10µg/ml), respectively. The following day, all wells were blocked 
with T-cell medium (30 minutes, at room temperature, 200µl) after a thorough wash 
with  Hank’s  balanced  salt  solution  (HBSS)  for  five  times.  At  the  end  of  incubation,  
T-cell medium was removed, and responders cells were added to wells 
([lymphocytes 5 x 105, 100µl], [T-cell clones 0.5 x 105, 50µl + autologous irradiated 
antigen-presenting cell 0.1 x 105, 50µl]) and the preferred concentration of the 
antigen (100µl). Medium and phytohemagglutinin (PHA 5µg/ml) were then added to 
corresponding wells. Plates were incubated at 37°C, 5% CO2, and developed after 48 
hours, according to the instructions of the manufacturers. At the end of the 
incubation cells were removed and wells were washed five times with 250µl 
phosphate buffer solution (PBS). Biotin-labelled detection antibodies specific to 
IFN-γ  and  IL-13 were diluted to 1µg/ml in PBS containing 0.5% FBS and added to 
each well (100µl). Plates then were incubated for 2 hours at room temperature before 
wells were washed for 5 times with PBS (250µl/well). Streptavidin-ALP was diluted 
(1:1000) in PBS containing 0.5% FBS and added to wells (100µl/well, at room 
temperature for 1 hour). At the end of the incubation, wells were washed again five 
times with PBS (250µl) and spots were visualised by the addition of the substrate 
BCIP/NBT at 100µl/well and left for 15 minutes until spots appear. All plates then 
were rinsed gently under tap water and left to dry to be ready for spots counting on 
an AID ELISpot reader (Cadama Medical, Stourbridge, UK). A schematic 
illustration of the ELISpot assay is shown in Figure 2.1.   
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Figure 2.1- Schematic illustration of the enzyme-linked immunospot (ELISpot) assay. (1) 96-
well ELISpot plate is coated over night at 4°C with specific antibody for the molecule of 
interest. (2) The following day cells are added and incubated in the plate for 48 hours and 
the interested molecule is captured. (3) Biotinylated specific secondary antibody for the 
molecule of interest is added, after the cells being removed. (4) Streptavidin conjugated 
alkaline phosphatase is added and it binds to the biotinylated secondary antibody. (5) 
Finally, alkaline phosphatase will catalyse a colour change reaction, after addition of the 
substrate solution. This will result in the development of dark distinct spots.       
 
2.3.5.3 Measurement of cytokine and chemokine secretion using LUMINEX 
 Levels of secreted cytokines (IL-4, IL-5, IL-6, IL-10, IL-13, IL-1β,  IFN-γ,  TNF-α,  
MIP-1α   and   MIP-1β)   were   analysed   and   measured   using   Luminex   (xMAP-based 
platform, Biorad laboratories, Hercules, USA) multiplex biorad bead assay. The 
Luminex assay allows multiple cytokines to be simultaneously quantified within the 
same sample (Figure 2.2). Antibodies coupled to colour-coded beads directed at 
every target molecules, are added and incubated with the sample. Different bead with 
a distinctive unique colour is attached to each antibody. Reporter labelled with 
fluorescent, also specific for the target is added later to quantify the amount of 
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analyte attached to every single bead. The bead colour and the bounded analyte 
amount are both detected by the Luminex reader.  
 
Figure 2.2- Luminex assay principle. Antibodies coupled to colour-coded beads directed at 
every target molecules, are added and incubated with the sample. Different bead with a 
distinctive unique colour is attached to each antibody allowing multiple analytes to be 
investigated within the same sample.  
 
Samples used comprised supernatants of lymphocytes or drug-specific   clones’  
cultures -/+ culprit drug. Lymphocytes (1.5 x 105) from five piperacillin 
hypersensitive patients and seven piperacillin-specific T-cell clones (0.5 x 105 + 
autologous irradiated EBV-transformed B-cells 0.1 x 105) were incubated in the 
presence and absence of 2mM piperacillin. After 48 hours supernatants (100µl) were 
collected from the wells and stored at -80°C until the time of analysis by Luminex. 
On the day of the Luminex assay, samples were firstly thawed on ice then diluted 
with sample buffer. One single vial of standards was reconstituted in 250µl water, 
mixed, vortexed and diluted as shown in Table 2.2.  
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Standard (pg/ml) Water to add (µl) Standard to add (µl) 
10,000 250 0 
 
Standard (pg/ml) Assay buffer to add (µl) Standard to add (µl) 
2000 200 50µl of 10,000pg/ml 
400 200 50µl of 2000pg/ml 
80 200 50µl of 400pg/ml 
16 200 50µl of 80pg/ml 
3.2 200 50µl of 16pg/ml 
 
Table 2.2- Serial dilution of standards for Luminex assay.   
 
Analysis   of   supernatants   was   performed   following   the   manufacturers’   protocol  
(Linco   Research,   Inc).   The   filter   plate   was   prewet   with   assay   buffer   (200μl,   10  
minutes incubation on plate shaker, at room temperature) followed by assay buffer 
removal by vacuum. Standards, controls and samples were then added to the 
appropriate   wells   in   duplicate   (25μl/well).   Magnetic   beads   (50μl/well)   were   also  
added and incubated in the dark for 30 minutes at room temperature on a plate 
shaker. After that wells were washed twice before incubation with detection antibody 
(25μl/well,   30  minutes,   at   room   temperature,   on   plate   shaker).   Samples  were   then  
incubated   again   for   extra   10   minutes   with   streptavidin   phycoerythrin   (25μl/well)  
under the same conditions. Wells were washed two times with wash buffer before 
sheath  fluid  was  added  (150μl/well,  5  minutes,  on  plate  shaker).  The  plate  was  then  
analysed using Bio-Plex suspension array system (Bio-Rad Laboratories, Hercules, 
CA).  
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2.3.6 T-cell cloning  
Theoretically, T-cell cloning is considered as a simple technique where PBMCs are 
freshly isolated and seeded at one cell per well then induced with PHA to proliferate. 
Antigenic specificity of proliferated cells is then experimentally tested. Practically, 
T-cell cloning method is difficult as many different problems can be encountered. T-
cell cloning entails handling of long-term cultures in an aseptic technique which 
requires a high level of expertise. Moreover, several thousand separate cultures must 
be generated to establish working numbers of specific T-cell clones, as antigen 
specific T-cells frequency is incredibly low. Limiting dilution was the procedure 
used to generate T-cell clones following previously described method (Schnyder et 
al., 1997; Wu et al., 2006). The aim of T-cell cloning is to generate monoclonal 
populations of antigen-specific T-cells that survive in the in vitro cultures for long 
enough time to be tested and completely studied.    
 
2.3.6.1 Generation of piperacillin-specific T-cell clones  
Freshly isolated PBMCs (1 x 106;;   500μl)   from   piperacillin   hypersensitive   patients  
were incubated in 48-well   plates   with   piperacillin   (1,   2mM,   500μl)   in   T-cell 
medium. Cultures were supplemented on days 6 and 9 with IL-2 (60U/ml) 
(Peprotech, UK). On day 14, cultures treated with drug were pooled, washed with 
medium and cells were counted by trypan blue dye exclusion. CD4+ and CD8+ cells 
were separated by CD8+ positive selection using CD8 Multisort kit (Miltenyi 
Biotech, Bisley, UK). Cells were harvested and resuspended in HBSS containing 
0.5% bovine serum albumin (BSA) and 2mM ethylenediaminetetraacetic acid 
(EDTA).   CD8  magnetic  microbeads   (20μl)  were   added   to   the   cells,  mix  well   and  
incubated at 4°C for 15 minutes. The cells were then centrifuged, washed two times 
and   added   to   an   MS   column   (no.   of   cells   ≤   107) held in a magnet. Unlabelled, 
negative cells pass via the column were considered as the CD4+ fraction. The MS 
column was then detached from the magnet and the CD8+ cells were promptly 
flushed   out.   The   cell   populations’   purity   was   determined   using   fluorescence  
activated cell sorting (FACS) analysis. Phycoerythrin (PE)-labelled  CD4   (3μl)   and 
fluorescein isothiocyanate (FITC)-labelled  CD8   (3μl)   antibodies  were   added   to   the  
separated cells aliquot and incubated for 20 minutes in the dark at 4°C. A BD FACS 
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Canto II flow cytometer (BD Biosciences, Oxford) was used for events collection. In 
general purity was > 95%. Separated cells were then serially diluted following an 
established method (Wu et al., 2006). Cells were seeded in 96-well U-bottom plates 
into three different densities 0.3, 1 and cells/well and restimulated with a stimulation 
cocktail containing allogenic irradiated PBMCs (5 x 104 cells/well), IL-2 (60U/ml) 
and   PHA   (5μg/ml).  Well-growing clones were marked and transferred to new 96-
well U-bottom plates and split as required to 4wells/clone. Every 14 days, clones 
were restimulated as described above in order to maintain T-cell expansion.  
 
2.3.6.2 Generation of autologous antigen-presenting cells 
 Epstein-Barr virus (EBV) transformed B-cell lines were generated by transformation 
of freshly isolated PBMCs using supernatant from the virus-producing cell line 
B9.58.  5ml  of  the  supernatant  was  filtered  by  a  0.45μm  syringe  filter  on  to  a  PBMC  
pellet containing 5 x 106 cells.   5μl   of   cyclosporin   A   (CSA)   was   then   added   to  
prevent T-cell mediated suppression of B-cell infection and to inhibit EBV from 
inducing T-cell proliferation. After overnight incubation (37°C, 5% CO2), cells were 
washed, resuspended at 1 x 106/ml in antigen-presenting cell medium containing 
CSA  (1μg/ml)  and transferred to a 24-well cell culture plate (1ml/well). Cells were 
fed twice per week with fresh antigen-presenting cell medium and CSA was omitted 
from the culture medium after 14 days. When confluent observed, cells were 
transferred to a tissue culture flask.  
 
2.3.6.3 Antigen-specificity of T-cell clones                           
At least four weeks after serial dilution, piperacillin-specificity was determined by 
the   addition   of   piperacillin   (2mM;;   100μl)   and   autologous   irradiated   EBV-
transformed B-cells   (1   x   104/well;;   50μl)   to  T-cell clones (5 x 104/well;;   50μl)   and  
incubated for 48 hours. [3H]-Thymidine  (0.5μCi)  was  added  in  the  final  16  hours  of  
incubation to measure the proliferation by scintillation counting. Clones that have 
stimulation   index   of   2≥  were taken and expanded in IL-2 containing medium by 
repetitive mitogen stimulation for further analysis.  
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2.3.6.4 Proliferation assay  
The most common technique used to measure proliferation in vitro is depending 
mainly on the [3H]-Thymidine uptake. After two weeks of T-cell   clones’  
restimulation, 5 x 104 T-cells were incubated for 48 hours in duplicate with 
autologous irradiated EBV-transformed B-cells (1 x 104) in the presence and absence 
of  piperacillin  (0.1,  0.5,  1,  2  and  3mM)  in  a  total  volume  of  200μl in U-bottom 96-
well plate. It is useful to do the proliferation assay using a wide range of drug 
concentrations to find out the best concentration that gives the optimal proliferative 
response. In the final 16 hour of incubation, [3H]-Thymidine   (0.5μCi/well) was 
added and then cells were harvested by a multiwell harvester to aspirate and transfer 
them onto a filter paper. Only [3H]-Thymidine labelled DNA were transferred onto 
the filter paper, while any non-incorporated [3H]-Thymidine in the medium were 
discarded. The incorporated radioactivity was determined by a liquid scintillation 
counter (Wallac microbeta trilux, PerkinElmer, Cambridge, UK) as count per minute 
(cpm). T-cell clones with a stimulation index equal or greater than two were taken to 
be piperacillin-specific T-cell clones and maintained in IL-2 containing medium in 
48-well culture plate. Antigen-induced T-cell response was quantified by both 
proliferation and measuring cytokine secretion using multiplex technique (see 
2.3.5.3) and IFN-γ  ELISpot assay (see 2.3.5.2). If multiplex technique was planned, 
the culture supernatants from each condition were pooled and collected prior the 
addition of [3H]-Thymidine and stored at -80°C until the day of the assay.  
 
2.3.6.5 Phenotypic characterisation of piperacillin-specific T-cell clones 
T-cell clones (1 x 105) were washed and incubated with CD4-PE and CD8-FITC 
antihuman  monoclonal   antibodies   (3μl)   in   a   96-well V bottomed plate (at 4°C, 20 
minutes) in the dark in HBSS. At the end of incubation, cells were washed three 
times by centrifuging the plate (at 4°C, 5 minutes, 1500 r.p.m). Finally the pellets of 
the  cells  were  resuspended  in  300μl  FACS  buffer  (HBSS  containing  0.5%  BSA  and  
2mM EDTA) and transferred to FACS tubes for flow cytometeric analysis on the BD 
FACS Canto II flow cytometer (BD Biosciences, Oxford).  
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2.3.6.6 Chemical cross-reactivity  
T-cell clones (5 x 104/well) were incubated with irradiated autologous EBV-
transformed B-cells (1 x 104/well) in the presence and absence of each of the 
compounds (piperacillin, penicillin G, ampicillin, amoxicillin, carbenicillin, 
cefoperazone, cefalexin, 7-amino-desacetoxycephalosporanic acid and D-
penicillamine; [Figure 1.7] (1, 2 and 4mM) for 48 hours. All cells were seeded in 
duplicate in 96-well U-bottomed plates and kept in 37°C, 5% CO2. In the final 16 
hour of incubation, [3H]-Thymidine   (0.5μCi/well)   was   added   and   proliferation  
determined  by  scintillation  counting.  Stimulation  index  calculated  accepting  values  ≥  
2 as a positive response.  
 
 2.3.6.7 Detection of cytotoxic activity of piperacillin-specific T-cell clones 
2.3.6.7.1 Standard 51Cr-release assay  
Autologous EBV-transformed B-cells (1 x 106) were centrifuged (1500 r.p.m, 5 
minutes) and cell pellet were loaded with 51Cr   (0.5μCi,   50μl)   and   incubated for 1 
hour at room temperature. Cells were then washed thoroughly for three times with 
50ml RPMI medium to unincorporated radiation and resuspended in 20ml of culture 
medium to adjust cell concentration (5 x 104cells/ml).  
 
T-cell clones were seeded, and incubated with chromium loaded autologous EBV-
transformed B-cell, in 96-well U-bottom plate in duplicate in different 
concentrations to bring effector: target ratio to 25:1 and 50:1 in the presence and 
absence of piperacillin (2 and 4mM). After 4 hour incubation at 37°C in 5% CO2, 
100μl   of   the   supernatant   was   collected   from   each   well   culture   and   transferred   to  
polypropylene scintillation vials (Perkin Elmer life sciences, Cambridge, UK) then 
topped up with 4ml scintillation fluid (Perkin Elmer life sciences, Cambridge, UK). 
Additional spontaneous and maximum 51Cr release controls were determined by 
parallel incubations of 51Cr labelled autologous EBV-transformed B-cells with 
medium and methanol in the presence and absence of piperacillin. A total of eight 
wells replicates were established for each single condition of spontaneous and 
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maximum release. Piperacillin direct toxicity was excluded by incubating 
piperacillin with 51Cr loaded autologous EBV-transformed B-cells for four hours in 
the absence of T-cells. Radioactivity in supernatants was measured using Gamma 
counter. Cytolytic activity was then calculated using the following formula: 
percentage of cytolytic activity = [(average of medium or drug treated culture) – 
(average of spontaneous release)] / [(average of maximum release) – (average of 
spontaneous release)] x 100. 
                                       
 In case of revised 51Cr-release assay, autologous EBV-transformed B-cells were 
pulsed for 16 hour with piperacillin or medium. At the end of the incubation, cells 
were washed extensively for three times to remove unbound drug then loaded with 
51Cr as described above.  
 
 
2.3.6.7.2 Detection of increased cell surface CD107a expression using flow 
cytometery  
T-cell clones (5 x 104 cells/well; total  volume  200μl)  were   incubated   in  96-wll V-
bottom culture plate in duplicate, with irradiated autologous EBV-transformed B-
cells (1 x 104cells/well) in the presence and absence of piperacillin for 16 hour. At 
the end of the incubation, cells were incubated for 20 minutes with FITC-labelled 
anti-human CD107a monoclonal antibody (BD pharmingen, Oxford, UK) at 4°C. 
The   cells   were   then   washed   and   resuspended   in   300μl   FACS   buffer   (HBSS  
containing 0.5% BSA and 2mM EDTA) and transferred to FACS tubes for flow 
cytometeric analysis on the BD FACS Canto II flow cytometer (BD Biosciences, 
Oxford). The protocol was adjusted to acquire a minimum of 30,000 cells per 
sample.  
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2.3.6.8 Secretion of cytokines from piperacillin-specific T-cell clones 
Levels of secreted cytokines (IL-4, IL-5, IL-10, IL-13, IL-1β,   IFN-γ,   TNF-α   and 
MIP-1β)  from  piperacillin-specific T-cell clones were analysed and measured using 
Luminex assay as described above (see 2.3.5.3).  
 
2.3.7 Statistical analysis 
The Mann-Whitney test was used for comparison of proliferation in control vs. drug 
treated wells.  
                     
2.4 Results  
2.4.1 Piperacillin-specific Lymphocytes proliferative responses and cytokine 
release from tolerant and hypersensitive patients.     
Lymphocytes from the 8 piperacillin-hypersensitive patients [Table 2.1] were 
stimulated to proliferate with piperacillin in a concentration-dependent fashion (0.06-
8 mM). Maximum responses were detected at a concentration of 1-2 mM (control: 
1526 ± 2171 cpm, piperacillin 2 mM: 19108 ± 2957 cpm). Therefore these two 
concentrations of piperacillin were used in the functional studies described below 
[Figure 2.3, 2.4].  
 
Lymphocytes from the piperacillin-tolerant patients [Table 2.1] did not proliferate in 
response to piperacillin. However responses were detected to the control protein 
antigen tetanus toxoid (TT = 5µg/ml) (control: 437 ± 310 cpm, TT: 5104 ± 2409 
cpm, piperacillin 2 mM: 449 ± 170 cpm) [Figure 2.4].  
 
ELISpot was used to detect active secretion of the Th1 and Th2 cytokines IFN-γ  and  
IL-13. Lymphocytes from hypersensitive patients, but not tolerant controls, were 
stimulated to secrete IFN-γ  and  IL-13 in the presence of piperacillin (2mM) [Figure 
2.3]. Furthermore, lymphocytes from both piperacillin tolerant and hypersensitive 
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patients secreted both cytokines when stimulated with the positive control 
phytohaemaglutinin (PHA: 5µg/ml).  
 
Patient 
ID 
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Patient 
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Patient 
ID 
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Figure 2.3 – Isolated PBMCs from   cystic   fibrosis   hypersensitive   patients’   respond   to  
piperacillin as detected by (A) lymphocytes transformation test and (B) ELISpot. (A) PBMCs 
were specifically stimulated with piperacillin (0.06-8 mM) for 6 days. In the last 16h of the 
incubation, cultures were pulsed with [3H]-thymidine. Data presented as the average count 
per minute of triplicate cultures (cpm±SD). Tetanus Toxoid was used as a positive control 
(TT= 5µg/ml). (* p<0.05).  ; (B) (0.5 x 106) lymphocytes were added to wells in the presence 
and absence of piperacillin (2mM). Plates were incubated at 37 °C and 5% CO2 and 
developed  after  48  hours  following  the  manufacturer’s  instructions.  IL-13 and   IFN-γ  spots  
were visualised and counted using AID Software. 
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Figure 2.4 –Lymphocyte proliferation of piperacillin tolerant allergic patients. Tetanus 
Toxoid was used as positive control (TT= 5 µg/ml). Data statistically analysed using Mann-
Whitney test accepting **p<0.005, ***p<0.0005 as significant difference, control vs. 
treated.  
 
2.4.2 Specificity and functionality of piperacillin responsive T-cell clones                  
From five piperacillin-hypersensitive patients (P1, P2, P4, P7 and P8) a total of 1420 
T cell clones were generated and most of them were picked from 0.3 cell 
concentration per well. Of these 414 CD8+, CD4+ and CD4+8+ were stimulated to 
proliferate with piperacillin [Table 2.3]. CD4+8+ and CD8+ T cell clones were 
detected with lower frequency compared to CD4+ clones, with an approximate ratio 
of 1:2:4 CD4+8+, CD8+ and CD4+ T cell clones [Figure 2.5], respectively.   
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Patient 
ID 
Clones 
tested (n) 
Specific 
clones (n) 
Proliferation (cpm±SD) Phenotype (%) 
Control Piperacillin  (2 mM) CD4+ CD8+ 
CD4+ 
CD8+ 
P1 187 30 3232.7 ± 2566.2 
10608.4 ± 
10950.6 55 45 0 
P2 209 120 5712.4 ± 5514.3 
25709 ± 
22145.9 75 13 12 
P4 192 100 1361.1 ± 995.3  
15526.9 ± 
16868 100 0 0 
P7 736 152 3954.5 ± 3721.9 
12596.6 ± 
11915.2  66 22 12 
P8 96 12 17416.8 ± 2440.7 
47903.7 ± 
28946.3 N.A. N.A. N.A. 
  
Table 2.3 – Origin, phenotype and specificity of piperacillin T-cell clones generated from 
hypersensitive patients (n= 5). Proliferative response to piperacillin responsive T-cell clones 
presented as [3H] thymidine incorporation (counts per minute ± SD). N.A., not analysed.  
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Figure 2.5 –Lymphocyte proliferation of piperacillin-specific T-cell clones. CD4+8+ and CD8+ 
T cell clones were detected with lower frequency compared to CD4+ clones, with an 
approximate ratio of 1:2:4 CD4+8+, CD8+ and CD4+ T cell clones, respectively.  Data 
statistically analysed using Mann-Whitney test accepting ***p<0.0005 as significant 
difference, control vs. treated.  
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2.4.2.1 Piperacillin specific T-cell clones proliferate in a concentration-
dependent fashion.  
Out of 414 piperacillin specific T cell clones, eighty well-growing clones were 
chosen for further studies. These clones displayed wide-range of proliferative 
responses with piperacillin and expressed CD4+ and/or CD8+ receptors. The chosen 
T cell clones were expanded further and used in the functional studies described 
below to define antigen functionality and specificity.  
 
Figure 2.6 shows 16 representative piperacillin-specific T cell clones, with different 
phenotypes, proliferating in response to piperacillin in a dose dependent manner 
when incubated with irradiated autologous EBV-transformed B-cells. In terms of 
drug structure, the response of CD4+, CD8+ and CD4+CD8+ T cell clones to 
piperacillin was found to be highly specific. Piperacillin-specific T cell clones were 
incubated with piperacillin and 8 structurally related compounds (1-4 mM) [Figure 
1.7]. All tested clones proliferated in the presence of piperacillin, but not with the 8 
structurally related compounds [Figure 2.7].      
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Figure 2.6 Piperacillin specific T-cell clones proliferation. Sixteen representative piperacillin-
specific T-cell clones out of one hundred tested show concentration-dependent 
proliferation. Cells were incubated for 48h with irradiated autologous EBV transformed B-
cells and piperacillin (top clones: 0.5, 1, 2 and 3 mM; bottom clones: 0.1, 0.5 and 1 mM). 
Data presented as average [3H]-thymidine incorporation of replicate cultures. TCR-Vβ  
expression is also displayed for 4 piperacillin-specific clones.     
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Figure 2.7- CD4+, CD8+, and CD4+8+ clones were stimulated with piperacillin, but not 
related drug structures. Data are presented as average cpm at each drug concentration. 7-
ADACSA= 7-aminodesacetoxycephalosporanic   acid.   Stimulation   indices   were   ≥2   with  
piperacillin  while  ≤2  with  all  other  tested  drugs.    
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2.4.2.2 Cytotoxicity of piperacillin stimulated T-cell clones 
To evaluate cytotoxic activity of piperacillin-specific T cell clones a chromium-51 
release assay was used. The assay involves an incubation of piperacillin-specific T 
cell clones for 4h with 51Cr-loaded autologous EBV-transformed B-cells at different 
effector/target ratio (25:1 and 50:1). Piperacillin was added as an antigen in two 
forms: either (1) as a soluble drug (2 and 4 mM) in the traditional 51Cr-release assay 
or (2) used to pulse antigen presenting cells (2 and 4 mM) for 16 hours prior to 
chromium loading in the modified 51Cr-release assay. Supernatant of these cultures 
were collected at the end of incubation time to measure the release of radioactivity. 
Increased radioactivity in culture supernatant when compared with controls 
represents the cytolytic avtivity of piperacillin-specific T cell clones. Data is 
presented as percentage of cytolytic activity.  
 
Cytotoxicity was undetectable with the traditional 4 hour 51Cr-release assay where 
soluble piperacillin was used [Figure 2.8-B, Table 2.4]. However, when using the 
revised protocol where antigen presenting cells were pulsed with piperacillin over 
night are used, certain piperacillin-specific T cell clones with different phenotypes 
(CD4+, CD8+ and CD4+8+) displayed cytotoxic activity at an effector: target ratio 
of 50:1 [Figure 2.8-A, Table 2.4].  
 
Furthermore, by using flow cytomerty, we have been able to detect CD107a receptor 
upregulation on the surface of piperacillin-specific T cell clones after piperacillin 
stimulation. This indicates a cytotoxic response because normally CD107a is not 
detected on the cell surface unless lysosomal degranulation occurred. Increased 
membrane expression of the degranulation marker CD107a was detected on CD4+, 
CD8+ and CD4+8+ clones (n=18 out of 32 clones) [Figure 2.9].   
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Figure 2.8- Cytotoxic activity of pepracillin specific T-cell clones. (A) cytolytic activity of 
CD8+ and CD4+8+ T-cell clones exposed to soluble piperacillin (2,4 mM) or antigen- 
presenting cells pulsed with piperacillin (2,4 mM)  for 16h. (B) piperacillin specific T-cell 
clones were incubated with soluble piperacillin (2, 4 mM) and 51Cr-loaded autologous 
antigen presenting cells at different effector/target ratios (25:1, 50:1). Data show the mean 
51Cr released from replicate wells and presented as the (%) cytotoxic activity of piperacillin 
treated incubations compared to controls.     
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Patient 
ID 
Clone 
ID 
Phenotype 
(CD) 
Proliferation 
(SI) 
Cytotoxicity % 
Effector/target ratio 
25:1 50:1 
2 mM 4 mM 2 mM 4 mM 
P7 
Standard assay (4h soluble drug) 
55 4 67 0 0 0 0 
64 4 110.22 2.3 2.1 4 3.6 
61 8 1.89 0 0 0.7 8.08 
66 8 N.P. 0 0 1.7 0.1 
71 8 N.P . 0 1.8 20.93 2.5 
77 8 1.6 3.8 9.9 6.5 12.4 
80 8 20.33 2.9 3.2 0 0 
91 8 2.3 0 0 0.8 3.8 
100 8 4 8.3 4.4 3.4 6.5 
105 8 N.P. 0 0 6 11.3 
60 4/8 43.5 0 0 3.3 3.25 
62 4/8 15 1.6 1.6 2.05 4.36 
  
P4 
Revised assay (16h antigen presenting cell pulse) 
28 4 54 17.2 
N.P. 
20.7 
N.P. 
36 4 35.6 16 33.6 
39 4 17.9 10.9 14.4 
74 4 29.5 9 5.2 
18 4 40.2 11.6 N.P. 
46 4 11.8 0 N.P. 
58 4 32.9 N.P. 23.7 
81 4 15.4 0 N.P. 
92 4 4.9 7.6 N.P. 
96 4 30.9 6.6 N.P. 
 
Table 2.4 Cytotoxic activity of piperacillin specific T-cell clones in response to piperacillin. T-
cell clones (n= 22 clones) generated from two piperacillin hypersensitive patients [P7 (n= 12 
clones), P4 (n= 10 clones)]. Data presented as percentage cytotoxicity. N.P., not performed.   
 
 
 
 
 
 
 
81 
 
 
 
 
2.4.2.3 Secretion of cytokines by piperacillin-specific T-cell clones.  
Supernatants were collected from incubations of piperacillin-specific T cell clones 
(n= 7 clones) -/+ piperacillin to measure cytokine release. The majority of clones 
secreted high levels of Th2 cytokines IL-4, IL-5 and IL-13 following piperacillin 
stimulation. In contrast, cytokines IFN-γ   and   IL-10 were secreted at lower levels 
after antigen stimulation. The chemokine MIP-1β,  was  secreted  at  high  levels  from  
all piperacillin-specific T cell clones except one [Table 2.5].  
 
 
 
 
 
 
 
 
 
Figure 2.9- Increased CD107a 
expression on T-cell clones after 
piperacillin stimulation. Cells 
were labelled with anti-CD107 
antibody and analysed by flow 
cytometry; a minimum of 30,000 
cells were acquired by using 
forward scatter/side scatter 
characteristics. Results show the 
increase in CD107a expression 
when piperacillin-stimulated and 
unstimulated clones were 
compared. 
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Cytokine (pg/ml) 
Clone ID 
Phenotype 
(CD) 
Proliferation 
(SI)  IL-4 IL-5 IL-10 IL-13 IFN-у TNF-α IL-1β MIP-1β 
60 4/8 43.50 >10000 >10000 66 >10000 80 >10000 1 >10000 
62 4/8 15.60 6974 >10000 24 >10000 3346 >10000 N.D. >10000 
64 4 110 >10000 >10000 2746 >10000 8371 >10000 2 8721 
55 4 67 >10000 >10000 93 >10000 56 >10000 2 >10000 
77 8 1.59 1.5 N.D. 191 3051 2404 5628 N.D. >10000 
91 8 2.30 74 1937 6 4511 370 1808 0.5 >10000 
100 8 4 2740 3544 17 5897 5667 3311 N.D. >10000 
 
Table 2.5 Luminex analysis of secreted cytokines (pg/ml) from 7 piperacillin stimulated T-
cell clones. Data represent mean of duplicate cultures with cytokine levels (less than 10 
pg/ml IFN-у;  less  than  20  pg/ml  IL-5, IL-1β;  less  than  50  pg/ml  IL-4, IL-10, IL-13, TNF-α,  MIP-
1β)  in  drug-free wells subtracted. N.D., not detectable.  
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2.5 Discussion 
Piperacillin, is widely used to treat patients with CF. The preferable route to 
administer piperacillin is the parenteral route as it is poorly absorbed orally. 30-50% 
of CF patients who are treated by piperacillin suffer from mild and moderate 
piperacillin hypersensitive reactions (Parmar and Nasser, 2005; Burrows et al., 
2007). Importantly the role of T-cells in hypersensitivity reactions in patients with 
CF has not been defined.   
 
It has been shown that T lymphocytes play a vital role in coordinating immune 
responses against drug-derived antigen (Lopez et al., 2007; Torres et al., 2009).To 
activate T cells, the culprit drug should act as an antigen by ligation to specific T cell 
receptors. Studies by (Landsteiner and Jacobs, 1935), to break immune tolerance a 
drug must irreversibly bind to self-protein. Subsequently, T cells are activated by 
peptides liberated, by antigen processing, from the modified protein. However, 
Pichler and co-workers have challenged this basic concept by their influential 
studies. By using isolated T cells from human patients with hypersensitivity, they 
found that many characteristics of the drug-specific T cell response could be 
explained much more  precisely via a reversible, direct readily interaction between 
the immunological receptors and the parent drug (PI concept) (Pichler, 2002a; 
Naisbitt et al., 2003c).  
 
Thus, the aim of this work was to characterise the specificity and functionality of 
piperacillin responsive T lymphocytes in order to understand their role in non-
immediate hypersensitive reactions in patients with CF.  
 
Eight piperacillin hypersensitive patients presenting with arthritis, fever, flu-like 
symptoms and mild to moderate skin exanthema were included in the study. 
Patients’   blood   was   collected   to   isolate   T   lymphocytes which were then used in 
different experimental assays to characterise and define drug-specific T cell 
stimulation.  
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Using the lyhmphocyte transformation test and IL-13/IFN-γ  ELISpot  we  found  drug  
responsive lymphocytes in all eighteen hypersensitive patients. The lymphocyte 
transformation test is a simple cell culture method, based on analysis of lymphocyte 
proliferative responses in antigen-treated and control wells. Incorporation of [3H]-
thymidine is used to measure levels of proliferation. The lymphocyte transformation 
test has been used extensively in specialised facilities for the diagnosis of non-
immediate cutaneous hypersensitivity reactions. Detailed review (Nyfeler and 
Pichler, 1997; Pichler and Tilch, 2004) of the published literature revealed that the 
assay has an estimated sensitivity of 78% (the percentage of positive results in 
hypersensitive patients) and specificity (percentage of responders in control groups) 
approaching 85%. In our laboratory similar results have been obtained in patients 
hypersensitive to the anti-convulsants carbamazepine and lamotrigine (Naisbitt et al., 
2003a; Naisbitt et al., 2003b; Wu et al., 2006; Wu et al., 2007). ELISpot assays 
involve similar culture conditions, i.e., suspect drug antigens are titrated in PBMC 
cultures; however, the end-point to detect drug-specific T-cell proliferation is 
cytokine secretion. A detailed comparison of lymphocyte proliferative responses and 
cytokine secretion in penicillin hypersensitive patients indicated that IFN-γ  ELISpot  
was the most sensitive and could be used in a greater number of individuals for the 
diagnosis of penicillin hypersensitivity. Our study found similar results in that 
piperacillin-specific IFN-γ   secretion   was   detected   in   all   8   hypersensitive   patients.  
Analysis of the Th2 cytokine IL-13 revealed that a potion of hypersensitive patients 
PBMC secrete a mixed panel of cytokines (discussed in more detail below).   
        
The proliferative response of piperacillin-specific T lymphocytes was dose-
dependent and reproducible on repeated testing, with the maximum response noticed 
within therapeutic piperacillin concentrations that are likely to be in the range of 0.5-
1 mM. These data indicate that T-cells likely participate in the cutaneous 
manifestations of piperacillin hypersensitivity. It is also possible that drug-specific 
lymphocytes are also involved in other clinical features of the disease (flu-like 
symptoms, arthralgia and fever). This conclusion is based on the fact that 
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piperacillin-specific lymphocytes were detected in both hypersensitive patients with 
and without cutaneous symptoms.    
 
Importantly, the lymphocyte transformation test was negative in all five tolerant 
controls; thus, in our limited control the lymphocyte transformation test specificity 
was 100%. Accordingly, in regard with the diagnosis of piperacillin allergy, the in 
vitro assay revealed an advantage over the skin testing (Pichler and Tilch, 2004). 
 
The nature of the induced immune response is determined by the cytokine profile 
accompanied with a particular reaction (Hertl et al., 1993a; Hertl et al., 1993b; 
Yawalkar et al., 2000; Beeler et al., 2006; Lochmatter et al., 2009; Rozieres et al., 
2009). A mixed panel of cytokines (IL-13, IFN-γ, IL-6, IL-1β,  TNF-α,   and  MIP-1 
α/β)   was   detected   after   antigen   stimulation   of   piperacillin   hypersensitive patients 
lymphocytes. IL-6, IL-1β   and   TNF-α   detection   in   the   supernatant   of   piperacillin  
containing cultures are indicative of a dendritic cell response against piperacillin, 
which agrees with what has been recently described with amoxicillin(Rodriguez-
Pena et al., 2006). 
 
Over four hundred piperacillin-specific T cell clones were generated from peripheral 
blood of five patients with piperacillin hypersensitivity. The most dominant 
phenotype of the clones was the CD4+. All different T-cell phenotypes (CD4+, 
CD8+ and CD4+CD8+) were detected, indicating that both CD4+ and CD8+ T-cells 
participate in the disease pathogenesis [Figure 2.5]. High levels of TNF-α,  MIP-1β  
and Th2 cytokines (IL-4, IL-5 and IL-13) was secreted from T cell clones after 
piperacillin stimulation [Table 2.5]. IL-10 and IFN-γ   were   also   secreted   by   all  
stimulated clones with piperacillin but in low levels, which probably links to the 
positive IFN-γ  ELISpot  detected  using  peripheral  blood  lymphocytes.  The  different  
profile of cytokines seen in PBMC and clone assays may relate to the methods 
employed (PBMC, ELISpot, clone, Luminex). It might however relate to the 
uncovering of T-cell populations that are masked in PBMC cultures, which is an area 
of on-going research in our laboratory.   
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Cytolytic activity was detected against autologous antigen presenting cells pulsed 
with piperacillin, using a revised 51Cr- release assay which accounts for the time 
required for piperacillin to modify protein and form a T-cell antigen. Moreover, up-
regulation of CD107a, a lysosomal membrane marker, was detected on the surface of 
CD4+, CD8+ and CD4+CD8+ clones after piperacillin stimulation demonstrating 
their degranulation and cytolytic activity. These data indicate that piperacillin-
specific   clones’   have   the   potential   to   cause   tissue injury and the adverse reactions 
seen in patients with CF.  
 
β-Lactam antibiotics are known to be targeted by specific Lys residues on protein 
(Levine and Ovary, 1961; Batchelor et al., 1965b; Meng et al., 2011). Nucleophilic 
attack leads to ring opening, binding of the penicilloyl group, and ultimately 
formation of a stable adduct. We found that clones were stimulated to proliferate 
with piperacillin, but not other β-lactam-containing antibiotics. This indicates that 
the penicilloyl core structure alone does not deliver specific antigenic signals to 
activate T-cells. To investigate the fine specificity of the piperacillin-specific T-cell 
response, clones were cultured with cefoperazone, which contains a side chain 
closely related in structure to piperacillin, whereas the thiazolidine ring is replaced 
by a six-membered ring. Once more, clones were activated with piperacillin, but not 
with cefoperazone, demonstrating that piperacillin-responsive T-cells are highly 
drug-specific and recognise the penicilloyl structure and the specific side chain of 
piperacillin.     
 
To conclude, by utilising blood samples from hypersensitive patients with CF we 
have been able to characterise antigen-specific CD4+,CD8+ and CD4+8+ T cells. 
The existence of these cells together with their cytolytic features suggests that they 
may play a role in the pathogenesis of the disease.                                              
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3.1 Introduction 
β-lactam antibiotics provide the foundation for treatment of pulmonary infections in 
patients with CF. Unfortunately, the use is often limited by a high frequency of 
hypersensitive reactions. Several studies report a reaction prevalence of 26-50%, 
compared with 1-10% in the general population (Pleasants et al., 1994; Parmar and 
Nasser, 2005; Burrows et al., 2007; Whitaker et al., 2011b). β-lactam allergies in 
patients with cystic fibrosis are usually non-immediate with a mean time of onset of 
9.1 days (Whitaker et al., 2011a). Reactions consist of rashes, fever and/or flu-like 
symptoms. In 375 patients at the Leeds Regional Adult Cystic Fibrosis Unit only 6% 
of  302  β-lactam reactions were identified as being immediate. Severe skin reactions 
and systemic involvement were not encountered.  
 
 
To explore the immunological mechanisms of β-lactam allergy in patients with 
cystic fibrosis, we have previously focused on piperacillin. Peripheral blood 
mononuclear cells (PBMC) isolated from 68% of allergic patients, but not drug-
exposed tolerant controls, were found to proliferate following piperacillin 
stimulation in vitro (Whitaker et al., 2011a). In chapter 3, over 400 piperacillin-
responsive T-cell clones were isolated from hypersensitive patients and used to 
characterize the cellular pathophysiology of the reaction. Drug-responsive clones 
were CD4+ and CD8+ and secreted IFN-γ,  TNF-α  and  Th2  cytokines.       
 
 
 
If an allergic reaction to a β-lactam antibiotic such as piperacillin (penicillin class) is 
observed, it is replaced by another drug often from a different class (e.g., aztreonam 
from a monobactam class, meropenem from carbapenem class) [Figure 1.6]. 
However, approximately 20% of patients develop allergic reactions to these drugs 
(Whitaker et al., 2011b). Patients who have exhausted all conventional therapeutic 
options are usually older and sicker and require more frequent treatment. This results 
in prolonged hospital admissions for observation of treatment.  
 
89 
 
Clinical studies suggest that the extent of cross-reactivity between different classes 
of  β-lactam antibiotic is low. Moss et al. (Moss et al., 1991) reported that 19 out of 
20 patients with previous penicillin or cephalosporin allergy safely tolerated 
aztreonam. Cross-reactivity rates between penicillin and meropenem in patients with 
immediate reactions are estimated at less than 1%; however, several patients have 
been reported to become sensitized against the alternative drug following repeated 
exposure (Moss, 1991; Moss et al., 1991; Atanaskovic-Markovic et al., 2008; 
Frumin and Gallagher, 2009).  
 
 
 
3.2 Aims  
The factors that drive allergic reactions against multiple drugs are not known. We 
therefore looked to:  
x Identify drug-responsive PBMC in multi-allergic patients with cystic fibrosis. 
x Generate drug-responsive T-cell clones to investigate T-cell receptor cross-
reactivity with the different β-lactam antibiotics.  
 
 
3.3 Patients and methods   
3.3.1 Patients’  demographics   
Four patients with cystic fibrosis and allergies to piperacillin, aztreonam and 
meropenem, and four drug-exposed tolerant patients with cystic fibrosis were 
recruited. Table 3.1 summarises  the  patients’  demographics  and  the  clinical  features  
of the reactions. Approval for the study was acquired from the local research ethics 
committee, and informed written consent was obtained from each donor. Detailed 
experimental method for cloning, specificity and ELISpot assays are described in 
chapter two.  
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Allergic patients 
ID Age/sex Drug reaction 
Details of the 
reaction 
Time to 
reaction 
(days) 
Time 
since 
reaction 
(years) 
Courses 
prior to 
reaction 
LTT a 
(maximum 
SI) 
1 21/M 
Piperacillin MPEb, fever 9 7 3 13.3 
Aztreonam MPE 4 5 2 <2 
Meropenem MPE 5 5 3 8.0 
2 26/M 
Piperacillin MPE 5 2 3 31.1 
Aztreonam Urticarial rash 2 1 4 2.4 
Meropenem MPE 3 3 5 4.4 
3 28/F 
Piperacillin Fever, arthralgia 9 6 7 6.8 
Aztreonam Fever, arthralgia 6 5 4 4.1 
Meropenem 
Flu-like 
symptoms, 
vomiting 
6 4 5 5.8 
4 22/M 
Piperacillin MPE/fever 2 1 4 62.5 
Aztreonam Urticarial rash 1 1 2 <2 
Meropenem Lip swelling 1 2 3 4 
Tolerant patients 
ID Age/sex Drug reaction Drug exposure 
LTT 
(maximum 
SI) 
1 28/M none 
exposed to piperacillin, aztreonam and 
meropenem in the last 3 years  
In 1 year prior to his death, he required 73 
days of antibiotic treatment. 
<2c 
2 24/F none 
exposed to piperacillin, aztreonam and 
meropenem in the last 3 years  
In the last 12 months, the patient received 33 
days of antibiotic treatment. 
<2 
3 21/M none 
exposed to piperacillin, aztreonam and 
meropenem in the last 3 years  
averaged 81 days of antibiotic treatment per 
year 
<2 
4 29/M none 
exposed to piperacillin, aztreonam and 
meropenem in the last 3 years  
averaged 14 days of antibiotic treatment per 
year 
<2 
 
Table 3.1 – Clinical details of the tolerant and allergic patients. a LTT, lymphocyte 
transformation test; b MPE, maculopapular eruption; c <2, LTT SI <2 with each drug (0.1-
2mM). 
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3.4 Results  
3.4.1 Stimulation of PBMC from allergic pateints with piperacillin, aztreonam 
and meropenem 
PBMC from all four multi-allergic patients were stimulated to proliferate in the 
presence of piperacillin, aztreonam and meropenem [Table 3.1]. The proliferative 
response was drug concentration dependent and associated with the release of IFN-γ  
and/or IL-13 [Figure 3.1]. In contrast, PBMC from patients exposed to several 
courses of the three drugs with no apparent allergies were not stimulated to 
proliferate or release cytokines [Table 3.1].   
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Figure 3.1- Drug-specific stimulation of allergic pateints PBMC. (A) PBMC were cultured for 5 days in the presence of piperacillin, 
meropenem, or aztreonam. Proliferation was measured on day 6 by the addition of [3H]-thymidine for the last 16h of the incubation. 
Reasults are shown as the mean cpm readings of triplicate cultures. (B) Drug-specific ELISpot for IFN-γ  and  IL-13. (0.5 x 106) PBMC from 
allergic patients secreted IFN-γ  and  IL-13 after 48h of incubation with drugs. Well images were taken by AID Software. 
Piperacillin 
93 
 
3.4.2 Generation of piperacillin, aztreonam and meropenem-responsive T cell 
clones  
One thousand six hundred and sixty three T-cell clones were generated from the 4 
allergic patients following PBMC stimulation with piperacillin, aztreonam or 
meropenem and tested for drug specificity. A total of 122 were found to display 
reactivity against piperacillin (n=89), aztreonam (n=22) or meropenem (n=14) 
[Figure 3.2]. Although the majority of drug-response clones were CD4+, CD8+ 
clones were generated from each allergic patient. The number of piperacillin-, 
aztreonam and meropenem-responsive clones generated from each patient and the 
phenotype is summarised in Table 3.2. Sixty well-growing CD4+ and CD8+ clones 
selected from all 4 allergic patients were used to characterise concentration-
dependent proliferative responses, cytokine release and cross-reactivity.  
 
 
 
      
Figure 3.2- T-cell clones activation with piperacillin, meropenem and aztreonam. T-cell 
clones were cultured for 72h with antigen presenting cells and the drugs (2 mM). The figure 
displays the proliferative response of representative clones, piperacillin (n = 10), 
meropenem  (n  =  6)  and  aztreonam  (n  =  10).  Data  statistically  analysed  using  Student’s   t-
test accepting **p<0.005 as significant difference, control vs. treated 
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ID Drug 
Tested 
clones 
(n) 
Specific 
clones 
(n) 
Proliferation (cpm) Phenotype (%) 
control Drug (2 mM) CD4+ CD8+ CD4+CD8+ 
1 
Piperacillin 58 2 1422 ± 365 
10512 ± 
7907 100   
Aztreonam 111 2 2043 ± 788 
6683 ± 
2042  100   
Meropenem 111 5 4340 ± 3988 
11744 ± 
11173 80 20  
2 
Piperacillin 67 23 5477 ± 4137 
36004 ± 
23732 78 9 13 
Aztreonam 160 6 3529 ± 1761 
15711 ± 
19623 65 17 17 
Meropenem 100 4 1046 ± 441 
2399 ± 
938 100   
3 
Piperacillin 144 16 8133 ± 4353 
53954 ± 
18612 50 50  
Aztreonam 216 13 8984 ± 5963  
23323 ± 
12356 84 8 8 
Meropenem 72 1 3504  9550 100   
4 
Piperacillin 216 48 2134 ± 2412 
24461 ± 
18542 88 6 6 
Aztreonam 208 1 6867 33942 100   
Meropenem 200 5 3795 ± 2827 
11493± 
6948  100   
 
Table 3.2- Origin, specificity and phenotype of T-cell clones from allergic pateints.  
 
3.4.3 Drug-antigen specificity of T cell clones 
Proliferation of piperacillin-, aztreonam- and meropenem-responsive CD4+ and 
CD8+ clones was drug concentration-dependent; maximal responses were detected 
between 0.5-2mM [Figure 3.3]. Around one thousands and six hundred sixty three 
clones were generated but only one hundred and twenty six were drug-specific. Fifty 
five clones were tested for reactivity against piperacillin, aztreonam and meropenem 
(figure 3.4 showed only six representative clones) and the response to each drug was 
found to be highly specific. Clones were stimulated to proliferate [Figure 3.3] and 
release IFN-γ  [Figure  3.4] in the presence of the drug PBMC were cultured with to 
generate  the  clones,  but  not  the  other  β-lactam antibiotics.  
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Figure 3.3 -Cross reactivity of piperacillin, meropenem, and aztreonam T cell clones. Clones were incubated for 72h with antigen presenting cells in 
the presence of the drugs (0.1-2 mM). Proliferative responses were measured by [3H]-thymidine incorporation of the final 16h of the incubation. 
Results are shown as the mean cpm of triplicate cultures.     
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Figure 3.4- Drug-specific IFN-γ   ELISpot.   T   cell   clones   generated   from   patients   were  
stimulated with the drugs for 48h. Each drug-specific clone was tested with the other 2 
drugs to test its cross-reactivity. Well images were taken by AID Software.   
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3.5 Discussion 
β-lactam antibiotics form covalent bonds with lysine residues on protein in drug 
exposed patients (Levine, 1960; Batchelor et al., 1965b; Jenkins et al., 2009a; 
Whitaker et al., 2011a) to generate antigenic determinants for T-cells. Several studies 
have   shown   that   processing   of   β-lactam albumin conjugates liberate peptide 
sequences that stimulate T-cells (Brander et al., 1995; Padovan et al., 1997; Whitaker 
et al., 2011a; El-Ghaiesh et al., 2012). Under in vitro conditions, β-lactams bypass 
this requirement for protein processing by binding directly to MHC-associated 
peptides (Brander et al., 1995; Padovan et al., 1996a). Cross-reactivity studies using 
PBMC and T-cell clones from penicillin allergic patients reveal a plethora of drug 
response profiles (Mauri-Hellweg et al., 1996; Sachs et al., 2004; Rozieres et al., 
2009). In most allergic patients, the peptide-bound penicilloyl ring structure is 
thought to represent the main structural determinant for T-cell receptors, as β-
lactams that contain a different core structure do not stimulate T-cells. However, 
individual T-cells display a range of side-chain reactivity. Cross-reactive clones can 
be stimulated with several penicillins, some of which the allergic patient will have 
never knowingly been exposed to. In contrast, other clones are incredibly drug 
antigen-specific. Our recent studies with piperacillin mono-allergic patients revealed 
that PBMC and clones were not stimulated with other penicillins (see chapter 2).   
Collectively, these data suggest that different antigenic determinants derived from 
penicillins can be accommodated within the MHC binding cleft without interfering 
with the T-cell receptor binding interaction. However, the degree of cross-reactivity 
observed is drug and patient-specific and might be influenced by previous drug 
exposure. Thus, there is a need to further delineate the structural features that 
determine T-cell receptor cross-reactivity.   
 
Symptoms   of   the   reactions  were   classified   according   to   patient’s  medical   records.  
Patients 1, 2 and 4 developed maculopapular exanthema and/or non-immediate 
urticarial eruptions against the 3 drugs [Table 3.1]. Patient 3 developed less-classical 
symptoms of drug allergy (arthralgia, nausea and vomiting). Reactions were 
relatively mild but in every case treatment had to be discontinued. Each patient 
received and tolerated several courses of the individual drugs prior to the allergic 
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reaction. Our primary objective was to determine whether it was possible to detect T-
lymphocyte responses to each drug in the allergic patients. A secondary objective 
was the analysis of T-cell receptor cross-reactivity through the generation of T-cell 
clones.   
 
The lymphocyte transformation test and IFN-γ   ELISpot   are   the   biological   assays  
most commonly applied to diagnose drug allergy in vitro (Pichler and Tilch, 2004; 
Rozieres et al., 2009). Our study utilised both approaches to show that piperacillin, 
aztreonam and meropenem stimulate PBMC from allergic patients, but not drug-
exposed tolerant controls, to proliferate and secrete cytokines. These data confirm 
our previous findings in chapter 2 with piperacillin hypersensitive patients and 
demonstrate that T-cell responses are also readily detectable with aztreonam and 
meropenem. The drug-specific response was dose-dependent and reproducible on 
repeated testing. PBMC were stimulated with similar concentrations of the drugs. 
For three of the patients piperacillin stimulated the strongest proliferative response 
and the highest levels of IFN-γ   secretion,   when   the   three drugs were compared 
[Table 3.1; Figure 3.1]. This may relate to intrinsic chemical reactivity and 
differences in the level of drug protein conjugates formed in vitro.  
 
CD4+, CD8+ and CD4+CD8+ T-cell clones were isolated from piperacillin, 
aztreonam and meropenem-stimulated PBMC to explore T-cell receptor cross-
reactivity. Antigen-specificity was measured using proliferation and cytokine release 
as readouts and no cross-reactivity was observed. Over 50 clones were analysed 
[Figure 3.2]. These data clearly demonstrate that non-immediate reactions to 
different classes of β-lactam antibiotic in patients with cystic fibrosis are instigated, 
not by cross-reactive T-cells, but through priming naive T-cells against the different 
drug antigens. Daubner et al. (Daubner et al., 2012) have recently demonstrated that 
drug-responsive T-cells in certain patients with a history of multiple drug allergies 
reside in an in vivo activated (CD4+CD25dim, with elevated CD38 and PD-1) T-cell 
fraction. Thus, we are currently exploring whether a similar phenotype of drug-
responsive T-cells exist in patients with cystic fibrosis and multiple drug allergies 
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and indeed whether increased numbers of such T-cells might explain why multiple 
drug allergy is such a common occurrence in this patient group.    
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4.1 Introduction 
Adverse drug reactions are a major complication of drug therapy and an impediment 
to drug development. Immunological reactions are extremely important because of 
their severity and they account for many cases of drug withdrawal. They cannot 
easily be predicted and no simple dose-response is discernible. Skin is the tissue 
most commonly targeted by immune cells; however, other organs, including the 
liver, can be damaged either in isolation or as part of a generalised hypersensitivity 
syndrome (Park et al., 2011).  
 
T-lymphocytes are believed to cause drug-induced skin injury through the action of 
cytokines and cytolytic molecules. To stimulate a T-cell response the drug must bind 
to human leukocyte antigen (HLA) and in some way crosslink specific T-cell 
receptors. Recently, a number of cutaneous drug reactions have been strongly 
associated with expression of HLA alleles (e.g., abacavir hypersensitivity [HLA-
B*57:01] (Mallal et al., 2002), carbamazepine hypersensitivity in Caucasians, and 
Japanese [HLA-A*31:01] (McCormack et al., 2011; Ozeki et al., 2011) 
carbamazepine-induced Stevens Johnson syndrome in Han Chinese [HLA-B*15:02]) 
(Chung et al., 2004), which implies a direct/indirect effect of the gene product on the 
disease. For abacavir and carbamazepine, it has been possible to relate the genetic 
association to the mechanism of disease by characterising drug-specific CD8+ T-cell 
responses in volunteers expressing HLA-B*57:01 and B*15:02, respectively 
(Chessman et al., 2008; Ko et al., 2011).  
 
The role of T cells in drug reactions targeting the liver is less well defined. In 1997, 
Maria and Victorino (Maria and Victorino, 1997) described lymphocyte proliferative 
responses to drugs in over 50% of patients with drug-induced liver injury (DILI). 
More recently, histological examination of an inflamed liver from a single patient 
exposed to sulfasalazine revealed an infiltration of granzyme B secreting T-
lymphocytes (Mennicke et al., 2009). The discovery of HLA alleles as risk factors 
for DILI (e.g., flucloxacillin [B*57:01] (Daly et al., 2009), ximelagatran 
[DRB1*07:01] (Kindmark et al., 2007), lumiracoxib [DRB1*15:01] (Singer et al., 
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2010)) is supportive of an immune mechanism; however, biological data showing 
HLA restriction of drug-responsive cytotoxic T cells is lacking.   
 
4.2 Aims 
The strength of the association described for flucloxacillin-approximately 85% of 
cases carry at least one copy of HLA-B*57:01-prompted us 
x To investigate the cellular response in patients with flucloxacillin-induced 
liver injury.  
x To investigate whether flucloxacillin activates naïve CD8+ T cells from 
HLA-B*57:01 positive volunteers.  
 
4.3 Pateints and Methods  
4.3.1  Patients’  demographics   
Six patients with flucloxacillin-induced liver injury and six flucloxacillin-exposed 
tolerant controls were recruited. Table 4.1 lists the clinical features of the reactions 
and concomitant medications. Three HLA-B*57:01-positive flucloxacillin-naïve 
individuals were also selected from our frozen cell bank containing peripheral blood 
mononuclear cells (PBMCs) from four hundreds healthy volunteers recruited from 
northwest England. A total of 100 mL of blood was collected for both DNA and 
PBMC isolation. Genomic DNA was extracted using Chemagic magnetic separation 
(Chemagen, Baesweiler, Germany) and high-resolution sequence-based HLA typing 
was performed by the Histogenetics laboratory (Histogenetics, Ossining, NY) at the 
following loci: HLA-A, -B, -C, -DRB1, -DQB1, and DQA1. Approval for the study 
was acquired from the Liverpool local Research Ethics Committee and informed 
written consent was obtained from each donor.   
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Subject 
ID Age sex 
Peak liver function tests at time of liver injury* Time to onset 
Since 
reaction 
International 
Consensus 
Criterion 
RUCAMᵻ 
score 
Concomitant medication and comments 
ALT Bilirubin ALP GGT (weeks) (Years) 
3-5 Possible, 
6-8 
Probable, 
>8 Highly 
probable 
 
P1 73 F 18x ULN 7x ULN 6x ULN 22x ULN 4 11 10 
Reaction included maculopapular 
exanthema. Other causes of cholestatic 
hepatitis excluded 
P2 61 M 23x ULN 3x ULN 9x ULN Not measured 3 11 7 Eosinophilia and arthralgia; Other causes of cholestatic hepatitis excluded 
P3 73 F 13x ULN 12x ULN 2x ULN 12x ULN 4 2 3 
Also taking co-amoxiclav at time of the 
reaction. Other causes of cholestatic 
hepatitis excluded 
P4 90 F 11x ULN 13x ULN 4.5x ULN 14x ULN 3 3 6 Other causes of cholestatic hepatitis excluded 
P5 65 F 4x ULN 36x ULN 2x ULN 1.5x ULN 3 3 5 
Also taking co-amoxiclav at time of the 
reaction. Reaction included maculopapular 
rash. Other causes of cholestatic hepatitis 
excluded 
P6 78 F 36x ULN 17x ULN 5x ULN 16x ULN 3 6 10 
Reaction included maculopapular 
exanthema. Other causes of cholestatic 
hepatitis excluded 
 
Table 4.1 Clinical features of the patients. *ULN, upper limit of normal; ALT, alanine aminotransferase; ALP, alkaline phosphatase; GGT, gamma-glutamyl 
transferase. ᵻ The cases were evaluated by application of the Council for International Organisations of Medical Science scale, also called the Roussel Uclaf 
Causality Assessment Method (RUCAM). The pattern of liver injury was classified according to the International Consensus Meeting Criteria. Only cases having 
at least possible causality (score 3+) were included in the study. Diagnosis of DILI was done by expert hepatologists. 
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4.3.2 Detection of flucloxacillin-specific PBMC responses 
Proliferation of patient PBMC (0.15 x 106/well) against flucloxacillin (0.1-2 mM) 
and tetanus toxoid (5 μg/mL) was measured using the lymphocyte transformation 
test. Interferon-gamma (IFN-γ)   and   granzyme  B-secreting PBMCs were visualized 
using ELISpot (MabTech, Nacka Strand, Sweden) by culturing PBMC (0.5 x 
106/well; 200 μL) with flucloxacillin (1–2 mM) or PHA (5 μg/mL) for 48 hours. 
Detailed experimental procedure is described in chapter 2.  
 
 
4.3.3 Generation of T-cell clones from patients with flucloxacillin-induced liver 
injury 
PBMC (1 x106/well; 0.5 mL) from patients with DILI were cultured with 
flucloxacillin (1-2 mM) in RPMI 1640 supplemented with 10% human AB serum 
(Innovative Research, Class A), 25 mM HEPES, 10 mM  L-glutamine, and 25 
μg/mL transferrin (Sigma-Aldrich, Gillingham, UK). Cultures were supplemented 
with 200 IU/mL rhIL-2 (PeproTech, London, UK) on days 6 and 9. On day 14, 
CD8+ cells were isolated by positive selection using CD14 microbeads (Miltenyi 
Biotec, Bisley, UK) and the remaining cells designated as CD4+. The separated cells 
were then cloned by serial dilution (see chapter 2).  
 
 
Epstein-Barr virus (EBV) transformed B-cell lines were created from PBMC by 
transformation with supernatant from the virus-producing cell line B9.58. Lines were 
maintained in RPMI 1640 supplemented with 10% fetal bovine serum (Invitrogen, 
Paisley, UK), 100 mM L-glutamine, 100 μg/mL penicillin, 100 U/mL streptomycin, 
and used as a source of autologous antigen-presenting cells.  
 
 
4.3.4 Protocol for priming naive T Cells from healthy volunteers with 
flucloxacillin 
 
T-cell priming was performed with naive CD3+ T cells using our recently 
established protocol (Faulkner et al., 2012b). Blood was taken from healthy 
volunteers and PBMCs were isolated following previously described protocol. 
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CD14+ cells were isolated by positive selection utilising CD14 microbeads. CD4 
naïve T-cells were isolated by negative selection which involves CD25 depletion. 
CD3 cells were also isolated by negative selection utilising the Pan T isolation kit II, 
then CD25 and CD45RO positive cells were removed by positive selection leaving 
untouched CD3 naive cells. All cell isolations were carried out according to 
manufacturer’s  instructions  (Miltenyi  Biotec  Ltd).  Isolated cells were phenotyped by 
flow cytometry using CD25-PE, CD8-FITC, CD4-PE, CD45RA-FITC, CD45RO-
PerCP-Cy5.5, CD3-APC and CD14-FITC antibodies. The purity of isolated naïve T-
cells was more than 97%.  
 
 
Isolated CD14+ monocytes were differentiated for 7-8 days in medium containing 
800 U/ml IL-4 and 800 U/ml granulocyte-macrophage colony-stimulating factor 
(GM-CSF) (Pepro Tech EC Ltd., London, U.K.) to generate dendritic cells. Either 
fresh or frozen cells were resuspended at 1-2 x 106cells/ml and seeded at 3ml/well in 
six-well culture plates. Every 2 days, cells were fed with 3ml/well fresh medium 
containing 800 U/ml IL-4 and 800 U/ml GM-CSF. Tumour necrosis factor alpha 
(TNF-α);;  25ng/ml  (PeproTech)  and  lipopolysaccharide  (LPS);;  1μg/ml  (E.  coli  strain  
0111:B4, Sigma-Aldrich) were added for the last 16 hours of culture. The phenotype 
of immature Monocyte derived dendritic cells (Mo-DC) was detected by flow 
cytometry. Cells were CD1a and CD14negative, and CD11a, CD11c, CD40, CD80, 
CD83, CD86, CD274 and HLA Class II positive. 
 
 
At the end of 7-8 days incubation, immature Mo-DC were harvested and seeded at 8 
x 104 cell/well   in  500μl   in  24-well culture plates. Naïve CD3 T-cells were thawed 
quickly at 37°C then washed and added at 2 x 106 cell/well in 1ml of fresh medium. 
Flucloxacillin was then added at 1-2mM  in  500μl  to  cells.  Cultures  were  incubated  at  
37°C in 5% CO2 for 7-8   days.   Nitroso   sulfamethoxazole   (50μM)   was   used   as   a  
control antigen in all experiments.          
      
 
After the co-culture period, primed T cells (1 x 105/well; 200 μL) were restimulated 
with flucloxacillin (0.5-2 mM) or nitroso sulfamethoxazole (10-80   μM),   and   fresh  
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dendritic cells (4 x 103/well). Proliferation was assessed by [3H]-Thymidine 
corporation after 3 days and IFN-γ  release  was  assessed  by  ELISpot  after  2  days  in  
culture. The remaining cells were cloned as described above.  
 
 
4.3.5 Phenotype and specificity of T-cell clones  
Drug specificity was assessed by culturing autologous irradiated EBV-transformed B 
cells (1 x 104/well) and flucloxacillin (1-2 mM) with T-cell clones (5 x 104/well; 200 
μL) for 48 hours. Proliferation was measured by [3H] thymidine incorporation (0.5 
μCi/well, 5 Ci/ mmol, Morovek Biochemicals, Brea, CA) for the last 16 hours of 
culture followed by scintillation counting. Clones with a stimulation index of greater 
than 2 were expanded by repetitive stimulation with irradiated allogeneic PBMC (5 x 
104/well; 200 mL) and 5 mg/mL phytohemagglutinin (PHA) in interleukin (IL)-2 
containing medium (250 IU/mL). Drug-specificity of the selected T-cell clones was 
assessed by proliferation and ELISpot for IL13, IFN-γ,   FAS   ligand,   perforin,   and  
granzyme B (Mabtech). Autologous irradiated EBV transformed B cells (1 x 
104/well), flucloxacillin (1-2 mM), and T-cell clones (5 x 104/well; 200 μL) were 
incubated for 48 hours. Cell phenotyping was performed by flow cytometry on a BD 
FACSCanto II using CD4, CD8, CDR1, CCR2, CCR3, CCR4, CCR5, CCR8, CCR9, 
CCR10, CXCR3, CXCR6, and CLA antibodies (BD Biosciences) and the IO test 
Beta Mark TCR Vβ repertoire kit.  
 
 
4.3.6 Migration assay  
The 24-well transwell chambers were used with 5-lm pores. A total of 0.1 x 106 T 
cells (n = 4 CD8+ clones) in 100 μL chemotaxis buffer (RPMI 1640 + 0.5% bovine 
serum albumin [BSA]) were placed in the upper chambers. CCL17 (CCR4 ligand) 
and CCL25 (CCR9 ligand; 100 ng/ mL) in 600 μL chemotaxis buffer were placed in 
the lower wells and the cells were incubated for 2 hours. Cells migrating to the lower 
chamber were collected and counted using a hemocytometer.  
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4.3.7 Mechanistic studies to characterise HLA molecules involved in the 
presentation of flucloxacillin to T-cells  
 Two assays were used to study pathways of flucloxacillin presentation to T-cell 
clones. First, clones (5 x 104/well) were stimulated with autologous EBVtransformed 
B cells (1 x 104/well) in the presence of anti-HLA class I and class II blocking 
antibodies   (5   μL;;   BD   Biosciences,   Oxford, UK); second, clones were stimulated 
with autologous and allogeneic EBV-transformed B cells expressing different HLA-
B allotypes.   
 
 
4.4Results  
4.4.1 Flucloxacillin-specific PBMC responses in patients with DILI.  
Five of the six patients with DILI were positive for the risk allele HLA-B*57:01 
[Table 4.2]. The remaining patient, patient number 6, expressed HLA-B*44:02 and 
55:01. PBMCs were not stimulated to proliferate with flucloxacillin; however, 
flucloxacillin-specific PBMC responses were detected using an IFN-γ   ELISpot.  
PBMCs from five out of the six patients, including the patient who was positive for 
the HLA-B alleles other than B*57:01 (patient 6), were activated with the drug 
[Figure 4.1-A]. The ELISpot assay was repeated with PBMC from three patients at 
least 1 month after the initial test and the flucloxacillin-specific response remained 
the same. Figures 5.1-B and C shows the dose-dependent secretion of IFN-γ   and  
granzyme B from PBMC and a T-cell line, generated from patient 6, respectively. 
PBMC from flucloxacillin tolerant patients and drug- naïve volunteers were not 
stimulated with flucloxacillin to proliferate or secrete cytokines (data not shown).  
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Subject 
ID 
HLA profile 
HLA-A HLA-B HLA-C HLA-DRB1 
HLA-
DQB1 
HLA-
DQA1 
Patients with flucloxacillin-induced liver injury 
P1 02:01/29:02 07:02/57:01 06:02/07:02 15:01/07:01 03:03/06:02 01:02/02:01 
P2 01:01/02:01 44:02/57:01 05:01/06:02 01:01/07:01 03:03/05:01 01:01/02:01 
P3 02:01/03:01 07:02/57:01 06:02/07:02 15:01/07:01 03:03/06:02 01:02/02:01 
P4 01:01/29:02 45:01/57:01 06:02/06:02 03:01/07:01 02:01/03:03 02:01/05:01 
P5 01:01/29:02 08:01/57:01 06:02/07:01 03:01/07:01 02:01/03:03 02:01/05:01 
P6 02:01/11:01 44:02/55:01 03:03/05:01 14:01/04:01 03:01/05:03 01:01/03:01 
HLA-B*5701+volunteers used for in vitro T-cell priming 
V1 01:01/24:02 52:01/57:01 06:02/07:02 11:06/07:01 03:03/03:01 npa 
V 2 01:01/02:01 08:01/57:01 06:02/07:01 03:01/03:01 02:01/02:01 05:01/05:01 
V3 01:01/02:01 44:02/57:01 05:01/06:02 15:01/07:01 03:03/06:02 np 
 
Table 4.2- HLA type of patients and volunteers. anot performed.  
 
  
 
   
   
 
                                                                                      
                                                                                      
 
            
 
Figure 4.1- Stimulation of DILI patient lymphocytes with flucloxacillin. (A) Flucloxacillin-
induced IFN-γ   release   in   PBMC   from   patients   (P1-6). (B) Dose response to flucloxacillin 
using PBMC from patient 6 in an IFN-γ  and  Granzyme  B  ELISpot.  (C) IFN-γ  and  Granzyme  B  
ELISpot for a T-cell line from patient 6. 
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4.4.2 Characterisation of flucloxacillin-responsive CD4+ and CD8+ T-cell clones 
from patients with DILI.  
A total of 38 flucloxacillin-responsive T-cell clones expressing different Vβ 
receptors were isolated from PBMC of the four IFN-γ   ELISpot-positive patients 
expressing HLA-B*57:01. Of these, 35 were identified as CD8+ by flow cytometry 
[Table 4.3; 4.4]. Flucloxacillin-specific proliferation was dose-dependent, with 
clones displaying different response profiles up to a concentration of 2 mM. The 
proliferative response of CD4+ and CD8+ clones was associated with the secretion 
of T helper (Th) 1 and Th2 cytokines and cytolytic molecules perforin, granzyme B, 
and FasL [Figure 4.2]. Interestingly, the levels of cytolytic molecules secreted from 
the CD4+ clones was lower when CD4+ and CD8+ clones were compared.  
 
Seven flucloxacillin-responsive CD4+ clones were isolated from patient 6, who 
expressed HLA-B*44:02/55:01. Over 100 other CD8+ clones were also isolated, but 
flucloxacillin responses were not detected.  
 
 
Patient ID HLA-B allele PBMC ELISpot No. of flucloxacillin-specific clones CD4+ CD8+ 
P1 5701 - 0 0 
P2-5 5701 + 3 35 
P6 4402/5501 + 7 0 
 
Table 4.3- Table summarising the phenotype of T-cell clones isolated from patients with 
DILI 1-6.    
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Clone 
ID 
CD4+/ 
CD8+ Vβ 
Proliferation IFN-ƴ  ELISpot 
0 Flucloxacillin 0 Flucloxacillin 
cpm Fold change Spots 
Fold 
change 
Patients clones 
P2-50 CD8+ 1 9239 48693 5.3 128 320 2.5 
P2-180 CD8+ 21.3 4304 54007 12.5 66 228 3.5 
P2-207 CD8+ 21.3 8496 20615 2.4 51 TNTCa - 
P2-231 CD8+ 14 3793 15829 4.2 186 346 1.9 
P2-58 CD8+ NDb 3907 34785 8.9 14 191 13.6 
P5-75 CD8+ 3 5357 10496 2.0 49 197 4.0 
P3-2 CD4+ 12 6516 75533 11.6 49 197 4.0 
Volunteer clones 
V1-17 CD8+ 16 2608 12075 4.6 53 300 5.7 
V1-23 CD8+ 8 3244 8493 2.6 26 332 12.8 
V1-75 CD8+ 9 3271 14156 4.3 6 149 24.8 
V1-111 CD8+ 21.3 2497 8546 3.4 59 309 5.2 
V1-126 CD8+ 14 2982 28214 9.5 41 264 6.4 
V1-80 CD8+ 13.2 4152 9807 2.4 11 210 19.1 
V2-15 CD8+ 2 4682 27004 5.8 42 204 4.9 
V2-16 CD8+ 1 3779 218890 57.9 28 332 11.9 
V3-10 CD8+ 1 4190 86916 20.7 48 TNTC - 
   
Table 4.4- Phenotype of the clones from HLA-B*5701+ patients with flucloxacillin-induced 
liver injury and HLA-B*5701 volunteers. atoo numerous to count; bnot detected.  
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Figure 4.2- Stimulation of DILI patient T-cell clones with flucloxacillin. Proliferative response 
(black lines) and the secretion of cytokines and cytolytic molecules (coloured lines and 
pictures) from T-cell clones following flucloxacillin stimulation. Five representative clones 
isolated from patients 2-6 are shown. The data show the mean of replicate wells. SFC = 
spot forming cell.   
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4.4.3 Flucloxacillin activates naïve CD45RA+CD8+ T cells from volunteers 
expressing HLA-B*57:01.  
In an attempt to prime flucloxacillin-specific T-cell responses, naïve CD3+ T cells 
from HLA-B*57:01-positive volunteers (n = 3) were cocultured with autologous 
dendritic cells in the presence of flucloxacillin (HLA type of the volunteers shown in 
Table 4.2). After 8 days the primed T cells were restimulated with fresh dendritic 
cells and the drug and antigen-specificity were assessed using an IFN-γ   ELISpot.  
Low levels of IFN-γ  release with flucloxacillin was detectable and the response was 
found to be antigen-specific and dose-dependent [Figure 4.3]. IFN-γ  release  was  not  
detectable when the volunteer PBMCs were cultured with flucloxacillin. A total of 
600 CD4+ and CD8+ T-cell clones were generated from the flucloxacillin-primed 
PBMC. Of these, 35 CD8+ clones were identified as flucloxacillin-responsive by 
analysis of proliferation in the presence and absence of the drug [Table 4.4]. The 
flucloxacillin-specific dose-dependent proliferative response and the profile of 
cytokines and cytolytic molecules released were similar when CD8+ clones from 
patients with DILI and volunteers were compared [Figure 4.4]. Flucloxacillin-
responsive CD4+ clones were not detected in volunteers expressing HLA-B*57:01.  
 
 
 
     
 
 
 
     
Figure 4.3- Priming of naïve T cells from HLA-B*57:01 volunteers with autologous dendritic 
cells and flucloxacillin. IFN-γ  ELISpot  after  T-cell priming with flucloxacillin.  
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Figure 4.4- Priming of naïve T cells from HLA-B*57:01 volunteers with dendritic cells 
and flucloxacillin. Proliferative response (black lines) and the secretion of cytokines 
and cytolytic molecules (coloured lines and pictures) following flucloxacillin 
stimulation in five representative clones. The data show the mean of replicate wells. 
SCF = spot forming cell.  
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4.4.4 Flucloxacillin-responsive CD8+ T cells are restricted by HLA-B*57:01 and 
HLA-B*58:01.  
Activation of CD8+ T-cell clones from patients with DILI and volunteers expressing 
HLA-B*57:01 by flucloxacillin pulsed (16h) antigen presenting cells was inhibited 
with an anti-HLA class I, but not a class II, blocking antibody [Figure 4.5]. The APC 
was pulsed with drug to permit flucloxacillin protein binding, but to limit the 
availability of the drug. Thus, flucloxacillin responses are dependent on the drug-
derived antigen interacting with MHC class I molecules. HLA-B*57:01 restriction 
was studied using 16 flucloxacillin-responsive clones from patients and volunteers 
and antigen-presenting cells from 10 donors expressing different HLA-B molecules 
[Figure 4.6-A]. Six of the donors were selected based on expression of either HLA-
B*57:01 or the structurally related HLA-B*58:01, which have an overlap in the 
peptides they display (Barber et al., 1997). Importantly, abacavir-specific T-cell 
responses are not detectable using antigen-presenting cells expressing HLA-B*58:01 
(Chessman et al., 2008). Flucloxacillin-responsive clones were stimulated to 
proliferate with flucloxacillin-pulsed autologous antigen-presenting cells and 
antigen-presenting cells from the three donors expressing HLA-B*57:01. 
Furthermore, several clones were stimulated by flucloxacillin-derived antigens 
presented on antigen-presenting cells expressing HLA-B*58:01. Antigen-presenting 
cells expressing other B-alleles did not stimulate the clones [Figure 4.6-B]. Figure 
4.7 shows that activation of a single clone with flucloxacillin-pulsed autologous 
APC, but not with APCs from 12 additional donors, each expressing different HLA-
B alleles.  
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Figure 4.5- Inhibition of CD8+ flucloxacillin-specific proliferation with HLA-class I blocking 
antibodies in six clones using autologous antigen-presenting cells.   
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Figure 4.6- Flucloxacillin-specific stimulation of CD8+ clones is restricted by HLA-B*57:01 and 
B*58:01. (A) HLA-B alleles expressed by antigen-presenting cells used in (B). (B) Flucloxacillin-specific 
activation of six clones with flucloxacillin-pulsed (16 hours) antigen-presenting cells expressing HLA-
B*57:01 and B*58:01, but not other B alleles (open bars: medium only, filled bars: 2 mM 
flucloxacillin). Soluble drug was not used to prevent self-presentation by MHC class I molecules 
expressed on the clones. Part (B) show data from different clones.  
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4.4.5 Expression of distinct patterns of homing receptors on flucloxacillin-
specific T-cell clones.  
Distinct chemokine receptor expression profiles control, at least in part, the 
migration of immune cells. A panel of antibodies were used to demonstrate that 
flucloxacillin-responsive CD8+ clones from patients with DILI and HLA-B*57:01-
positive volunteers express high levels of the receptors CCR2, CCR4, CCR9, and 
CXCR3, but only low levels of CCR10 and CLA. Other chemokine receptors 
including CCR1, CCR3, CCR5, and CXCR6 were expressed al low levels on a 
limited number of clones [Table 4.5]. To show that the chemokine expression was 
functionally relevant, migration assays using transwells and the CCR4 and CCR9 
ligands, CCL17 and CCL25, respectively, were established. Both chemokines 
induced the migration of CD8+ clones from patients with DILI and drug-naïve HLA-
B* 57:01-positive subjects [Figure 4.8].   
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Clone 
ID 
Patient clones Volunteer clones 
1 2 3 4 5 6ᵻ 1ᵻ 2 3 4 5 6ᵻ 
CCR1 -* - 1.9ǂ - - - - - 1.6 - 2.0 1.6 
CCR2 1.7 2.0 2.5 1.3 2.4 1.9 1.7 1.6 2.0 - 2.3 2.1 
CCR3 - - 1.6 - - - - - - - - - 
CCR4 5.0 44.7 11.4 116 4.3 81.4 6.0 7.5 16.0 92.6 70.5 19.7 
CCR5 1.8 - - - - - 1.8 - 1.6 - 1.8 1.9 
CCR8 - - 1.6 - 1.6 - - - 1.6 - - - 
CCR9 2.9 2.9 4.1 2.1 3.4 3.2 2.3 5.9 3.9 2.5 2.0 2.9 
CCR10 - - 1.6 - - 1.6 - - 1.6 - 1.7 - 
CXCR3 30.2 11.9 25 9.9 11.9 6.4 16.5 19.2 18.3 7.9 37.4 28.5 
CXCR6 - - - - - - - - - - - - 
CLA - - - - - - - - - - - - 
 
Table 4.5- Tissue homing receptors expressed on T-cell clones. *(-) indicates a value of 1.5 
or   less;   ǂ   Data   presented   as   mean   fluorescent   index   (fluorescence   with  
antibody/fluorescence with isotype); ᵻ Clones also used in chemotaxis assay (see Figure 5.8).   
 
 
                            
 
 
                       
 
Figure 4.8- CD8+ clones migrate toward CCL17 and CCL25 in transwell chambers. Clones 
were placed in the top chamber. Chemokines were placed in the bottom chamber. After 2 
hour, the number of migrated cells in the bottom chamber was counted under the 
microscope. 
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4.5 Discussion  
PBMCs were isolated from six patients who developed cholestatic liver injury 
following flucloxacillin therapy to characterise for the first time the drug specific T-
cell response. PBMC activation with flucloxacillin was detected with five patients, 
including a HLA-B*57:01-negative individual (P6), using ELISpot to detect antigen-
driven cytokine release. Subsequently, CD4+ and CD8+ T cells were isolated from 
flucloxacillin-treated PBMC and cloned to characterise the cellular pathophysiology 
of the reaction in each patient. Flucloxacillin-responsive CD8+ clones expressing a 
range of different Vβ receptors were successfully isolated from the four HLA-
B*57:01 ELISpot-positive patients. Contrary to the finding of Chessman et al., 
(Chessman et al., 2008) showing that abacavir-activated T-cells were exclusively 
CD8+, we were also successful in isolating flucloxacillin-responsive CD4+ clones, 
albeit in low numbers. Activation of clones with flucloxacillin was concentration-
dependent and provoked the secretion of IFN-γ  and  cytolytic  molecules   (granzyme 
B, FasL, and perforin). Individuals given flucloxacillin achieve peak serum levels of 
60 µM. However, as there is significant biliary excretion, it is likely that a local 
concentration in the liver of 100 µM, which activates clones, could be achieved. All 
of the clones expressed the chemokine receptors CCR2, CCR4, and CCR9. CCR2 
and CCR9 are thought to be involved in the migration and accumulation of immune 
cells in the liver (Eksteen et al., 2004; Miura et al., 2012). Migration of the clones in 
response to CCR4 and CCR9 ligands demonstrated that the receptor expression was 
functionally relevant. In contrast to our previous studies with clones from patients 
with anticonvulsant-induced cutaneous eruptions (Homey et al., 2002; Naisbitt et al., 
2003b; Wu et al., 2007), the skin homing lymphocyte receptors CCR10 and CLA 
were detected at low levels. Flucloxacillin-responsive clones were also isolated from 
the HLA-B*44:02/55:01-positive patient. However, the clones were all CD4+. 
Collectively, these data argue that immune phenomena contribute to the 
development of flucloxacillin-induced liver injury.  
 
 
If the HLA-B*57:01 genotype is a functional determinant of flucloxacillin-induced 
liver injury, it should be possible to prime naïve T cells from HLA-B*57:01-positive 
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volunteers. To explore whether flucloxacillin activates naïve T cells, we employed 
our recently established T-cell priming assay that recapitulates key elements of 
events that occur in vivo during elicitation of an immunological drug reaction 
(Faulkner et al., 2012b). Flucloxacillin-primed T cells from HLA-B*57:01-positive 
volunteers were found to secrete IFN-γ   following   restimulation,  whereas   the   cells  
that had divided were shown to be CD8+ by T-cell cloning. Over 30 flucloxacillin-
specific CD8+ clones generated from three volunteers were found to proliferate and 
secrete cytokines and cytolytic molecules following drug stimulation. The profile of 
secretory molecules and chemokine receptor expression was similar to those 
observed with CD8+ clones from patients with DILI.  
 
 
Genetic restriction of the flucloxacillin-specific response was studied using a panel 
of CD8+ clones from patients with DILI and HLA-B*57:01-positive drug-naïve 
volunteers. Activation of CD8+ clones was detected with flucloxacillin-pulsed 
antigen-presenting cells from volunteers expressing HLA-B*57:01 and B*58:01. 
Flucloxacillin-pulsed antigen-presenting cells expressing other HLA-B alleles did 
not activate the clones. Importantly, HLA-B*57:01 and B*58:01 are part of the same 
HLA-B17 serotype; they differ in structure by only five amino acids and have a 
significant overlap in their antigenic peptide repertoire (Chessman et al., 2008). 
Given that the HLA-B*57:01 allele is in the strongest linkage disequilibrium with 
DRB1*07:01 in worldwide population (Adam et al., 2012), it is not surprising that 
all patients positive for B*57:01 were also carriers of DRB1*07:01. We are actively 
pursuing whether flucloxacillin-responsive CD4+ T cells are DRB1*07:01-
restricted.  
 
 
The discovery of surprisingly strong association between the expression of HLA 
alleles and DILI has changed the way in which researchers view this form of 
iatrogenic disease. Our data characterising flucloxacillin-responsive T cells in 
patients represents a fundamental breakthrough in our understanding of the role of 
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the adaptive immune system in liver injury. Moreover, the successful priming of 
naïve CD8 T cells using PBMC from HLA-B*57:01-positive volunteers effectively 
links the genetic association to the disease pathogenesis. In ongoing studies we are 
seeking to investigate how and why flucloxacillin-specific T cells kill liver cells in 
susceptible patients.         
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5.1 Introduction  
The existence of antigen-specific T cells in the peripheral blood and target organs 
such as skin and liver of drug hypersensitive patients provides a strong evidence for 
their contribution in the pathogenesis of a reaction (Brander et al., 1995; Schnyder et 
al., 2000; Nassif et al., 2004a; Beeler et al., 2006; Wu et al., 2007; Castrejon et al., 
2010a). It is believed that T cells are activated by drugs through covalent 
modification of protein which lead to generation of novel antigenic determinants 
(Padovan et al., 1996a; Padovan et al., 1997; Beeler et al., 2006; Castrejon et al., 
2010a; Elsheikh et al., 2010). However, the lack of studies that delineates the 
chemistry of drug-protein binding in hypersensitive patients has severely limited 
mechanistic studies that correlate immune function to the chemistry of antigen. 
Indeed, the basic theory of the hapten hypothesis of drugs hypersensitivity has been 
questioned by studies which reveal that drugs stimulate T cells via non-covalent 
interactions with MHC (Schnyder et al., 1997; Schnyder et al., 2000; Burkhart et al., 
2001; Hashizume et al., 2002; Farrell et al., 2003; Naisbitt et al., 2003a; Depta et al., 
2004; Nassif et al., 2004a; Keller et al., 2010).  
 
 
Non-immediate hypersensitive allergic reactions to β-lactam antibiotics persist as a 
significant clinical issue. It is well known that β-lactam antibiotics form irreversible 
covalent bonds with lysine residues on protein. Then, the nucleophilic lysine 
residues will target the β-lactam ring. This nucleophilic attack will lead to ring 
opening and penicilloyl group binding (Batchelor et al., 1965b). The penicilloyl 
antigen may also be formed by binding of the reactive degradation product 
penicillenic acid (Levine, 1960). Additionally, drug-protein antigens can derive from 
the conversion of β-lactam antibiotics into penicilloate and penicilloic acid (Levine 
and Redmond, 1969). Accordingly, binding of drug-protein is thought to be an 
essential step to initiate an immune response and to develop the clinical signs of 
hypersensitivity in high risk patients (Brander et al., 1995; Padovan et al., 1996a).  
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Flucloxacillin is an antistaphylococcal β-lactam antibiotic that is widely prescribed 
in the UK and Australia. Flucloxacillin can cause a cholestatic hepatitis which might 
be accompanied by a rash in some cases (Olsson et al., 1992). Healthy volunteers 
and in vitro research studies have revealed that 95%-97% of flucloxacillin is bound 
to plasma protein which is mainly albumin (Roder et al., 1995). Therefore, 
substituting flucloxacillin with alternate antistaphylococcal agents such as 
dicloxacillin, oxacillin, and cloxacillin should be considered. However, the structural 
similarities between these antistaphylococcal agents might lead to cross-reactivity 
(Baldo, 1999)which required further studies.  
 
 
Mass spectrometry methods have been recently developed in Liverpool to 
characterise the amino acids residues modified with drugs (Callan et al., 2009a; 
Jenkins et al., 2009a). Therefore, it was possible to further investigate the functional 
antigens formed from flucloxacillin in ex vivo cultures with T cells from DILI 
patients in order to correlate protein modification to drug antigenicity and 
immunogenicity. I acknowledge Dr Roz Jenkins from the proteomic team (Principal 
Experimental Officer) as all samples were analysed on the mass spectrometer by her.  
                                          
 
5.2 Aims  
The aim of this work was to;  
 
x Characterise the mechanisms of flucloxacillin antigen presentation to T cells. 
x Investigate T-cell receptor cross reactivity of the flucloxacillin-responsive T-
cell  clones  with  the  different  β-lactam antibiotics.  
    
  
126 
 
5.3 Patients and methods  
 
5.3.1  Patients’  demographics   
Six patients with flucloxacillin-induced liver injury and six flucloxacillin-exposed 
tolerant controls were enrolled for this study. Detailed clinical history on patients 
with flucloxacillin-induced liver injury is presented in chapter 4 [Table 4.1].  
 
5.3.2 Flucloxacillin-specific T cell clones cross reactivity  
T-cell clones were tested for reactivity against piperacillin, penicillin G, amoxicillin, 
oxacillin, cloxacillin, and dicloxacillin (all 0.1-2) mM, nitroso sulfamethoxazole (10-
100 μM), and abacavir (10-100 μM). Detailed method is described in chapter 2. Dose 
ranges have been shown to be optimal for the activation of T cells.  
 
5.3.3 Mechanistic studies of antigen presentation  
Autologus EBV-transformed B cells were subjected to glutaraldehyde fixation 
(0.05%) (Sigma-Aldrich, Gillingham, Dorset, UK) to terminate metabolic process 
and/or were incubated for 1,4, 16, or 48 hours with flucloxacillin (2 mM) followed 
by three washes to remove soluble drug. 
 
5.3.4 Characterisation of β-lactam albumin binding in culture  
To identify the key drug-modified lysine residues in albumin, we utilized our 
recently described mass spectrometry methods (Jenkins et al., 2009a; Whitaker et al., 
2011a; El-Ghaiesh et al., 2012). Flucloxacillin was incubated with EBV transformed 
B cells in RPMI 1640 medium containing 10% human AB serum for 1-48 hours. At 
each timepoint the cells were removed by centrifugation at 450g. Serum proteins 
were precipitated from culture supernatant by the addition of nine volumes of ice-
cold methanol followed by centrifugation at 14,000g and 4° C for 15 minutes. 
Flucloxacillin, piperacillin, penicillin G, amoxicillin oxacillin, cloxacillin, and 
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dicloxacillin were also incubated with human serum albumin at a molar ratio of drug 
to protein of 10:1 for 16 hours and methanol precipitated.  
 
 
Prior to mass spectrometry, all samples were reduced and alkylated before again 
being subjected to methanol precipitation. They were reconstituted in ammonium 
bicarbonate buffer (50 mM), digested with trypsin overnight at 37° C, and then 
desalted using C18 Zip-Tips (Millipore). Samples (2.4-5 pmole) were delivered into a 
QTRAP 5500 hybrid quadrupole-linear ion trap mass spectrometer (ABSciex) by 
automated in-line liquid chromatography (U3000 HPLC System, 5 mm C18 nano-
precolumn, and 75 μm x 15 cm C18 Pep-Map column [Dionex, Sunnyvale, CA]) by 
way of a 10-μm inner diameter PicoTip (New Objective,Woburn, MA). A gradient 
from 2% ACN/0.1% FA (v/v) to 50% ACN/0.1% FA (v/v) in 70 minutes was 
applied at a flow rate of 280 nL/min. The ionspray potential was set to 2,200–
3,500V, the nebulizer gas to 18, and the interface heater to 150° C. Established 
multiple reaction monitoring (MRM) transitions specific for drug-modified peptides 
were employed. MRM survey scans were used to trigger enhanced product ion dual 
mass spectrometry (MS/MS) scans of drug modified peptides. Total ion counts were 
determined from a second aliquot of each sample analysed by conventional liquid 
chromatography (LC)-MS/MS on the same instrument and were used to normalise 
sample loading on column. MRM peak areas were determined by MultiQuant 1.2 
software (ABSciex). The relative intensity of MRM peaks for each of the modified 
lysine residues within a sample were compared and were normalized across samples. 
All samples were analysed on the mass spectrometer by Dr Roz Jenkins (Principal 
Experimental Officer). 
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5.3.5 Immune epitope database analysis (IEDB) software  
The MHC class I T cell epitope prediction tool on the IEDB website 
(http://tools.immuneepitope.org/main/html/tcell_tools.html)  was used to predict 
which peptides from human serum albumin were likely to be high affinity binders to 
HLA-B*57:01. The IEDB recommended prediction method was used, the relevant 
allele was selected, and all lengths of peptides were allowed. Peptides with median 
inhibitory concentrations (IC50s) of <50 nM (high affinity binders) or <500 nM 
(intermediate affinity binders) containing lysine residues modified by all of the β-
lactams studied were listed. 
 
5.3.6 Statistical analysis  
 Student t test was used to analyse the proliferation and ELISpot data. 
 
5.4 Results  
5.4.1 Level of flucloxacillin-albumin binding at specific lysine residues 
correlates with the processing-dependent activation of T-cell clones  
To investigate the role of drug protein binding in the generation of flucloxacillin-
derived antigens for T cells, antigen-presenting cells were pulsed with the drug for 
1,4,16, and 48 hour, prior to washing and exposure to clones. A 16 to 48-hour 
incubation period was required to stimulate a reproducible proliferative response 
with all clones [Figure 5.1-A] and the strength of the response was similar to that 
seen with the soluble drug.  
 
  
Mass spectrometric analysis of albumin in flucloxacillin-treated cell cultures 
revealed an irreversibly bound hapten of the predicted mass of 453 amu, which was 
formed from direct adduction of flucloxacillin. After 48 hours, 12/59 lysine residues 
were modified, including Lys190 and Lys212, which are modified on albumin 
isolated from plasma of all flucloxacillin-exposed patients (Jenkins et al., 2009a). 
Adduct formation on albumin at each modified Lys residues was dependent on 
129 
 
incubation time [Figure 5.1-B] and a strong positive correlation between the level of 
flucloxacillin binding and the strength of the proliferative response stimulated by 
flucloxacillin-pulsed antigen-presenting cells was observed [Figure 5.1-C]. 
Glutraldehyde fixation of antigen-presenting cells, which inactivates protease 
enzyme activity and antigen processing, inhibited the proliferation of clones against 
flucloxacillin-pulsed antigen-presenting cells [Figure 5.1-D].    
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Figure 5.1- Flucloxacillin binds irreversibly to protein to stimulate T-cell clones. (A) 
Stimulation of a panel of 10 clones with flucloxacillin-pulsed antigen-presenting cells. 
Antigen-presenting cells were washed repeatedly after pulsing to remove unbound drug. 
The  data  shows  the  mean  of  replicate  wells.  Results  were  analysed  by  Student’s  t test. (B) 
Flucloxacillin binds to multiple lysine residues on serum albumin in a time-dependent 
manner in cell culture, as detected by mass spectrometry. (C) Correlation between the 
time-dependent relative level of flucloxacillin covalent binding to albumin in serum-
supplemented culture medium and the strength of the mean drug-specific T-cell response 
(n = 10 clones; cpm in control wells subtracted). (D) Stimulation of a panel of 10 clones with 
flucloxacillin and irradiated or glutaraldehyde-fixed antigen-presenting cells. Fixation blocks 
protein processing. The data show the mean of replicate wells. Results were analysed by 
Student t test.      
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5.4.2 Flucloxacillin-responsive clones display additional reactivity against 
alternative   β-lactam antibiotics that form similar haptenic determinants on 
albumin.  
To study chemical restriction of the flucloxacillin-specific T-cell response, clones 
were cultured with antigen-presenting cells and 4 β-lactam antibiotics (flucloxacillin, 
piperacillin, amoxicillin, and penicillin G) and hapten albumin binding profiles and 
proliferation were measured. Greater than 80% of the clones displayed additional 
reactivity against at least one β-lactam, which form similar haptenic determinants 
with Lys residues on albumin. In fact, drug modifications were detectable at eight 
Lys residues (Lys132, Lys190, Lys199, Lys212, Lys351, Lys432, Lys525, and 
Lys541) with all four drugs. Figure 5.2 shows the drug structures, the proliferative 
response of four representative clones that show the different crossreactivity profiles 
observed, and the sites of lysine modification on albumin. Figure 5.3 shows the 
dose-dependent proliferative response of clones with optimal stimulatory 
concentrations of the different drugs.  
 
 
In subsequent experiments, hapten albumin binding profiles and T-cell responses 
were studied with oxacillin, cloxacillin, and dicloxacillin [Figure 5.4-A], which are 
used in certain countries as an alternative to flucloxacillin. Hapten modifications 
were detected on the same 12 lysine residues with all four drugs and the level of 
modification at each site was comparable [Figure 5.4-B]. Furthermore, all of the 
flucloxacillin-responsive clones tested displayed reactivity against the structurally 
related drugs [Figure 5.4-C].  
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Figure 5.2- Flucloxacillin binds irreversibly to protein to stimulate T-cell clones. (A) Variable 
crossreactivity of flucloxacillin-specific clones with related β-lactam antibiotics and mass 
spectrometric analysis of the profile of lysine modification with each drug in vitro (table 
shows Lys residues modified after 16 hours [10:1; drug: albumin]). Four representative 
clones that illustrate the different response profiles are shown (see Figure 5.3 for dose-
response curves). The data show the mean of replicate wells. (B) Identification of peptides 
from serum albumin with high binding affinity to HLA-B*57:01, which contain lysine 
residues consistently modified with the crossreactive   β-lactam antibiotics. IEDB analysis 
software was used to identify the peptides.      
0
5
10
15
20
0
20
40
60
80
0
10
20
30
0
10
20
30
 Sites of lysine modification on albumin 
 4 12 137 162 190 195 199 212 351 432 436 475 525 541 545 
Flucloxacillin x 9 9 9 9 9 9 9 9 9 9 9 9 9 9 
Amoxicillin x 9 9 9 9 x 9 9 9 9 9 9 9 9 x 
Penicillin G 9 x 9 x 9 x 9 9 9 9 x x 9 9 9 
Piperacillin x 9 9 9 9 9 9 9 9 9 9 x 9 9 x 
0 1 2 1 2 1 2 1 2 mM 
 Piperacillin 
 Penicillin G 
Flucloxacillin 
Amoxicillin 
Amoxicillin 
Flucloxacillin  Penicillin G  Piperacillin 
P
ro
lif
er
at
io
n 
(c
pm
x1
0 
3 )
 
Al lele Start End
Peptide 
Length Sequence Method used
Percenti le 
Rank IC50 (nM) Lys ine
HLA-B*57:01 212 219 8 KAWAVARL NetMHCpan 0.5 396.76 212
HLA-B*57:01 209 219 11 RAFKAWAVARL NetMHCpan 0.5 427.98 212
HLA-B*57:01 190 199 10 KASSAKQRLK SMM 0.6 72.68 190, 199
HLA-B*57:01 191 200 10 ASSAKQRLKC SMM 2 228.03 199
HLA-B*57:01 538 547 10 KATKEQLKAV SMM 2 216.05 432, 436
Prediction method: IEDB recommended | Low percentile = good binders
...QAADKAACLLPKLDELDELRDEGKASSAKQRLKCASLQKFGERAFKAWAVARLSQRFPKAEFAEVSK....
Lys190 Lys212Lys199
Bold text – tryptic peptide 
Large text – MHC binding peptide 
Red text – flucloxacillin-modified Lys 
A 
B 
133 
 
 
 
 
  
  
 
 
                 
 
               
 
Figure 5.3- Concentration-dependent activation of CD8+ T-cell clones with flucloxacillin, 
amoxicillin, penicillin G, and piperacillin. Proliferation was measured by incorporation of 
[3H]-thymidine. Results show mean cpm in the presence and absence of drug.   
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Figure 5.4- Flucloxacillin-responsive CD8+ clones are stimulated with oxacillin, cloxacillin, 
and dicloxacillin, which, bind irreversibly to similar lysine residues on albumin. (A) 
Structures of the drugs. (B) Mass spectrometric analysis of the profile of lysine modification 
on albumin with each drug in vitro after 16 hours (10:1; drug: albumin). (C) Stimulation of 
six flucloxacillin-responsive T-cell clones with oxacillin, cloxacillin, and dicloxacillin. 
Proliferation was measured by incorporation of [3H]-thymidine. Results show mean cpm in 
the presence and absence of drug.  
 
 
 
 
 
 
0
5
10
15
20
25
30
35
0 0.5 1 1.5 2
0
5
10
15
20
0 0.5 1 1.5 2
0
10
20
30
40
50
60
0 0.5 1 1.5 2
0
2
4
6
8
10
0 0.5 1 1.5 2
P
ro
lif
er
at
io
n 
(c
pm
x1
0
-3
)
Volunteer clones Patient clones
Concentration (mM) Concentration (mM)
XFlucloxacillin Oxacillin Cloxacillin Dicloxacillin
Flucloxacillin
Oxacillin
Cloxacillin
Dicloxacillin
0
20
40
60
80
100
120
140
0 0.5 1 1.5 2
0
5
10
15
20
25
30
35
0 0.5 1 1.5 2
a.
b.
c.
0.0E+00
5.0E+07
1.0E+08
1.5E+08
2.0E+08
4 1
2
1
3
7
1
6
2
1
9
0
1
9
5
1
9
9
2
1
2
3
5
1
4
3
2
4
3
6
4
7
5
5
2
5
5
4
1
5
4
5
0.0E+00
5.0E+07
1.0E+08
1.5E+08
2.0E+08
4 1
2
1
3
7
1
6
2
1
9
0
1
9
5
1
9
9
2
1
2
3
5
1
4
3
2
4
3
6
4
7
5
5
2
5
5
4
1
5
4
5
0.0E+00
5.0E+07
1.0E+08
1.5E+08
2.0E+08
0.0E+00
5.0E+07
1.0E+08
1.5E+08
2.0E+08
Lysine residue
N
o
rm
al
iz
ed
 io
n 
co
un
t
Flucloxacillin
Oxacillin
Cloxacillin
Dicloxacillin
A 
C 
B 
135 
 
The drug metabolite nitroso sulfamethoxazole, which binds irreversibly to cysteine 
residues on multiple proteins generating antigenic determinants for Tcells, was used 
as a specificity control. Flucloxacillin-responsive clones were not activated with the 
nitroso metabolite [Figure 5.5-A].    
  
5.4.3 Albumin peptide sequence incorporating the flucloxacillin binding sites 
Lys190 and Lys212 interact with HLA-B*57:01 
The Immune Epitope Database Analysis Resource was utilised to explore potential 
high affinity HLA-B*57:01 binding peptides derived from human serum albumin. 
Several peptide sequences that contain flucloxacillin-modifiable Lys residues were 
identified as high affinity HLA-B*57:01 binders [Figure 5.2-B], including Lys190 
and Lys212, which are targets for flucloxacillin-derived haptens in drug-exposed 
patients.  
 
5.4.4 Flucloxacillin-responsive CD8+ T cells are not activated with abacavir  
The drug-specific T-cells response in abacavir hypersensitive patients is exclusively 
HLA-B*57:01 restricted; thus, we conducted experiments to determine whether 
flucloxacillin-responsive clones are activated with abacavir. All 14 clones tested 
proliferated in the presence of flucloxacillin, but not abacavir [Figure 5.5-B]. 
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Figure 5.5- Flucloxacillin-responsive HLA-B*57:01 restricted CD8+ clones from patients and 
volunteers are not stimulated with nitroso sulfamethoxazole or abacavir . (A) Stimulation of 
7 flucloxacillin-responsive T-cell clones (4 from patients with liver injury; 3 from volunteers) 
with flucloxacillin and nitroso sulfamethoxazole. (B) Stimulation of 14 flucloxacillin-
responsive T-cell clones (7 from patients with liver injury; 7 from volunteers) with 
flucloxacillin and abacavir. Proliferation was measured by incorporation of [
3
H]-thymidine. 
Results show mean cpm±SD in the presence and absence of drug.  
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5.5 Discussion  
 
It is well established that an obligatory step in β-lactam allergy is the formation of 
covalent bonds between drug and lysine residues on protein. The β-lactam ring is 
targeted directly by nucleophilic lysine residues. Nucleophilic attack leads to ring 
opening and binding of the penicilloyl group. The protein conjugate can also be 
formed through binding of the reactive degradation product penicillenic acid. Using 
mass spectrometric methods, we recently identified albumin as a major circulating 
protein modified with β-lactam antibiotics including flucloxacillin, defined the 
profile of drug protein conjugation at specific lysine residues with respect to dose 
and incubation time, and characterised for the first time the sites of modification 
associated with the stimulation of a clinically relevant drug-specific T-cell response 
(Jenkins et al., 2009a; Whitaker et al., 2011a; El-Ghaiesh et al., 2012). Herein, we 
show that (1) the stimulation of clones with flucloxacillin-pulsed antigen-presenting 
cells, and (2) the detection of flucloxacillin haptens on albumin in culture are time-
dependent. Furthermore, simultaneous measurement of antigenicity and immune 
responsiveness revealed that the cumulative level of flucloxacillin protein binding at 
each timepoint studied correlated directly with the strength of the T-cell proliferative 
response. Aldehyde fixation of antigen-presenting cells, which inhibits processing, 
blocked the flucloxacillin-specific stimulation of clones [Figure 5.1-D]. Collectively, 
these data indicate that flucloxacillin-protein binding is critical for the formation of 
functional T-cell antigens. Interestingly, the β-lactam antibiotics piperacillin, 
amoxicillin, and penicillin G, which bind to similar albumin lysine residues, also 
stimulated the flucloxacillin-responsive clones. The detection of broadly 
crossreactive T cells is in contrast to our recent studies describing highly drug-
specific T-cells in piperacillin-hypersensitive patients (see chapter 2), and suggests 
that MHC binding peptides and the core penicilloyl structure provide the binding 
energy to drive T-cell responses in patients with flucloxacillin-induced liver injury.  
 
 
Carey and van Pelt (Carey and van Pelt, 2005) raised an antibody specific for 
flucloxacillin-modified proteins to characterise whether flucloxacillin treatment 
results in adduct formation in vivo. Interestingly, they found that western blot 
analysis of liver cytosol from treated rats revealed a single-flucloxacillin-modified 
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band with a weight of ~66 kDa, (i.e., the molecular weight of albumin). Thus, in our 
next series of experiments the IEDB analysis resource was used to identify HLA-
B*57:01 binding peptides derived from albumin. Peptide sequences containing 
Lys190, Lys199, and Lys212 were identified as high affinity binders at HLA-
B*57:01. Interestingly, all the penicillins investigated modify albumin at these 
residues.   
 
 
Previous studies have reported that it may be feasible to substitute flucloxacillin with 
an alternative anti-staphylococcal agent such as oxacillin, cloxacillin, or dicloxacillin 
in HLA-B*57:01-positive individuals (Daly et al., 2009). Our data shows remarkably 
consistent albumin binding profiles and stimulation of HLA-B*57:01-restricted 
CD8+ clones across the different drugs. Thus, loss of fluorine, which has the same 
volume as hydrogen, and chlorine, does not alter the binding of flucloxacillin to 
protein or indeed the assembly of haptenic determinants that stimulate T cells. This 
clearly highlights a potential risk of using alternative oxacillins in HLA-B*57:01-
positive patients with liver injury.  
 
 
Abacavir has recently been shown to interact with amino acid residues located deep 
within the HLA-B*57:01 (but not HLA-B*58:01) binding groove and alter the 
repertotire of self-peptides that are presented to CD8+ T cells (Chessman et al., 
2008; Alfirevic et al., 2012; Illing et al., 2012; Norcross et al., 2012; Ostrov et al., 
2012). In contrast, flucloxacillin does not alter peptide binding to HLA-B*57:01 
(Norcross et al., 2012), which supports our hypothesis that functional flucloxacillin 
antigens derive from naturally processed drug-protein conjugates. Flucloxacillin-
responsive CD8+ clones from patients with liver injury and HLA-B*57:01-positive 
volunteers were not stimulated with abacavir. Furthermore, abacavir-responsive 
CD8+ clones generated from the same volunteers were not activated with 
flucloxacillin (results not shown).  
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Collectively, these data demonstrate that the different chemistries associated with 
these two drugs result in the presentation of unique HLA-B*57:01-restricted 
epitopes to T cells.          
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Chapter Six  
Final Discussion 
β-lactam antibiotics are considered the cornerstone of therapy for the treatment of 
many bacterial infections. They work by inhibiting bacterial cell wall synthesis. 
Critical   to   their  mechanism   of   action   is   chemical   reactivity.   The   β-lactam nucleus 
binds irreversibly to amino acid residues within the active site of penicillin binding 
proteins – a group of bacteria cell wall proteins with high affinity for penicillin - 
preventing crosslinking of the nascent peptidoglycan layer, disrupting cell wall 
synthesis. Unfortunately,   the   intrinsic   reactivity   of   β-lactam antibiotics leads to 
covalent modification of other endogenous proteins, in particular lysine residues and 
such drug-protein adducts are thought to be involved in a variety of adverse events 
including hypersensitivity. Nucleophilic attack of the amino acid leads to ring 
opening and binding of the penicilloyl group. The penicilloyl moiety can also be 
formed through binding of the reactive degradation product penicillenic acid. 
Furthermore, drug-protein adducts derive  from  spontaneous  conversion  of  β-lactam 
antibiotics into penicilloic acid and penicilloate (Levine, 1960; Levine and Ovary, 
1961; Batchelor et al., 1965a; Pullen et al., 1968; Chang et al., 2012). Surprisingly, 
under cell culture conditions, adduct   formation   by   the   β-lactam antibiotics is 
incredibly protein-specific. All of the drugs analysed to date (penicillin G, 
amoxicillin, flucloxacillin, piperacillin) modify extracellular protein, but essentially 
ignore cellular protein (Meng et al., 2011; Whitaker et al., 2011a; El-Ghaiesh et al., 
2012; Monshi et al., 2013).   This   protein   selectivity   is   restricted   to   the   β-lactam 
antibiotics, other reactive chemicals and drug metabolites modify multiple cellular 
and extracellular proteins (Naisbitt et al., 2002; Pickard et al., 2007; Sanderson et al., 
2007; Callan et al., 2009b; Megherbi et al., 2009; Pickard et al., 2009; Castrejon et 
al., 2010b). Using novel mass spectrometric methods, we identified albumin as the 
major protein modified with the drugs and defined the profile of drug protein 
conjugation at specific lysine residues with respect to dose and incubation time.  
Since human serum albumin accounts for the majority of serum-bound penicilloyl 
groups in vivo (Pickard et al., 2009), we also considered it a suitable model for 
investigating  the  chemistry  underlying  β-lactam  adduct  formation  in  patients.  The  β-
lactam antibiotics piperacillin and flucloxacillin were found to bind to the same 
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lysine residues that are modified in vitro (Jenkins et al., 2009a; Whitaker et al., 
2011a). These data confirm that drug protein adducts are formed in exposed patients 
and hence have the potential to be recognized by the host immune system. However, 
since adducts were detected in 100% of exposed patients, factors in addition to 
antigen formation are needed to translate the antigenic signal into a pathogenic 
immune response.  
 
 
The presence of drug-specific T-cells in blood and target organs of hypersensitive 
patients provides a robust case for their involvement in the pathogenesis of the 
reaction. Previous studies have characterized CD4+ and CD8+ clones responsive to a 
range of drug and chemical allergens including p-phenylenediamine, anti-
convulsants, anti-bacterial agents and anti-HIV drugs (Schnyder et al., 2000; Naisbitt 
et al., 2003a; Naisbitt et al., 2003b; Naisbitt et al., 2005; Wu et al., 2006; Wu et al., 
2007; Elsheikh et al., 2010; Jenkinson et al., 2010; Whitaker et al., 2011a). β-lactam 
antibiotics stimulate CD4+ and CD8+ T-cells from hypersensitive patients to 
proliferate and secrete a diverse cytokine secretion profile (Hertl et al., 1993c; 
Mauri-Hellweg et al., 1996; Brugnolo et al., 1999; Sachs et al., 2002; Beeler et al., 
2006; Rozieres et al., 2009). Brander et al. (Brander et al., 1995) demonstrated that 
penicillin conjugated directly to MHC and synthetic penicillin-albumin constructs 
stimulate T-cells from allergic patients. Penicillin peptide conjugates designed to fit 
in specific MHC molecules have also been shown to stimulate specific T cell clones 
(Padovan et al., 1996b); however, experiments that relate the number of modified 
amino acid residues on albumin to the stimulation of specific T-cells have not been 
performed. 
 
   
 
The aim of this thesis was to explore the cellular and chemical basis of two very 
different  forms  of  β-lactam hypersensitivity reaction, piperacillin-induced skin injury 
in patients with cystic fibrosis and flucloxacillin-induced liver injury. The 
availability of samples collected from well-defined clinical cohorts and a cell bank of 
142 
 
HLA-typed drug naïve volunteers enabled us to delineate similarities and differences 
between the two pathogenic drug antigen-specific immune responses. 
Hypersensitivity   reactions   to   β-lactam antibiotics such as piperacillin were first 
reported in patients with cystic fibrosis in 1970. The majority of  β-lactam reactions 
in patients with cystic fibrosis are non-immediate; mean time of onset 9.1 days. An 
accelerated response is often seen following re-exposure. Reactions consist of 
maculopapular rashes, fever and/or flu-like symptoms. This clinical pattern suggests 
an   immunological   event   rather   than   direct   toxicity;;   however,   unlike   β-lactam 
reactions in patients without cystic fibrosis, an immune pathogenesis has not been 
confirmed by skin testing or in vitro analysis of drug-specific T-cell responses. The 
prevalence of hypersensitivity reactions in patients with cystic fibrosis, the 
appearance of multi-drug resistant organisms and the cost of new drugs makes it 
increasingly difficult to treat infective episodes effectively. Patients often have to be 
admitted to hospital disrupting education, work and family life. When a patient has 
had a history of a previous hypersensitivity reaction they need desensitizing to the 
drug through a dose escalation regimen at the start of every treatment course. Thus, it 
is especially important to understand mechanisms relating to the development of 
hypersensitivity in patients with cystic fibrosis. 
  
 
 
In initial experiments the lymphocyte transformation test was used to identify drug-
specific lymphocyte proliferative response in approximately 70% of clinically-
diagnosed piperacillin hypersensitive patients. The response was drug concentration 
dependent and associated with the secretion of cytokines and cytolytic molecules. 
Importantly, piperacillin-specific responses were not detected in drug-tolerant and 
drug-naïve controls with cystic fibrosis. These data suggest that it might be possible 
to administer piperacillin at therapeutic doses to hypersensitive patients with a 
negative lymphocyte transformation test; however, for this assay to be used 
diagnostically in the cystic fibrosis unit an improved understanding of drug-induced 
hypersensitivity reactions is required. Thus, Liverpool, in collaboration with the 
cystic fibrosis unit in Leeds, has recently initiated the first longitudinal study of drug 
hypersensitivity to probe the multiple pathways that regulate cellular immune 
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responses and delineate the key   “switches”   that   determine  whether   drug   exposure  
will be associated with the development of a hypersensitive or tolerant response. 
Patient samples are being collected prior to a reaction, in the acute phase and 
longitudinally as the patient recovers. Since these studies with patient PBMC 
provide limited information on the mechanism of drug antigen presentation and the 
phenotype and function of piperacillin-specific T-cells, T-cells were cloned from a 
cohort of hypersensitive patients with positive lymphocyte transformation test 
results. The majority of piperacillin-responsive T-cells were CD4+ and stimulation 
of the clones was highly drug-specific. These data indicate that the piperacillin side-
chain confers specificity at the MHC T-cell receptor interface as each of the drug 
structures  tested  contained  the  same  core  β-lactam nucleus. The activation of clones 
was drug concentration-dependent. Furthermore, T-cell responses were only detected 
after a culture period of 4-16h. These data indicate that the activation of clones is 
dependent on the degradation of the drug and irreversible modification of protein 
lysine residues or lysine residues found on MHC-binding peptides displayed on the 
surface of antigen presenting cells. To determine whether clones are activated via a 
hapten mechanism, a piperacillin-albumin adduct was synthesized with piperacillin 
bound to the same lysine residues modified in patient plasma and in cell culture. This 
conjugate was found to activate clones and the T-cell response was dependent on 
protein processing.  
 
 
Interestingly, the time-dependent activation of piperacillin clones explained why it 
was difficult to detect T-cell-mediated killing of 51Cr-loaded autologous target cells. 
The standard 51Cr-release assay is analysed 4h after drug antigen exposure. By pre-
treating antigen presenting cells with piperacillin for 16h, drug-specific T-cell 
mediated killing was readily detectable. 
 
 
Multiple hypersensitivity reactions in patients with cystic fibrosis is an important 
clinical problem. Thirty per cent of hypersensitive patients developed reactions to 
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more than 2 drugs. To investigate whether this clinical phenomenon relates to the 
activation of naïve T-cells   against   different   β-lactam antibiotics or T-cell receptor 
crossreactivity, PBMC responses were analysed in patients hypersensitive to the 
drugs piperacillin, meropenem and aztreonam and clones were generated to study 
crossreactivity. PBMC proliferative responses and cytokine release were detectable 
when PBMC were cultured with the different drugs. T-cell clones responsive against 
each drug were generated successfully from several hypersensitive patients; 
however, crossreactivity with the different compounds was not observed. 
Importantly, each drug formed a structurally distinct hapten, but bound to similar 
lysine residues on human serum albumin – albeit at different levels; hence, the 
different haptenic structures provide the chemical basis for the highly drug specific 
T-cell response detected in patients with multiple hypersensitivity. Interestingly, 
Daubner et al (Daubner et al., 2012) found that in patients with multiple drug 
hypersensitivity the drug-responsive T-cells are contained in a pre-activated T-cell 
fraction (CD38high [marker for cell activation]; PD-1high marker for cell exhaustion]); 
thus, as part of our longitudinal study, we are measuring these markers to explore 
whether this phenotype is a common characteristic of the drug-specific T-cell 
response in this patient group. 
 
 
In stark contrast to piperacillin, human exposure to flucloxacillin is associated with 
liver injury. The incidence of flucloxacillin-induced liver injury has been estimated 
at 8.5 in 100000 new users (Daly and Day, 2012). The majority of reactions are non-
immediate; symptoms are detected 1-45 days after starting treatment. Recently, Daly 
et al. (Daly et al., 2009) detected a strong association between susceptibility to 
flucloxacillin DILI and expression of HLA-B*5701, which implies a direct effect of 
the gene product on the disease pathogenesis. These findings suggest that a major 
susceptibility factor relates to the restriction of the fit of the antigen into particular 
immunological receptors in an appropriate chemical form. Flucloxacillin is known to 
form an antigen in patients and in vitro through the irreversible modification of 
specific lysine residues on albumin (Jenkins et al., 2009b); however, drug-responsive 
T-cell responses in patients with flucloxacillin-induced liver injury have not been 
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described. In fact, little is known about the role of the adaptive immune system in 
reactions targeting the liver. In 1997, Maria and Victorino (Maria and Victorino, 
1997) described lymphocyte responses to drugs in over 50% of patients with drug-
induced liver injury. However, the phenotype and function of T-cells and the 
mechanisms of antigen presentation have not been described. Thus, the final aim of 
my thesis was to characterize the cellular response in patients with flucloxacillin-
induced liver injury, investigate whether it is possible to prime naïve T-cell against 
flucloxacillin using PBMC from volunteers carrying the risk allele HLA-B*57:01 
and study mechanisms of flucloxacillin-specific T-cell activation.  
 
 
In initial experiment, somewhat disappointingly, the lymphocyte transformation test 
yielded negative results. Flucloxacillin-responsive T-cells were not detectable in 
patients with liver injury or drug-exposed controls. However, when the end-point of 
the PBMC assay was changed to an ELIspot, the flucloxacillin-specific secretion of 
cytokines and cytolytic molecules was detected in 5 out of 6 DILI patients. These 
data support the work of Rozieres et al., (Rozieres et al., 2009) who found that IFN-γ  
ELIspot  was  a  sensitive  assay  to  detect  β-lactam-induced skin injury.  
 
 
In agreement with the genetic association study of Daly et al, 4 patients with a 
positive flucloxacillin PBMC ELIspot expressed HLA-B*57:01. The majority of 
flucloxacillin clones isolated from these patients were CD8+ and presentation of the 
drug-derived antigen was HLA-class I restricted. Utilizing antigen presenting cells 
from blood donors expressing different HLA-B alleles it was possible to show that 
these clones were activated with flucloxacillin-pulsed antigen presenting cells only if 
the cells expressed B*57:01. These data are the first to fully characterize the nature 
of the drug-specific T-cell response in patients with liver injury. In on-going 
experiments, we have now isolated and are beginning to characterize drug-specific 
T-cells from patients with co-amoxiclav, isoniazid and trimethoprim-induced liver 
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injury. Thus, in years to come it is highly likely that the adaptive immune system is 
shown to play an important role in liver reactions to numerous drugs. 
 
Next, we utilised our HLA-typed cell bank containing PBMC from 400 HLA-typed 
(drug naïve) blood donors (Alfirevic et al., 2012) and a recently established dendritic 
cell T-cell priming assay (Faulkner et al., 2012a) to study whether flucloxacillin 
activates naïve T-cells in an HLA-B*57:01 restricted fashion. This assay relies on 
the isolation and culture of highly pure T-cell and antigen presenting cell 
populations. Immature monocyte-derived dendritic cells and naive T-cells are used 
as antigen presenting cells and responder cells, respectively. After an 8 day culture 
period, T-cells are re-exposed to flucloxacillin and dendritic cells and antigen 
specificity is measured shortly after. Through cloning of the drug primed T-cell 
cultures, flucloxacillin was shown to selectively activate CD8+ T-cells and again the 
T-cell response was HLA-B*57:01 restricted. Collectively, these studies link the 
genetic association to the disease pathogenesis. The one area that remains to be 
addressed is to investigate how and why flucloxacillin-specific T-cells kill liver cells 
in susceptible patients. A major obstacle to these studies is a lack of autologous 
immune and liver cells. On-going studies in Liverpool we are attempting to 
overcome this through the generation of HLA-matched induced pluripotent stem 
cell-derived hepatocyte-like cells.   
        
 
Utilising the same approach as described above with piperacillin we found that the 
T-cell response to flucloxacillin was concentration and time-dependent, which 
suggests that a protein adduct is needed to activate clones. Interestingly, in contrast 
to the piperacillin clones, flucloxacillin clones were broadly crossreactive. They 
were  activated  by  a  variety  of  β-lactam  antibiotics,  indicating  that  the  core  β-lactam 
ring structure is the main chemical component involved in the MHC T-cell receptor 
binding interaction [Figure 6.1].  
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Figure 6.1- Illustration of chemical structure of piperacillin and flucloxacillin.    
 
Studies originating after our findings were published (Monshi et al., 2013) from the 
group of Pichler (Wuillemin et al., 2013) using clones from generated from drug-
naïve volunteers found a similar hapten response. However, they also found that 
certain clones were activated rapidly, with flucloxacillin binding directly to MHC 
associated peptides. Whether this binding involves a covalent or non-covalent 
interaction with specific amino acid residues is still open to debate. In fact, it is 
feasible that certain drug-responsive clones are activated via direct (covalent and 
non-covalent) modification of MHC binding peptides and flucloxacillin protein 
adducts following processing.  
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Figure 6.2- The clinical and mechanistic basis of piperacillin and flucloxacillin 
hypersensitivity. Taken from (Uetrecht and Naisbitt, 2013). 
 
The   reason   why   these   two   β-lactam antibiotics piperacillin and flucloxacillin 
selectively target the skin and liver is still not fully understood. Furthermore, the 
reason for the difference in reaction frequency is not known. Figure 6.2 summarises 
the key clinical and mechanistic features of these two forms of drug hypersensitivity. 
If one first considers piperacillin-induced skin injury. This drug is administered at 
high doses and patients receive repeated courses (up to 4 per year). This equates to 
around 6.5kg of piperacillin over a 10 year period. This incredible drug burden 
coupled with the immune dysfunction associated with cystic fibrosis and repeated 
cycle of infection and inflammation could account for the high incidence of 
cutaneous reactions. Koch et al (Koch et al., 1991) found  that  4.5%  of  2793  β-lactam 
treatment courses resulted in an adverse reaction. Wills (Wills et al., 1998) found 
similar results, a retrospective analysis of 53 patients with cystic fibrosis identified 
hypersensitivity reactions in 34% of individuals. In the Leeds cystic fibrosis cohort, 
the   data   are   similar;;   an   analysis   in   2011   identified   302   β-lactam reactions in 375 
What  we  know  and  don’t  know!
Flucloxacillin
f Clinical features
– 1g per day
– oral
– Liver reaction 
(1/10000 patients)
f Mechanistic features
– Antigen in patients
(proteasomal processing 
of liver albumin?)
– B*5701 restricted
– T-cell (CD8+)
– Broadly cross-reactive
Piperacillin
f Clinical features
– 12g per day (in CF)
– iv
– Skin reaction 
(1/3 patients)
f Mechanistic features
– Antigen in patients
(lysosomal processing of 
plasma albumin?)
– No known HLA restriction
– T-cell (CD4+)
– No cross-reactivity
Why organ selectivity ?
Why the difference in frequency ?
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patients. Of particular interest is why piperacillin selectively activates CD4+ T-cells. 
Is it possible that piperacillin albumin adducts, represent the primary antigen that 
promotes reactions in patients? Human serum albumin is known to account for the 
majority of serum-bound penicilloyl groups in patients (Lafaye and Lapresle, 1988) 
and cell assays (Whitaker et al., 2011a; El-Ghaiesh et al., 2012) and such exogenous 
protein adducts would be preferentially processed via the lysosomal pathway 
generating MHC class II binding peptides. If this scenario is correct, one would still 
need to explain why flucloxacillin, which also binds selectively to albumin lysine 
residues preferentially activates CD8+ T-cells and causes liver injury. Hepatocytes 
are   the   bodies’  main   producer   of   albumin.   Thus,   one   possibility   that   the   group   in  
Liverpool group is working on is that flucloxacillin selectively binds to hepatocyte 
albumin generating an intracellular protein adduct that would be processed via a 
proteosomal pathway generating MHC class I binding peptides. Flucloxacillin is a 
potent inhibitor of the bile salt export pump (a membrane protein localized in the 
cholesterol-rich canalicular membrane of hepatocytes, which shows that it enters 
hepatocytes (Thompson et al., 2012; Warner et al., 2012). Furthermore, Carey et al. 
(Carey and van Pelt, 2005) identified a small number of drug-modified liver proteins 
(including albumin) in flucloxacillin-exposed rats using Western blot analysis. 
However, experiments to assess drug protein binding in human hepatocytes have not 
been performed; thus, the relationship between antigen formation in target tissue and 
HLA-restricted killing by cytotoxic T-cells has not been defined. 
 
 
Differential distribution of drug protein binding represents one possible                     
explanation as to why piperacillin and flucloxacillin cause drug-induced skin and 
liver injury, respectively. Other possible explanations include concomitant disease, 
which may regulate co-stimulatory signalling in different tissues. It is also possible 
that the site of T-cell priming has little bearing on the nature of the tissue injury and 
that the homing receptors expressed on the surface of drug-specific T-cells is the 
primary determinant. In this respect, we have shown that piperacillin and 
flucloxacillin-specific T-cell express high levels of skin-homing and gut-homing 
chemokine receptors, respectively. However, much more work is clearly needed to 
150 
 
elucidate the reasons why such structurally similar drugs cause different forms of 
adverse drug reaction. 
 
 
In conclusion, the aim of this thesis was to further our understanding of the chemical 
and   cellular   basis   of   β-lactam hypersensitivity reactions. I have been successful in 
both respects, however, research in this area must continue if we are to understand 
fully  why  β-lactam antibiotics cause immune-mediated adverse effects in susceptible 
patients and develop models for the pharmaceutical industry to assist the 
development of safer drugs.      
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